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Abstract 
 
Hepatitis C Virus (HCV) is expected to be an increasing global healthcare burden. 
HCV Infection can progress to major chronic hepatitis, liver cirrhosis and 
hepatocellular carcinoma (HCC). No protective vaccine currently exists against 
hepatitis C and current therapies are ineffective. NS5A is an essential component of 
the HCV with roles in RNA replication, modulation of the host cell and assembly of 
viral particles, however no precise function of NS5A has been established. New direct 
acting antivirals (DAA) such as daclatasvir (DCV), a dimeric compound which targets 
NS5A with picomolar potency, are showing promise in clinical trials. The exact 
nature of how these compounds have an inhibitory effect on HCV is unknown; 
however resistance mutations appear in the NS5A domain 1. Genotype 1a HCV is less 
affected by these compounds and resistance mutations have a greater effect than in the 
1b genotypes.  
 
We have obtained crystals of domain 1 of the important 1a NS5A genotype and 
intriguingly, our X-ray crystal structure shows two new dimeric forms of this domain. 
Our new NS5A domain 1 dimers serve as additional candidate targets for inhibitors 
and could explain the role of NS5A in the regulation of HCV replication. The high 
solvent content (75%) of our crystal form makes it ideal for ligand-soaking, however 
we did not observe the presence of DCV in soaks with our crystals. Using nuclear 
magnetic resonance (NMR) spectroscopy, we further investigated the binding of DCV 
to NS5A constructs which included the key resistance mutation sites. These extended 
constructs appeared to have slightly altered conformations which allow a weak 
interaction with DCV. This data and subsequent studies will give new insights into the 
roles of NS5A in the HCV replication complex and the mechanism of action of this 
class of DAA. 
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1.1 Structural Biology in Drug Discovery 
 
Drug discovery is the process of developing a therapeutically active substance for a 
defined target molecule or pathway (Segen, 2006). Historically, drugs were 
discovered serendipitously or through the identification of active ingredients of 
traditional remedies; it is only since the latter half of the 20
th
 century that the search 
for new drugs has found itself in the realm of science (Figure 1.1). Drug research has 
had more impact on the progress of medicine than any other scientific factor (Drews, 
2000); for example life expectancy at birth in the United States has increased from 47 
years in 1900 to 77 years in 2000, in part due to small molecule drugs in the form of 
antibiotics, statins, and other crucial medicines (Molla and Madans, 2011). The 
discovery and development of new drugs will continue to take a multidisciplinary 
approach to meet the arising healthcare challenges of the 21
st
 century. 
 
1.1.1 Historical background of drug discovery 
 
The use of natural extracts for medicinal purposes predates written human history: as 
Aldous Huxley put it, "Pharmacology is older than agriculture". Traditional medicine 
systems such as Ayurvedic, Unani and Chinese were developed through trial and error 
over millennia. Although lacking the rigour of the scientific method, these practices 
identified therapeutics containing bioactive compounds or precursors to control 
infection, diabetes mellitus, pain, respiratory disorders, dementia and cancer (Gurib-
Fakim, 2006). In the late 19
th
 century analytical chemistry allowed some isolation of 
individual bioactive ingredients from natural products. Advances in organic 
chemistry, such as August Kekulé’s theory of the structure of benzene in 1865, and 
Paul Ehrlich’s postulation of chemoreceptors led to early chemotherapy and the first 
screening of derivatives to create synthetic drugs, such as arsphenamine, introduced in 
1910 for the treatment of syphilis (Zaffiri et al., 2012). Microbiology flourished in the 
first half of 20th century and many medically-important microbes were investigated 
(Maloy and Schaechter, 2006). In 1928 Alexander Fleming discovered that a 
contaminating mould inhibited growth of Staphylococcus bacteria, by producing a 
substance he named Penicillin. Howard Florey and Ernst Chain advanced Fleming’s 
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work, discovering penicillin's therapeutic action and chemical composition (Chain et 
al., 1940), for which the three won the Nobel Prize in 1945. Chain also theorized on 
the chemical structure of penicillin which was confirmed with  X-ray crystallography 
in 1945 by Dorothy Hodgkin (Hodgkin, 1949). 
 
 
Knowledge of the chemical structures of drug molecules was a new paradigm in drug 
production. The pharmaceutical industry - which had arisen from pharmacies or as the 
divisions of chemical or dye companies - could mass-manufacture active compounds 
and new derivatives through chemical synthesis (Batchelor et al., 1959). Biology had 
to catch up and provide information at the molecular level concerning clinically-
relevant targets and pathways. Biochemical techniques using labelled isotopes and 
chromatography allowed a greater understanding of the biochemistry of the cell and 
metabolic pathways such as glycolysis and the Krebs cycle (Quastel, 1985). A 
plethora of new drugs targeting enzymes and receptors followed in the post-war era 
such as Monoamine oxidase inhibitors, oncology medicines and ACE inhibitors 
(Drews, 2000). 
 
 
Figure 1.1 Timeline of landmarks in drug discovery.  
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With the discovery of the structure of DNA (Watson and Crick, 1953), biology 
acquired a molecular and biochemical basis, leading to the development of molecular 
biology techniques. Insulin was the first protein therapeutic produced recombinantly 
in the late 1970s (Miller and Baxter, 1980) followed by with haemophiliac globulins, 
growth hormone, erythropoietin, colony stimulating factors and interferon (Buckel, 
2001); but the principal contribution of recombinant DNA technology to therapeutics 
is its role in the discovery process for conventional chemical drugs. 
 
Challenges such as dwindling targets for ‘blockbuster’ drugs and the increasingly 
stringent requirements for new medications force innovation and pioneering of the 
latest technologies in the search for new drugs. Towards the end of the 20
th
 century, 
the use of robotics and technologies which allowed greater miniaturisation of assays, 
gave rise to high-throughput screening (HTS). HTS allowed the screening of large 
libraries of compounds often numbering in the tens of millions and generated by 
combinatorial chemistry (Pereira and Williams, 2007); from this active compounds 
can be identified – so called ligand-based drug design (Stockwell, 2000). 
Alternatively, the advancement of structural biology techniques such as NMR and X-
ray crystallography allowing the routine atomic resolution of drug targets, offers a 
rational approach in finding new medicines based on the known structure of a specific 
target or its natural ligands. Structural biology’s traditional role in drug development 
was in validation and optimisation; however structural biology techniques are now 
using in designing drugs from scratch to fit their targets (Shuker et al., 1996; Hajduk 
and Greer, 2007) – structure-based drug design. Both holistic (ligand-based drug 
design) and reductionist (structure-based drug design) approaches are important in 
modern drug discovery and can complement each other. 
 
The publication of the human genome (Venter et al., 2001) has been slow to translate 
into developments for healthcare and drug discovery. Although few genome-derived 
targets have led to approved drugs (Fedorov et al., 2010; Edwards et al., 2011), 
routine profiling of genotypes (pharmacogenomics) promises to usher in a new era of 
personalized medicine whereby the optimisation  of drug therapy to patients’ genetic 
makeup to allow for maximum efficacy with minimal adverse effects and the broadest 
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coverage in the treatment of a particular disease (Samani et al., 2010). As human life 
expectancy continues to improve, the disease landscape will continue to change; 
diseases such as cardiovascular disease, dementia and cancer are likely to become 
increasingly prevalent (WHO, 2008). In addition current infectious diseases are 
becoming more prevalent or resistant to current drugs and there is always the risk of 
new diseases arising from zoonoses (Wolfe et al., 2007), requiring the constant need 
for new therapeutics. 
 
Analogous to the partnership between chemistry and pharmacology that formed the 
pharmaceutical industry at the start of the 20
th
 century, the incorporation of new 
technologies and areas of research such as genomics, bioinformatics and structural 
biology into modern and future drug discovery will mean drug discovery continues to 
be an ever-more interdisciplinary endeavour. Furthermore the scope and complexity 
of drug discovery will grow outside the pharmaceutical industry with further 
involvement of biotechnology companies and academic laboratories (Drews, 2000). 
 
1.1.2 Current Drug Discovery and Development 
 
Today the creation of new therapeutics is an expensive and time-consuming process. 
Drug discovery has a high attrition rate with new drugs taking an average of at least 
$1 billion and sometimes more than 10 years from discovery to market (DiMasi et al., 
2003). The key science disciplines at the heart of modern drug discovery include; 
chemistry to create new drug entities, pharmacology to assess their therapeutic action 
and structural biology to understand how the drug molecules interact with their target 
biomacromolecules. 
 
First the selection of potential ‘hit’ compounds is identified from high-throughput 
screening (in silico or in vitro), structure-based drug discovery or previously known 
drug structures. Hits which show activity and selectivity in a pharmacological or 
biochemically-relevant screening assay are considered as potential ‘lead’ compounds. 
At each stage, an evaluation of the structure-activity relationships (SARs) must be 
addressed, which involves the determination of the biological effects associated with 
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the chemical groups of a compound. ‘Drug-like’ properties need to be studied in vivo 
through pharmacokinetic studies to evaluate the absorption, distribution, metabolism, 
excretion, toxicity (ADMET), and interactions of a drug. These studies ascertain 
physicochemical properties (solubility, permeability, lipophilicity, and stability in 
vitro) (Lipinski et al., 2001; Kerns, 2003). Clinical trials for safety and efficacy are 
required before a drug can be approved and are regulated by the Food and Drug 
Administration (FDA) in North America or the European Agency for the Evaluation 
of Medicinal Products (EMEA) in Europe. 
 
Knowledge of the mechanism of action (MOA) of a drug, i.e. how it produces its 
pharmacological effect, is extremely useful not only in the development of the drug 
but also in its approval. The confidence of a MOA of a compound which supports 
empirical evidence of its safety and effectiveness aids regulatory bodies to approve it 
with making fewer assumptions (Katz, 2004). However a known MOA is not essential 
and indeed 18% of approved drugs lack a MOA (Gregori-Puigjané et al., 2012). 
 
1.1.3 Drug Targets 
 
Biological systems contain only four types of macromolecule which we can target 
with drug compounds: polysaccharides, lipids, nucleic acids and proteins. The 
challenges in obtaining specific, potent and nontoxic compounds against the former 
three types means that the vast majority of approved drugs achieve their activity by 
binding to and stimulating or blocking the activity of a protein (Hopkins and Groom, 
2002). 
 
Traditionally after establishing a hit compound through empirical methods, efforts are 
made to identify the drug target to aid in optimisation of the compound and an 
understanding of its MOA. This ‘one drug, one target’ philosophy, however, fails to 
account for the many drugs which elicit their responses through acting on multiple 
targets (Reddy and Zhang, 2013); 7% of approved drugs lack a known primary target 
(Gregori-Puigjané et al., 2012). Nevertheless the determination of a known target and 
a MOA are worthy goals - allowing for rational drug design and development. 
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For example, a common procedure to determine the target of an active antimicrobial 
of unknown MOA is to genetically map resistance mutants. In this approach, a model 
system is exposed to sub-maximal doses of the compound for extended periods of 
time to force the selection of resistance mutations. These resistance mutations can be 
identified to determine genes which are affected by the compound (Stockwell, 2000). 
 
1.1.4 Role of Structural Biology in Drug Discovery and Development 
 
Discussions of utilising the atomic structures for drug design commenced shortly after 
the advent of macromolecular crystallography (Beddell et al., 1976). However 
structural biology was slow to be adopted by industry due to the unavailability of 
structures and the expense of structural determination. Structural biology was first 
used in optimising drugs using homology models (Congreve et al., 2005), before 
drugs could be designed using the crystal structures of actual targets such as HIV-1 
protease and influenza neuraminidase (Miller et al., 1989; Varghese, 1999). 
 
1.1.4.1 Target Identification and Validation 
 
Target identification and validation of biomacromolecules is a crucial initial step in 
drug discovery. The identification of a hypothetical target is followed by target 
validation, to confirm its role with respect to a disease phenotype (Drews, 2000). 
Structural information about target proteins can identify new members of 
superfamilies, molecular function, potential binding sites allowing for an assessment 
of the tractability of the target (Congreve et al., 2005). Furthermore structural data of 
how a compound interacts with its target give clues to its MOA – reinforcing 
intellectual property claims and providing valuable insights to the drug discovery 
project and the biology of the disease (Mori et al., 2008). 
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1.1.4.2 Structure-based Drug Design 
 
The potential of structural biology in drug development emerged during the 1980s in 
lead optimisation  (Congreve et al., 2005). Structural data of ligands and their protein 
targets could reveal the topographies of their respective complementary surfaces 
providing valuable insights to guide medicinal chemistry and allow optimisation of 
the pharmacokinetic properties, potency and selectivity of ligands. 
 
HTS often fails to identify sufficient hits, as compound libraries may not contain 
molecules with an optimal fit for a target protein. In structure-based drug design, the 
atomic resolution structure of the target protein is used to design candidate drugs that 
will bind to the target with high affinity and selectivity (Congreve et al., 2005). 
Developments in computer-based de novo approaches to design ligands to target 
proteins can aid experimental drug discovery however ligand affinities are difficult to 
calculate accurately from electrostatic maps (Schneider and Fechner, 2005). A more 
practical approach has been to build out ligands from established moieties or 
‘fragments’ that are known to bind to the protein target. In fragment-based drug 
discovery (FBDD), libraries contain thousands of low-affinity compounds (fragments) 
are screened using biophysical techniques such as X-ray crystallography or NMR. 
Fragments can then be linked to create novel high-affinity ligands for lead 
optimisation  (Murray and Rees, 2009). 
 
1.1.5 Antiviral Drugs 
 
Antiviral drugs, or antivirals, are medicines that cure or control virus infections. 
Although effective antibacterials were developed in the early 20
th
 century, there were 
no drugs to treat viral infections. While prophylactic vaccines against viruses were 
and continue to be an important part of medical armamentariums, their creation is not 
always feasible and they are not able to cure infections (Field and De Clearcq, 2004).  
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1.1.5.1 Human Viral Pathogens 
 
Viruses contribute to both high morbidity and mortality in human health due to their 
ability to rapidly evolve new mechanisms to exploit their hosts (Worobey et al., 
2007). Examples of viruses which cause human diseases include clinically-relevant 
viruses such as the common cold, the human immunodeficiency virus (HIV), the 
hepatitis viruses; natural emerging and re-emerging viruses such as avian and swine 
influenza strains, SARS, dengue fever virus and yellow fever virus; and viruses 
relevant to potential bioterrorism such as Ebolavirus and smallpox. 
 
Viruses have evolved to transfer genetic material between cells, subjugating host cells 
to produce copies of themselves and thus ensuring their own continued propagation. 
In their most basic form viral particles consist of a small genome of DNA or RNA 
surrounded by a protein coat known as a capsid, or as British immunologist Peter 
Medawar succinctly described "a piece of bad news wrapped in protein". However the 
apparent simplicity of viruses is misleading; viruses infect virtually every organism in 
nature bringing about complex interactions with their hosts, and they display a vast 
diversity of structures and lifecycles. Although the viral lifecycles of different viruses 
vary in their precise details they all share a several basic stages: (i) viral entry - 
virions bind specific receptors on the host cell surface and then penetrate the host cell 
through receptor-mediated endocytosis or membrane fusion; (ii) uncoating - step-wise 
disassembly of viral components and release of the viral genomic nucleic acid; (iii) 
replication - expression and replication of the viral genome; (iv) assembly - viral 
components assemble into complete viral particle; (v) release - virions leave the host 
cell through lysis or budding (Knipe and Howley, 2007). All these aspects are crucial 
in the viral lifecycle and potential targets for antiviral drugs (De Clercq, 2011). 
 
The general strategy in modern antiviral drug design is to identify viral proteins or 
protein domains as targets for inhibition. Ideally such targets should be unique and 
unrelated to human proteins to reduce toxicity and increase specificity (De Clercq, 
2001). At present, most of the effective antivirals target virus-specific enzymes; such 
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as reverse transcriptase and the protease of HIV-1, and neuraminidase of influenza 
virus (Miller et al., 1989; Varghese, 1999).  
 
1.1.5.2 History of Antivirals 
 
The concept of a virus was developed with the beginning of modern medicine in the 
late 19
th
 century. Scientists built upon the advances and the work of Jacob Henle, 
Robert Koch, Louis Pasteur to establish a virus as an obligate parasite that was 
filterable and too small to detect with a light microscope (Knipe and Howley, 2007). 
Although the etiological agents were not known at the time, the first vaccine was 
developed in 1796 against smallpox by Edward Jenner. This was followed with 
antiviral vaccines against rabies in 1885 by Pasteur and a yellow fever vaccine in 
1932. However, there were no cures available in the first half of the 20
th
 century so an 
infected patient would have to wait for the disease to take its natural course or have 
the symptoms treated (Plotkin et al., 2013). 
 
Antiviral drug discovery was hindered until drug research institutions and virology 
had matured. During the early 20
th
 century new virus groups discovered were limited 
to growth in animals and fertile eggs. The development of tissue culture techniques 
between 1948 and 1955 transformed animal virology into a laboratory science (Knipe 
and Howley, 2007). Early experimental antiviral compounds were developed in the 
1950s and 1960s, including β-Thiosemicarbazone -  a bacterial antibiotic (Thompson 
et al., 1951), idoxuridine - which was initially developed as a cancer treatment, 
amantadine - a specific inhibitor of influenzavirus A, and vidarabine – used in early 
treatment against herpes simplex and varicella zoster viruses. However such 
compounds were either limited in their specificity and potency, or toxic to the host 
cells and restricted to topical applications; this lead to the conception that specific 
toxicity against viruses was unattainable since the viral lifecycle depends upon the 
host-cellular machinery (Field and De Clearcq, 2004). Acyclovir marked a 
breakthrough in antiviral treatment as the first compound that displayed high 
selectivity and low cytotoxicity (Elion et al., 1977) – acyclovir is active against 
herpesviruses and principally used for treating herpes simplex virus infections. 
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In the 1957 researchers at the National Institute for Medical Research in London 
(Isaacs and Lindenmann, 1957) and independently 3 years before, at the Institute for 
Infectious Diseases at the University of Tokyo (Nagano and Kojima, 1954) observed 
a phenomenon referred to as "virus interference" which prevented cells becoming 
infected. The interfering agents, Interferons (IFNs), are proteins made by host cells in 
response to the presence of pathogens and confer a broad spectrum of antiviral 
activity. However their use in the clinic was slow to be implemented (Cantell, 1998). 
Interferons have antiviral, antiproliferative and immunomodulatory activities, and act 
by inducing the IFN-stimulated genes (ISG), which establish a non-virus-specific 
antiviral state within the cell (Feld and Hoofnagle, 2005). The next broad-spectrum 
antiviral discovered was ribavirin in the 1970s as part of a search for synthetic 
nucleosides with antiviral and antitumor activity. Ribavirin is active against a variety 
of RNA and DNA virus families (Sidwell et al., 1972). As a guanosine analogue, 
several MOAs have been proposed for the antiviral activity of ribavirin and it 
consider to act as a general inhibitor of virus replication (Paeshuyse et al., 2011). In 
the context of RNA viruses, ribavirin is thought to be misincorporated into viral RNA 
leading to direct inhibition of viral replication, competitive inhibition of the 
nucleoside synthesis and increases the error rate in viral replication leading to an error 
catastrophe (Feld and Hoofnagle, 2005). The determination of the viral genome 
sequences in the 1980s (Koonin and Galperin, 2003) was pivotal in allowing for 
elucidation of viral molecular biology and the identification of viral targets for 
rational drug design (Egloff et al., 2005). Furthermore the emergence of the 
HIV/AIDS epidemic has rallied a renewed urgency for novel antivirals.  
 
1.1.5.3 Combinatorial Drug Therapy in HIV/AIDS Treatment 
 
Since its identification as the causative agent of acquired immunodeficiency 
syndrome (AIDS) in the early 1980s (Gallo et al., 1983), the human 
immunodeficiency virus (HIV) has led to more than 25 million deaths. HIV, a 
retrovirus, now causes more global mortalities than any other infectious disease and is 
the single most common cause of death in Africa (WHO, 2004). The development and 
 29 
 
implementation of antiretrovirals since 1996 has transformed an AIDS diagnosis from 
a terminal illness to a manageable disease. HIV is typically managed using a 
combination therapy known as highly active antiretroviral therapy (HAART) where 
multiple antiretrovirals act on at least three viral targets. Although HAART does not 
eliminate the virus, it has substantially decreased the mortality and morbidity of HIV-
infected patients, with declines of 60-80% in deaths from AIDS (Egger et al., 2002b). 
 
The use of combinations of antiretrovirals against different targets in HAART creates 
a high genetic barrier for HIV, meaning more mutations are required to overcome 
drug-selective pressure and evolve resistance to the treatment. There are five classes 
of antiretrovirals used in HAART which target different aspects of the viral lifecycle 
essential for viral replication: nucleoside (or nucleotide) reverse transcriptase 
inhibitors (NRTIs) – as nucleotide analogues, they are incorporated into viral DNA 
causing DNA synthesis to halt; nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) – which also inhibit reverse transcriptase but through a different MOA,  
binding allosterically to reverse transcriptase; protease inhibitors (PIs) – which bind to 
the viral protease and block cleavage of the viral polyprotein; integrase inhibitors (IIs) 
– which inhibit the binding of the integration complex to host cell DNA thus 
preventing the integration step; fusion and entry inhibitors (FI/EIs) – which interfere 
with the binding, fusion and entry of HIV virions into host cells (Apostolova et al., 
2011). Structure-based drug design has contributed to the repertoire of new agents for 
use in HIV/AIDS combination therapy (Blundell et al., 2002; Field and De Clearcq, 
2004). 
 
The successful implementation of combinatorial drug therapy in the management of 
HIV/AIDS highlights its importance to minimise the development of clinical 
resistance in the treatment of diseases and pathogens with high mutation rates 
including tuberculosis, leprosy, cancer, and malaria (Cottarel and Wierzbowski, 
2007). Their differences aside, HIV research and treatment holds up an interesting 
mirror to the young Hepatitis C Virus (HCV) field with the promise of a potential 
HCV cure with combination drug therapy (Edlin, 2011; Rice, 2011). 
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1.2 Hepatitis C Virus (HCV) 
 
HCV is a human pathogen affecting approximately 3% of the global population 
(WHO, 2003). In addition to grave morbidity, HCV is predicted to cause 166,000 
deaths from chronic liver disease, 27,000 deaths from hepatocellular carcinoma, $10 
billion in direct medical expenditure and $75 billion in societal costs between 2010 to 
2019 in the United States alone (Wong et al., 2000). The fact that chronic HCV 
infection is largely asymptomatic with the onset of end stage liver disease and 
hepatocellular carcinoma (HCC) having an average lag time of 20 to 30 years after 
infection (Leach and Schwartz, 2007) - the world health organisation (WHO) has 
labelled HCV as a “viral time bomb” (Piorkowsky, 2009). HCV is now the leading 
cause for liver transplant (Brown, 2005) and has a mortality rate higher than from 
HIV infection (Ly et al., 2012), making HCV an urgent global healthcare concern. 
 
HCV is a positive sense single strand RNA (ssRNA) virus with a diameter of about 50 
nm (Figure 1.2) (Gastaminza et al., 2010) and a member of the flaviviridae virus 
family (Miller and Purcell, 1990). A protective vaccination against HCV does not 
currently exist and its development has proven elusive (Houghton and Abrignani, 
2005). Current therapies consist of combination therapies using interferon (IFN) and 
ribavirin are effective in only a fraction of patients and these are plagued by adverse 
effects (Patel and McHutchison, 2004). Future treatment regimens are likely to move 
to combination therapies without the use of interferon using multiple direct acting 
antivirals (DAAs) (Ferenci, 2012) similar to HAART for HIV treatment. Combination 
therapy require multiple targets in order to be effective (Woodcock et al., 2011): with 
its crucial role in the viral lifecycle, NS5A is an important HCV antiviral target. 
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1.2.1 Viral Hepatitis 
 
Hepatitis is an inflammation of the liver; in addition to viral hepatitis, it is possible to 
suffer from alcoholic hepatitis and toxic/drug-induced hepatitis, and less commonly 
autoimmune hepatitis and non-viral infections (Bacon et al., 2000). Various non-
hepatitis viruses such as yellow fever virus (YFV), Epstein-Barr virus (EBV), 
cytomegalovirus (CMV), measles and herpes simplex are known to cause hepatitis 
(Hadziyannis, 1998), however the principal aetiological agents of viral hepatitis are 
the hepatitis viruses A, B, C, Delta (D) and E. 
 
Viral hepatitis is estimated to cause 1 million deaths worldwide each year from 
chronic hepatitis, liver cirrhosis and liver cancer (WHO, 2011). The hepatitis viruses 
come from a wide range of virus families and are unrelated except that they primarily 
infect the hepatocyte cells of the liver and share some epidemiology. Hepatitis A 
Virus (HAV) is a picornavirus transmitted by the faecal-oral route; Hepatitis B Virus 
(HBV) belongs to the hepadnaviridae family of double stranded DNA viruses and is 
the most common form of blood-borne hepatitis; hepatitis D is a circular single strand 
RNA satellite virus which can only propagate in the presence of the hepatitis B virus; 
Hepatitis E Virus (HEV) is the only known member of the hepeviridae family and is a 
A 
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Figure 1.2 Electron micrograph of negatively stained HCV particles of high purity. (A) HCV particles 
show pleomorphic shapes with a size of about 55 nm. Scale bar, 500 nm. (B) Close-up image of a 
HCV particle. Scale bar, 100 nm. Images reproduced from (Gastaminza et al., 2010). 
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non-enveloped spherical ssRNA virus (Wagner et al., 2008). Preventative vaccines 
exist against HAV, HBV and recently HEV (Park, 2012). 
 
In addition to the five hepatitis viruses, another causative agent was suggested (Deka 
et al., 1994) and tentatively named Hepatitis F virus (HFV) – but these reports were 
not substantiated. Subsequently samples of hepatitis G virus (HGV) and GB virus C 
(George Barker virus C) were obtained from patients with hepatitis; later analysis 
showed them to be two different isolates of the same viruses and hence they are 
considered synonymous – however neither virus shows any causal links to human 
disease (Kelly and Skidmore, 2002). 
 
1.2.1.1 History of Viral Hepatitis 
 
Evidence for a highly infectious form of liver disease, likely due to HAV, dates back 
to reports of jaundice epidemics in China and Babylon several millennia ago, and 
descriptions in Hippocrates’ Of the Epidemics in 400 BCE. In the 8th century Pope 
Zacharias suggested the infectious nature of jaundice and recommended quarantine 
for sufferers (Reuben, 2002). In 1885, the parenteral route of long-incubation jaundice 
infection, likely due to HBV, was established in studies following the patients of 
blood transfusions and vaccination programs implying the infection to be blood-borne 
(Lurman, 1885) and in the early 20
th
 century infectious jaundice was postulated to be 
caused by a virus (McDonald, 1908). After World War II, viral hepatitis was 
classified into two types: Viral Hepatitis A, or infectious hepatitis, and Viral Hepatitis 
B, or Serum hepatitis (MacCallum, 1947). In 1965, HBV was determined as the 
causative agent of Hepatitis B (Alter and Blumberg, 1966), shortly followed by the 
identification of the HBV (Dane et al., 1970) and the HAV viral particles by electron 
microscopy (Feinstone et al., 1973). 
 
With the development of sensitive serologic tests to HAV and HBV in the 1970s, it 
became apparent that approximately 75% of cases of transfusion-associated hepatitis 
were not attributable to either virus; the unidentified disease entity was termed non-A, 
non-B hepatitis (NANBH) (Feinstone et al., 1975; Alter, 1999). Due to its long and 
 33 
 
mild asymptomatic period clinicians initially regarded the illness as inconsequential, 
before epidemiological studies indicated NANBH to be a serious progressive disease 
associated with liver cirrhosis and HCC (Tabor, 1989). The inoculation of 
chimpanzees with serum from humans with NANBH showed that the disease was 
brought about by a transmissible agent (Alter et al., 1978; Realdi et al., 1982). Further 
experiments showed that the infectivity of the NANBH agent was destroyed by 
chloroform (Feinstone et al., 1983) and it could pass through 50 nm filters suggesting 
the agent to be a small enveloped virus (He et al., 1987). However, the NANBH agent 
continued to evade serologic detection due to an absence of animal models other than 
chimpanzees and no cell culture models.  
 
Almost a decade since the disease’s discovery, the NANBH virus was identified with 
newly developed recombinant DNA technology in the 1980s. The low concentration 
of viral antigen in NANBH infections hampered conventional immunological 
methods from identifying specific viral antibodies and antigens; Chiron Corporation 
(Emeryville, California) circumvented this limitation by extracting nucleic acids from 
large volumes of infectious chimpanzee plasma to create a cDNA expression library 
which was screened with the sera of chronic NANBH patients resulting in the 
identification of a clone (5-1-1) specific for NANBH. Further experiments 
demonstrated that the cDNA 5-1-1 clone bound to a positive-sense RNA molecule 
present in the chimpanzee liver samples identifying the virus as a single-stranded 
RNA (ssRNA) virus. Using primer walking techniques the viral genome was 
identified and the virus was termed HCV (Choo et al., 1989). 
 
1.2.2 Classification and Genetic Variability of HCV 
 
The identification of HCV as an enveloped positive-sense ssRNA virus led to 
suggestions that it be placed within the Togaviridae or Flaviviridae families of viruses 
(Choo et al., 1989). As HCV shares amino acid sequence similarity and genome 
organisation with pestiviruses and flaviviruses, it was also grouped into the 
Flaviviridae family (Miller and Purcell, 1990); however, due to their divergent 
sequence homology, the HCV species were assigned into a distinct genus Hepacivirus 
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within the flaviviridae family (Figure 1.3A) (Robertson et al., 1998). The flaviviridae 
family contains: the flavirvirus genus which itself includes dengue virus (DENV), 
yellow fever virus (YFV) and Japanese encephalitis virus; viruses within the 
pestiviruses genus such as bovine viral diarrhoea virus (BVDV) and classical swine 
fever virus (CSFV), and the tentative genus pegivirus which contains the GB viruses; 
GBV-A, GBV-C (HGV) and GBV-D (Stapleton et al., 2011). HCV was the sole 
member within the genus Hepacivirus until the recent discovery of canine hepacivirus 
(CHV) which causes pulmonary infections in dogs (Kapoor et al., 2011). Since then 
additional hepaciviruses which infect rodents, bats and horses have been described 
(Kapoor et al., 2013). 
 
HCV is highly heterogeneous: the HCV species is divided into at least six 
phylogenetically distinct groups, described as genotypes 1-7 which can be further 
divided into 67 different more closely related subtypes (Figure 1.3B) (Robertson et 
al., 1998; Smith et al., 2014). Furthermore HCV subtypes consist of viral quasispecies 
based on their genetic diversity. The distribution of HCV genotypes varies globally 
and this heterogeneity affects the viruses’ virulence or pathogenicity, their 
responsiveness to interferon/ribavirin combination therapy and furthermore retards the 
development of vaccines. The genotype of an HCV infection is used to assess whether 
patients achieve a sustained viral response (SVR) to HCV therapy – with Genotype 1 
being the most common and most difficult one to treat (WHO, 2003; Schlütter, 2011).  
 
The lifecycle of HCV is only a few hours resulting in the production of approximately 
10
12
 virions per day in infected patients (Neumann, 1998).  This high replication rate, 
in conjunction with the low fidelity of the HCV RNA polymerase (Margeridon-
Thermet and Shafer, 2010), leads to substantial variability and mutability of the viral 
genome, resulting in a high propensity to cause chronic infections and the 
development of drug resistance (Rehermann and Nascimbeni, 2005). 
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Figure 1.3 HCV genotypes within the flaviviridae family. (A) Phylogenetic tree of conserved regions 
in the RNA-dependent RNA polymerase (RdRp) gene of CHV aligned with representative members of 
the Hepacivirus, Pegivirus (GB viruses A, C, and D), Pestivirus, and Flavivirus genera. Image 
reproduced from (Kapoor et al., 2011). (B) Evolutionary tree of available complete open-reading frame 
sequences for each HCV genotype. Image reproduced from (Smith et al., 2014). 
A 
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1.2.3 Epidemiology of HCV 
 
Hepatitis C has been to referred to as the ‘silent epidemic’ due to the asymptomatic 
nature of its disease (Gravitz, 2011). HCV is thought to have coevolved with humans 
for over 100,000 years, with HCV genotypes spread by blood-borne contact 
throughout global human populations (Simmonds, 2001). As a considerable cause of 
chronic hepatitis and hepatocellular carcinoma, HCV presents a major disease burden 
worldwide. 
 
1.2.3.1 Global Prevalence of HCV 
 
Precise data for the prevalence and distribution of HCV are difficult to determine as 
HCV infections can be asymptomatic for decades and routine screens for HCV 
infection are not feasible in most countries. Nevertheless, the WHO has made 
estimates of the prevalence of HCV infections to be between 130 and 170 million 
worldwide, or 2-3% of the global population (WHO, 2003; WHO, 2008). Although 
HCV is endemic worldwide, its distribution shows geographic variability (Figure 1.5); 
generally there is a lower prevalence in more developed countries, with low rates of 
prevalence the UK (0·6%), Germany (0·6%), Canada (0·8%), France (1·1%), and 
Australia (1·1%), but studies have revealed marginally higher prevalence rates in the 
USA (1·8%), Japan (1·5–2·3%), and Italy (2·2%). While there is a higher prevalence 
of HCV in most developing nations, there is a wide range of reported prevalence 
estimate: There are relatively low rates of prevalence in India (0·9%) and higher rates 
of prevalence in China (3·2%), Indonesia (2·1%), and Pakistan (4·0%) – while the 
highest estimates of rates of prevalence have been in Egypt (22%) (Shepard et al., 
2005). Genotypes 1a and 1b are the most common, accounting for about 60% of 
global infections (Macdonald and Harris, 2004) (Figure 1.4). 
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1.2.3.2 Transmission of HCV 
 
HCV is transmitted most efficiently by parenteral exposure to infected blood or blood 
products, and contaminated therapeutic injections. The introduction of donated blood 
screening since the early 1990s (Van der Poel et al., 1991) have virtually eliminated 
post-transfusion hepatitis C infections in more developed countries where intravenous 
drug use is now the primary mode of transmission, accounting for example, for 68% 
and 80% of current infections in the USA and Austria respectively (Alter, 2002; 
Shepard et al., 2005). In the developing world, unscreened transfusions and the use of 
contaminated injection equipment are still major risk factors in transmission of HCV. 
Indeed in Egypt, the use of contaminated glass syringes in national schistosomiasis 
treatment programmes in the 1960s – 1980s have had a major role in HCV 
transmission and  the high prevalence rates (Frank et al., 2000). 
 
 
Figure 1.4 Estimated global hepatitis C prevalence. Image reproduced from (Gravitz, 2011). 
 38 
 
Transmission of HCV occurs seldom through perinatal or sexual routes; occupational 
exposures and other human activities where there is the possibility of percutaneous 
exposure to blood or blood-derived body fluids and are thought to be minor sources of 
new HCV infections (Shepard et al., 2005). 
 
1.2.3.3 Natural History and Pathogenesis of HCV infection 
 
The clinical outcome of HCV infection is dependent on several host and viral factors. 
Risk factors leaving patients more susceptible to fast disease progression include male 
gender, African American ethnicity, an age greater than 25 at infection, a history of 
alcohol abuse and the use of immunosuppressive medications (Chen and Morgan, 
2006). Differences in the distributions of polymorphisms in host genes explain how 
varying ethnicities show different susceptibilities (Ge et al., 2009; Pasha et al., 2013). 
In addition viral factors including co-infection with HIV (Kim and Chung, 2009) and 
the HCV genotype(s) involved in the infection show differences in progression to 
liver disease. For example, genotype 1 HCV strains are more aggressive and are less 
likely to respond to interferon treatment than genotype 2 and 3 strains (Zein, 2000). 
 
HCV infection causes acute hepatitis, which is resolved in approximately 20% to 50% 
of patients. The majority of individuals infected with HCV (50–80%) develop chronic 
infections, of which about 20% will develop cirrhosis (after 10–20 years) and that 
generally (75%) results in death by liver failure or hepatocellular carcinoma (Figure 
1.5) (Pawlotsky, 2004). 
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Acute HCV infections are rarely recognised and diagnosed as they are asymptomatic 
in the majority of individuals. Symptoms which present can include malaise, fatigue, 
nausea, and jaundice – indistinguishable from hepatitis A and hepatitis B infections. 
Initial infections can result in fulminant hepatitis which is characterised by a severe 
acute phase and though potentially fatal this condition is rare (Knipe and Howley, 
2007). Acute infection resolves spontaneously in about 15% to 30% of infected 
patients - the exact mechanisms underlying this viral clearance are currently unknown 
and patients do not acquire permanent immunity (Bowen and Walker, 2005). 
 
Chronic hepatitis C is defined as the persistance of viremia for more than 6 months 
and is typified by a long period without symptoms. Chronically infected patients can 
remain symptomless for several decades, but are at risk of progressive liver damage 
including steatosis (where excessive amounts of lipids collect inside liver cells), 
hepatic fibrosis (resulting from sustained inflammation), cirrhosis and HCC and liver 
failure (Knipe and Howley, 2007) – making HCV infection the leading cause for liver 
transplantation in the US (40-50%) and retransplantation (Brown, 2005). The clinical 
outcome of chronically infected individuals is dependent on the HCV genotype 
involved and certain complications have varying prevalences such as hepatic steatosis 
which is associated with genotype 3 strains (Rubbia-Brandt et al., 2000). As much as 
 
Figure 1.5 Schematic representation of the natural history of HCV infection.  Image reproduced from 
(Pawlotsky, 2004). 
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4% of patients with an initial HCV infection will go on to develop HCC (Pawlotsky, 
2004). 
 
1.2.3.4 HCV and Hepatocellular Carcinoma 
 
Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and third most 
fatal cancer worldwide resulting in the deaths of 600,000 individuals. Hepatitis C is a 
major cause of HCC with HCV infection accounting for 75-80% of HCC cases in the 
Americas and Europe (Ferenci et al., 2010). The mechanisms how HCC arises from 
HCV infection are not well defined, indirect mechanisms have been proposed as 
HCV-induced cirrhosis and long-term inflammatory responses cause oxidative stress 
and cellular DNA damage (Okuda et al., 2002). The expression of the viral 
polyprotein in the liver cells of transgenic mice suggests the non-structural proteins of 
HCV increase the risk of HCC (Lerat et al., 2002) and consistent with these reports, 
viral proteins such as core and NS5A have been shown to affects cell proliferation and 
cause HCC (Moriya et al., 1998; Macdonald and Harris, 2004). These means may 
contribute to oncogenesis in addition to proliferation from liver regeneration (Knipe 
and Howley, 2007). 
 
1.2.4 HCV Genome and Molecular Virology 
 
HCV has a positive sense single-stranded RNA genome which is 9.6 kb long. The 
RNA genome contains a single open reading frame encoding the viral polyprotein, 
which is flanked by 5’and 3’ untranslated regions (UTRs). The HCV polyprotein is 
cleaved by host and viral proteases to produce the HCV proteins (Figure 1.6) 
(Pawlotsky, 2004), consisting of the structural proteins core, E1 glycoprotein and E2; 
and the non-structural viral proteins p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B 
(Moradpour et al., 2007). 
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1.2.5 HCV Models 
 
The common chimpanzee, Pan troglodytes, is the only known organism other than 
humans susceptible to HCV infection, with both species developing a similar disease. 
In addition to being instrumental in the early studies of NANB hepatitis and the 
identification of HCV, chimpanzees have provided an important model for the 
analysis of the initial events in HCV infection, its natural history, and vaccine  
development (Walker, 1997). However the ethical and economic issues make 
chimpanzees a poor model, and the absence of any other HCV model system have 
historically hampered HCV research. As a consequence of a lack of knowledge about 
viral replication and pathogenesis, there have only been only two treatments to HCV 
developed in 22 years since its identification. 
 
 
Figure 1.6 HCV Genome and NS5A. Schematic depicting the HCV genome organisation – the HCV 
genome is expressed as a polyprotein containing 10 proteins; core, E1 and E2 glycoproteins, p7, NS3, 
NS4A, NS4B, NS5A and NS5B. Based on data from (Schmitz and Tan, 2008). Host cellular 
signalases cleave the polyprotein between core, E1, E2, p7 and NS2. NS2-3 protease autocleaves to 
release the NS3 serine protease which cleaves between NS3, NS4A, NS4B, NS5A and NS5B. Image 
of HCV proteins reproduced from (Moradpour et al., 2007). 
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Before the discovery of a robust cell culture model, knowledge of the virus was 
gained from comparisons with other Flaviviridae viruses, such as BVDV for which an 
efficient cell culture model exists (Meyers and Thiel, 1996) and GBV-B which causes 
hepatitis in tamarins and serves a surrogate model for HCV infection (Beames et al., 
2001). The discovery of the replicon system - a nucleic acid that is capable of 
autonomous replication - was a breakthrough for research of HCV replication. The 
HCV subgenomic replicon consists of the HCV RNA genome with the 5' UTR linked 
to the neomycin resistance gene in place of the HCV structural proteins. An inserted 
internal ribosome entry site (IRES) from Encephalomyocarditis virus (EMCV) drives 
translation of the HCV non-structural coding region (NS3-NS5B) (Lohmann, 1999). 
The replicon is propagated in human hepatoma cell lines Huh-7 and the identification 
of cell culture adaptive mutations in the non-structural region of the genome (the 
majority of which clustered in NS5A) allowed the creation of genotype 1 replicons 
with high levels of replication (Krieger et al., 2001). Furthermore “curing” Huh-7 
clones of the replicon through prolonged treatment with IFN-α resulted in 
identification of the Huh-7 subline, Huh-7.5 which support higher levels of 
subgenomic HCV replication. HCV subgenomic replicons allow the study of the 
intracellular steps of viral replication of HCV strains from genotypes 1 and 2, but do 
not support infectious HCV virion production and hence the replicon system cannot 
be  utilized to study a the complete HCV cycle (Blight and Norgard, 2006).  
 
Initial studies of HCV cell entry used pseudo-particles containing the HCV 
glycoproteins (Bartosch et al., 2003). For several years, experiments with full-length 
replicons failed to produce infectious virus in vitro and genomes containing the cell 
culture-adaptive mutations were severely attenuated in vivo (Blight and Norgard, 
2006) presumably because these mutations prevented the assembly of virions. A 
subgenomic replicon clone derived from an isolate from a Japanese patient with 
fulminant hepatitis was capable of replication with high efficiency without cell 
culture-adaptive mutations (Kato et al., 2003). When the full-length replicon of this 
Japanese Fulminant Hepatitis (JFH-1) clone was transfected into Huh7 cells, it 
replicated efficiently and secreted infectious virions (Wakita et al., 2005). The JFH-1 
system formed the first HCV cell culture model allowing experiments on the complete 
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viral lifecycle, however chimeras consisting of JFH-1 genomes with the structural 
protein genes of other HCV genotypes still support replication and virion assembly 
(Lindenbach et al., 2005). 
 
Recent advances have allowed the expression of human receptors in mice livers to 
create the first small animals with fully functioning immune systems that are 
susceptible to to HCV infection (Ploss et al., 2009). 
 
1.2.6 HCV Lifecycle 
 
HCV is thought to follow the replication strategy of other positive-strand RNA 
viruses – with viral attachment and entry to human hepatocytes, translation and 
processing of the viral genome, synthesis of positive strand RNA via a negative-sense 
RNA molecule template, and assembly of progeny genomes into virions 
(Bartenschlager et al., 2004). Each stage of the lifecycle is a potential target for 
therapeutic intervention (Figure 1.7).  
 
Viral Attachment, Entry, and Fusion 
 
The primary tropism for HCV is human liver cells whereas HCV lymphotropism 
remains controversial. Viral entry is a multi-step process and in addition to the 
envelope glycoprotein complex E1E2 at the surface of HCV particles (which interacts 
with HCV receptors), circulating HCV is linked to lipoprotein-lipoprotein receptor 
interactions such as the low-density lipoprotein receptor (LDLR), which plays an 
essential role in virus uptake (Molina et al., 2007). Additionally, glycosaminoglycans 
form an initial docking site for HCV attachment, after which virions can bind specific 
receptors which in turn mediate HCV internalization (Bartosch and Dubuisson, 2010). 
Several entry factors have been proposed but how and in which order these receptors 
function is still being determined. E2 binds to human CD81, a tetraspanin expressed 
on hepatocytes, as well as other cell types such as B lymphocytes (Pileri, 1998). 
CD81 cooperates closely with scavenger receptor B type I (SR-BI) which also binds 
directly to E2 (Scarselli et al., 2002). Two additional factors that are necessary for 
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viral entry are occludin and claudin-1; these transmembrane components form part of 
tight junction complexes and are thought to function at a later stage of the entry 
process (Liu et al., 2009). It is speculated that HCV shares a similar mechanism to 
that of the Coxsackie B virus (CBV), whereby after viral attachment a virion-receptor 
complex migrates to tight junctions leading to internalisation of the virus (Bartosch 
and Dubuisson, 2010). 
 
 
 
 
Figure 1.7 Each stage of the HCV lifecycle can be targeted for  therapeutic intervention. (1) The  virus 
locates and attaches itself to hepatocytes before penetrating the plasma membrane and entering the cell 
to release the viral RNA. (2) The positive sense viral RNA is translated via the HCV IRES and the viral 
polyprotein is processed by host and viral proteases to mature viral proteins. (3) RNA Replication takes 
place at replication complexes at the ER membrane. Transcription of positive sense viral RNA yields 
negative sense viral RNA which itself is used to transcript into new positive sense HCV genomes. (4) 
Viral genomes are packaged into nucleocapsids and are budded into the ER to form a lipid coat before 
transportation to and secretion at the plasma membrane with associated lipids. Image reproduced from 
(Schlütter, 2011). 
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After the binding of HCV to cell surface molecules, the virus enters the cytoplasm via 
clathrin-mediated endocytosis (Blanchard et al., 2006). The low pH of endosomal 
compartments cause conformational changes in the viral envelope proteins which 
induce fusion between the lipid envelope of the virus with the cellular membrane 
allowing the release of the HCV genome into the cytosol (Moradpour et al., 2007). 
 
HCV RNA Translation and Post-translational Processing 
 
Once the genome has been released, HCV translation initiation occurs through the 
binding of a 40S ribosomal subunit to the HCV IRES  which consists of domains II, 
III and IV of the 5’UTR and the first 30 nt of the core-coding region (Knipe and 
Howley, 2007). The cryo-electron microscopy (cryo-EM) structure of the HCV IRES 
bound to the 40S ribosomal subunit shows it to have induced an extensive 
conformational change in the 40S subunit closing the mRNA binding cleft to allow 
for assembly of the rest of the ribosome (Spahn et al., 2001). This is brought about by 
the assembly of a 48S complex at the AUG initiation codon from the association of 
eukaryotic translation initiation factor 3 (eIF3) and ternary complex and followed by 
the rate limiting step of GTP-dependent association of the 60S subunit to form the 
80S complex (Otto and Puglisi, 2004). 
 
Translation of the HCV genome yields a polyprotein which is processed co- and post-
translationally into mature structural and non-structural proteins by host and viral 
proteases (Figure 1.6). The structural proteins and p7 are processed by the host 
endoplasmic reticulum (ER) signal peptidase whereas the non-structural proteins are 
processed by the viral proteases; NS2–3 protease and NS3–4A protease (Grakoui et 
al., 1993). 
 
HCV RNA Replication 
 
HCV like all positive-strand RNA viruses forms replication complexes where viral 
RNA replication, packaging and assembly occur. Replication complexes consist of 
processed viral proteins, viral RNA, host proteins and induce rearrangements of 
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intracellular membranes, often with spherules invaginations (Salonen et al., 2005). 
HCV replication occurs at small vesicles embedded in a membrane matrix derived 
from the endoplasmic reticulum membrane. Analysis of these membrane-associated 
replication complex structures by electron microscopy led to their description as 
"membranous webs" by analogy to other flaviviruses (Gosert et al., 2003), the 
formation of which has been shown to be induced by the HCV protein NS4B (Egger 
et al., 2002a). 
 
Analogous to other positive-strand RNA viruses, HCV replication consists of two 
steps, both catalysed by the NS5B RNA-dependent RNA Polymerase (RdRp). In the 
first step, the positive-strand genome RNA serves as a template for the synthesis of a 
negative-strand. In the second step, negative-strand RNA serves as a template to 
produce more positive-strand genomes (Bartenschlager et al., 2004). RNA replication 
results in a five to ten fold in excess in positive-strand versus negative-strand RNA 
progeny (Lohmann, 1999). 
 
Viral Assembly and Release 
 
Although the late stage of the lifecycle of HCV is less well-understood, HCV 
assembly is thought to occur at intracellular membranes like HCV RNA replication. 
In addition the membranous web may also serve as a scaffold for virion assembly in 
proximity to lipid droplets. Early in the assembly of HCV particles and in one model 
of nucleocapsid formation, the HCV core protein is initially localised on lipid droplets 
and is recruited to the ER membrane at assembly sites where it interacts with NS5A to 
load the viral RNA and form the viral capsid. The maturation and release of HCV 
particles is closely linked to cellular lipid metabolism. The envelopment of viral 
capsids may occur at lipid-rich regions at the ER membrane and exit the cell through 
the secretory pathway (Bartenschlager et al., 2011). 
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1.2.7 HCV Genome Control Elements 
 
The non-coding regions of the HCV RNA genome consist of a 5′ and 3′ untranslated 
region (5′UTR and 3′UTR). As in other positive-strand RNA viruses, these UTRs 
contain important sequence and structural elements for HCV translation and RNA 
replication alike (Shi and Lai, 2006). 
 
1.2.7.1 5’ Untranslated Region 
 
The 5’UTR is approximately 341 nucleotides long and is the most conserved region 
of the HCV genome. Secondary structure analysis revealed the 5′ UTR to contain four 
major domains, numbered I to IV (Brown et al., 1992; Honda et al., 1996) (Figure 
1.8A). Domains I and II are essential for HCV RNA replication. Domains II, III and 
IV are required for translation of the viral polyprotein, and together with the first 12 to 
30 nt of the core-coding region comprise an IRES, whereas domain I may fulfil a 
translational regulatory role (Knipe and Howley, 2007). The HCV IRES can form a 
stable pre-initiation complex by directly contacting and positioning the 40S ribosomal 
subunit in the absence of canonical translation initiation factors to mediate cap-
independent translation initiation (Lukavsky, 2009). Recent small-angle X-ray 
scattering studies showed the IRES to be an articulated molecule made of rigid parts 
which move relative to each other to allow the IRES to undergo a conformational 
change in forming the initiation complex (Perard et al., 2013). 
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The high conservation of the 5′ UTR makes this translation initiation region an 
exploitable target for therapeutics such as anti-sense oligonucleotides (Zhang et al., 
1999). 
 
1.2.7.2 3’ Untranslated Region 
 
The 3’-untranslated region (UTR) is approximately 200-235 nt in length and is 
composed of three regions; from 5' to 3': a variable region about 30–40 nt in length, a 
long U/C-rich region, and a highly conserved 3′-terminal stretch of 98 nt known as the 
3' X region (Figure 1.8B). The variable region is composed of two stem loops and is 
not essential for viral replication but deletions within it significantly reduce RNA 
replication efficiency (Friebe and Bartenschlager, 2002). The U/C-rich region varies 
with genotype, it is essential for replicon viability, and its length is associated with 
efficiency of replication (Friebe and Bartenschlager, 2002). The 3' X region includes 
 
 
 
Figure 1.8 Secondary RNA structure within the HCV genome. (A) Structure of the 5′NTR structures.  
Domains I and II replication whereas domains II, III, and IV form the IRES and are required for 
translation. (B) Structure of the 3′NTR RNA, showing the variable region, the poly U/C domain and the 
3′X. Image reproduced from (Knipe and Howley, 2007). 
 
A B 
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three stem-loop structures SL1, SL2 and SL3 that are highly conserved across the 
genotypes (Knipe and Howley, 2007). The entire X region is essential for translation 
and cross-linking studies have shown SL1 and SL3 to be present in the NS5B 
polymerase while SL2 is hypothesised to form a pseudoknot to allow for multiple 
conformations and interactions with RNA or proteins (Dutkiewicz and Ciesiolka, 
2005) such as NS5A which is believed to play a major role as part of the HCV 
replication complex (Foster et al., 2010). The 3’ UTR interacts with stem-loop 
structures in the RNA polymerase NS5B coding sequence which are thought to 
modulate replication (Lee et al., 2004a). In addition to translation and replication 
regulation, the sequences of 3’ UTR are conceivably involved in physical stabilization 
and packing of viral RNA (Shi and Lai, 2006). 
 
1.2.8 HCV Proteins 
 
Translation of the HCV genome produces 11 viral proteins; core protein, frameshift 
protein, glycoproteins E1 and E2, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B 
(Moradpour et al., 2007). 
 
1.2.8.1 Core Protein 
 
The immature core protein (23 kDa) comprises the N-terminal 191 amino acids of the 
HCV polyprotein and its main function is forming the viral capsid. The amino acid 
sequence of the core protein is highly conserved across the HCV genotypes and can 
be divided into three domains based on their hydrophobicity (McLauchlan, 2000): 
Domain 1 (residues 1-122) is highly basic and contains two short hydrophobic 
regions. It is primarily involved in RNA binding (Shavinskaya et al., 2007) but also 
facilitates nuclear localization via a bipartite nuclear localization signal (Suzuki et al., 
2005). Domain 2 (residues 123-174) is more hydrophobic than domain 1, and 
maintains association of the core protein with the endoplasmic reticulum (ER) 
membrane and lipid droplets (Suzuki et al., 2005) – which is essential for virus 
production (Miyanari et al., 2007). Domain 3 (175-191) is highly hydrophobic and 
serves as a signal peptide for the downstream envelope protein E1. After cleavage and 
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release of the E1 glycoprotein, domain 3 is further processed by signal-peptide 
peptidase (Figure 1.6) to give rise to the mature core protein (21 kDa) and releasing it 
from the ER (McLauchlan et al., 2002). The core protein can homo-oligomerise via 
domains 2 and 3 (Kunkel and Watowich, 2004) to form viral capsids. 
 
In addition to the assembly of the virions, core protein interacts with host proteins to 
interfere with cellular pathways which may be involved in viral pathogenesis 
(McLauchlan, 2000). Core protein alters the expression of cellular genes, and causes 
upregulation of viral promoters such as c-myc (Ray et al., 1995), modulation of 
apoptosis through suppression of the tumour necrosis factor alpha (TNF-a)- and Fas-
mediated apoptotic pathways (Marusawa et al., 1999), stimulation of hepatocyte 
growth through upregulation of growth-related genes (Fukutomi et al., 2005) and 
induces hepatic steatosis and hepatocellular carcinoma when expressed in transgenic 
mice (Moriya et al., 1997; Moriya et al., 1998). 
 
1.2.8.2 Frameshift (F) Protein 
 
Another protein is expressed from the HCV core protein-encoding sequence - the F 
(frameshift) protein or ARFP (alternate reading frame protein). The F protein (17 
kDa) is synthesised from the initiation codon of the HCV polyprotein but with a 
−2/+1 ribosomal frameshift. The gene is conserved between genotypes and antibodies 
to peptides from the F protein are present in chronically infected patient sera 
suggesting the F protein to have a role in the HCV lifecycle (Xu et al., 2001). 
However the precise translational mechanisms which control the frequency and yield 
of the F protein during HCV infection are not known. The frameshift protein is unique 
among Flaviviridae viruses and is localized to the cytosol. It is expressed in very low 
amounts in infected cells making it unlikely to be involved in virus assembly and 
additionally its absence in subgenomic replicons indicates it does not have a role in 
RNA replication – hence its role in HCV lifecycle remains enigmatic (Baril and 
Brakier-Gingras, 2005). 
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1.2.8.3 Glycoproteins E1 and E2 
 
The envelope glycoproteins E1 and E2 consist of 192 and 363 amino acids 
respectively when released from the viral polyprotein by Signal Peptide Peptidase 
(SPP) and are necessary and sufficient components of the virus for receptor binding 
and cell fusion (Bartosch et al., 2003). E1 and E2 have molecular weights of 33-35 
and 70-72 kDa respectively which assemble as a noncovalent E1E2 heterodimer in 
their native form and both proteins are each anchored into membranes via a C-
terminal transmembrane helix. The transmembrane helices consist of two stretches of 
hydrophobic residues flanking a short polar region containing fully conserved charged 
residues which play crucial roles in the assembly of the heterodimer, their localization 
to the ER and their retention in the ER during assembly of virions (Cocquerel et al., 
2001). The N-terminal ectodomains of E1 and E2 are orientated into the ER lumen by 
the C-terminal signal sequence of core and the C-terminal signal sequence in E1 
respectively (Santolini et al., 1994). The ectodomains are heavily glycosylated - 
depending on the genotype of the virus, at up to 6 and 11 sites in E1 and E2 
respectively, are modified by N-linked glycosylation by oligosaccharyltransferase. 
Glycosylation is thought to be important in the folding of the ectodomains and the 
formation of the heterodimer (Lavie et al., 2006). 
 
Viral entry is believed to be a multistep process initiated by E2 binding CD81 
(Rosenberg, 2001) whereas both E1 and E2 appear to be involved in cell fusion 
(Takikawa et al., 2000). In addition E2 interacts and inhibits the interferon-inducible 
protein kinase R (PKR), partly explaining the resistance of some HCV genotypes to 
interferon (Taylor, 1999). E2 contains a high degree of genetic variability within three 
hypervariable regions which are targets for neutralizing antibodies. These regions are 
subject to strong selective pressure yet sequence variations are tolerated allowing the 
virus to evade the immune system and establish persistent infections (Kato et al., 
1993) and explaining the difficulty in developing an HCV vaccine. Furthermore the 
first 27 aa of the E2 N-terminus, which constitute hypervariable region 1 (HVR1), 
show a high conservation of physiochemical properties suggesting an important role 
in the viral lifecycle such as in cell attachment (Penin et al., 2001). 
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1.2.8.4 p7 
 
 Situated between the structural and non-structural proteins in the viral polyprotein is 
p7. p7 (6.7 kDa) is a small 63 aa highly hydrophobic integral membrane protein and is 
classified as a viroporin as it modulates the ion permeability of membranes to 
facilitate virus production. Other viroporins include influenza A virus M2 and HIV-1 
Vpu (Steinmann and Pietschmann, 2010) and genomes of the pestivirus genus appear 
to possess a p7 protein that is analogous to HCV p7 (Elbers et al., 1996). p7 possesses 
two α-helical transmembrane domains and oligomerises in vitro to form an ion 
channel – electron microscopy studies have shown the structure of this channel to a 
resolution of 16 Å and that it consists of a p7 hexamer or heptamer (Luik et al., 2009). 
A recent NMR study (OuYang et al., 2013) showed the channel to form an unusual 
hexameric assembly as a funnel with each p7 monomer spanning out associating with 
remote monomers in addition to proximal monomers (Figure 1.9). 
 
Although the activity of the p7 ion channel is essential for virus infectivity 
(Montserret et al., 2010), its function is not clear. The absence of the p7 gene in 
functional replicon system rules out a role for it in RNA replication (Bartenschlager, 
 
Figure 1.9 NMR structure of p7 viroporin. The structure shows a hexameric assembly with p7 
monomers forming multiple links with immediate and distant neighbouring monomers to form a 
funnel-like architecture. Figure created from PDB ID 2M6X (OuYang et al., 2013). 
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2002). Studies using the JFH-1 culture system showed p7 functions before virion 
morphogenesis and its capacity to form ion channels are essential for the assembly 
and release of infectious virus (Jones et al., 2007). The infectivity of mutant virions 
was not affected inferring viral entry to be independent of p7 (Steinmann et al., 2007). 
Compounds like amantadine, a well-studied inhibitor of the influenza A virus M2 ion 
channel, may potentially be used in the treatment of HCV, by blocking the cation-
permeability of the p7 ion channel (Premkumar et al., 2004; StGelais et al., 2009). 
 
1.2.8.5 NS2-3 Autoprotease and NS2 
 
NS2, together with the N-terminus of NS3, constitute the NS2-3 protease, an 
autocatalytic cysteine protease that cleaves the site between NS2 and NS3 – a process 
that is essential for complete viral replication (Welbourn and Pause, 2006). The 
crystal structure of the NS2 C-terminus revealed it to form a dimeric domain swapped 
enzyme with two composite active sites (Lorenz et al., 2006). The function of the 
NS2-3 protease appears to be limited to autoproteolytic cleavage at the NS2-3 
junction but it may have central regulatory properties before releasing the NS3 
protease to cleave the downstream sites of the polyprotein (Welbourn and Pause, 
2006). 
 
After cleavage from NS3, NS2 is a short-lived protein that is targeted for degradation  
in a phosphorylation-dependent manner via protein kinase casein kinase 2 (Franck et 
al., 2005). NS2 (23 kDa) associates with the ER membrane via an N-terminal 
hydrophobic region (Santolini et al., 1995). The cleaved NS2 protein may have roles 
in the modulation of NS5A hyperphosphorylation, host gene expression and apoptosis 
(Welbourn and Pause, 2006), and interacts with the HCV structural and non-structural 
proteins in viral assembly (Popescu et al., 2011). 
 
1.2.8.6 NS3 and NS4A 
 
NS3 (68 kDa) is a multi-functional protein consisting of an N-terminal serine protease 
domain and a C-terminal helicase/NTPase domain separated by a single peptide 
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strand. NS4A (6 kDa) is a cofactor and regulator of NS3 protease activity. The NS3-
4A protease is essential for the HCV lifecycle for the catalysis of HCV polyprotein 
cleavage at the NS3/NS4A, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B junctions 
(Knipe and Howley, 2007). 
 
Crystal structures of the NS3 protease domain complexed with a NS4A peptide show 
it to comprise a chymotrypsin-like fold and a tetrahedrally coordinated metal ion 
distal from the active site where the catalytic triad is formed by the NS4 residues His-
57, Asp-81, Ser-139 (Kim et al., 1996) (Figure 1.10). NS3-4A cleavage occurs in cis, 
following by the trans-cleavage of the non-structural proteins by the mature NS3/4A 
protease with a preferential order of cleavage at the NS5A–NS5B > NS4A–NS4B > 
NS4B–NS5A junctions (Bartenschlager et al., 1994). Such relatively stable 
intermediates may have roles in the viral lifecycle as in other positive strand RNA 
viruses where such partial cleavage products show distinct independent activities 
(Sklan and Glenn, 2006). In addition to polyprotein processing, the NS3/4A protease 
is implicated in the cleavage of host cell signalling proteins to evade immune 
response and promote persistent infections (Li et al., 2005). 
 
The NS3 C-terminus encodes helicase and nucleoside triphosphatase activities. The 
crystal structure of the NS3 helicase with a bound oligonucleotide shows it to be a 
member of superfamily II helicases. The helicase consists of three structural domains 
with DNA held orthogonally in a cleft between the first two domains and the third 
(Kim et al., 1998). The helicase efficiently unwinds RNA-RNA, RNA-DNA and 
DNA-DNA duplexes (Gallinari et al., 1998) and although its exact function is 
unknown, it is essential and may have a role in dissociation of negative and positve 
RNA strands during viral replication (He et al., 2006). The need for the protease and 
helicase activities of NS3 to be physically linked is not understood, although NS5B 
has been shown to upregulate the helicase activity through association with the 
protease domain (Zhang et al., 2005). 
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Figure 1.10 Crystal structure of NS3/4A protease in complex with Telaprevir. Figure created from 
PDB ID 3SV6 (Romano et al., 2012). 
 
The 54 amino acid NS4A protein is an essential cofactor for full NS3 protease 
activity. In addition to intercalating into the amino terminal sequences of NS3 to form 
the catalytic site (Kim et al., 1996), an N-terminal alpha-helix of NS4A mediates 
membrane localisation of the NS3-4A protease (Brass et al., 2008) potentially 
allowing it to contribute to the assembly of the replicase complex. 
 
1.2.8.7 NS4B 
 
The 261 amino acid protein NS4B (27 kDa) is an integral membrane protein and 
although its exact function remains unknown, it is involved in the formation of the 
endoplasmic reticulum-derived membranous web, modulation of NS5B and various 
host signal transduction pathways (Sklan and Glenn, 2006). NS4B is predicted to 
contain at least four transmembrane domains, an N-terminal amphipathic helix and C-
terminal amphipathic helix which mediates membrane association and HCV 
replication complex formation (Elazar et al., 2004). Due to its hydrophobic nature, 
experimental studies of NS4B are challenging and other than the N-terminal and C-
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terminal amphipathic helices (Gouttenoire et al., 2009a; Gouttenoire et al., 2009b), 
NS4B remains structurally uncharacterised. 
 
NS4B is cotranslationally targeted to the ER membrane (Hügle et al., 2001) and NS3-
4A releases NS4B from the viral polyprotein. A variety of partial cleavage products 
arise such as NS4B-5A and the relatively stable NS4A-4B-5A intermediate 
(Bartenschlager et al., 1994) which may have activities independent from the 
completely processed individual proteins. The topology of the NS4B N-terminus 
changes post-translationally, giving NS4B a fifth transmembrane segment (Figure 
1.11) and this translocation is influenced by NS5A (Lundin et al., 2006). 
  
  
Figure 1.11 Schematic representation of NS4B and its topology with respect to the ER membrane. 
Shown are the two N-terminal amphipathic helices (AH1 and AH2), transmembrane domains 1 to 4 
(TM1-4), and the C-terminal helices (H1 and H2). A fraction of NS4B is post-translationally 
translocated whereby the NS4B N-terminus adopts an luminal configuration creating a fifth 
transmembrane domain with AH2 – a transition which is reduced by the presence of NS5A in vitro. 
Image reproduced from (Dvory-Sobol et al., 2010). 
 
NS4B is responsible for inducing morphological changes to the endoplasmic 
reticulum and forming the membranous web (Egger et al., 2002a) and a platform for 
the recruitment of other viral proteins and HCV replication (Sklan and Glenn, 2006). 
Furthermore NS4B may regulate the activity of the replication complex through its 
intrinsic GTPase activity (Einav et al., 2004). In addition NS4B is implicated in 
modulating NS5B RdRp activity, the inhibition of cellular syntheses, the modulation 
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of the production of cytokines such as interleukin-8 (Sklan and Glenn, 2006), and 
transformation and tumor formation (Einav et al., 2008). 
 
1.2.8.8 NS5A 
 
The NS5A protein first attracted attention due to its potential function in disrupting 
the intracellular interferon (IFN) signalling pathway (Enomoto et al., 1995). NS5A is 
an integral part of HCV and like many viral gene products is pleiotropic with roles in 
viral RNA replication, virus assembly and modulating multiple cellular pathways 
(Huang et al., 2005; Hanoulle et al., 2009b). NS5A has no known intrinsic enzymatic 
activity, no close sequence homologues nor recognizable functional motifs, and any 
specific functions of NS5A in RNA replication have remained a mystery since initial 
studies almost two decades ago (Ide et al., 1996; He et al., 2006). NS5A is thought to 
fulfil its multiple functions through interactions with host and other viral factors 
(Schmitz and Tan, 2008). 
 
Structural Features of NS5A 
 
NS5A is a 447 amino acid proline-rich hydrophilic phosphoprotein. The protein is 
made up of three domains (Figure 1.12) separated by low-complexity sequences 
(LCS1 and LCS2) as identified by comparative sequence analyses and verified by 
limited proteolysis experiments (Tellinghuisen et al., 2004). The domain 1 (a.a. 1–
213) N-terminus contains a membrane-anchoring amphipathic helix (AH) (Brass et 
al., 2002) and a folded globular region whose structure is essential for virus 
replication (Tellinghuisen et al., 2004). Domains 2 (a.a. 250–342) and domain 3 (a.a. 
356–447) appear to form an intrinsically unstructured region of the protein making 
their study more challenging (Liang et al., 2007; Hanoulle et al., 2009b). This 
flexibility in structural conformation presumably allows for vast range of interactions 
of NS5A (Macdonald and Harris, 2004) and it has been show that the unstructured 
domains can adopt structure to associate with binding partners (Gupta et al., 2012). 
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The N-terminal AH is necessary and sufficient for the association of NS5A with the 
ER membrane. The membrane association of NS5A protein occurs post-
translationally and confers NS5A with similar properties to that of an integral 
membrane protein (Brass et al., 2002). A three-dimensional structure of this region 
was solved by NMR spectroscopy (Penin et al., 2004) revealing an α-helix extending 
from aa 5 to 25 (Figure 1.12). The AH lies parallel to lipid membranes with its 
hydrophobic side buried within detergent micelles and its polar, charged side being 
solvent-exposed. These cytosolic residues of the helix may contribute to protein-
protein interactions with additional viral and cellular components (He et al., 2006), as 
mutations which disrupt helix formation reduce the efficiency of HCV replication 
(Elazar et al., 2003). 
 
NS5A Domain I is the most conserved region of NS5A and contains a zinc-binding 
motif necessary for domain I structural stability (Figure 1.12). The zinc-binding motif 
involves four cysteine residues C39, C57, C59, and C80 and this structural motif is 
conserved within Hepaciviruses and Pestiviruses genera. Mutation of any single 
cysteine residue in the motif disrupts zinc coordination by NS5A and abolishes HCV 
replicon RNA replication (Tellinghuisen et al., 2004; Tellinghuisen et al., 2006). 
Pulldown assays have revealed that the zinc-binding motif is critical for dimerization 
and RNA binding (Lim et al., 2012). However it is not known whether this motif is 
required for an enzymatic activity or purely the structural stability of NS5A.  
 
NS5A domain 1 crystal structures have revealed that it may form dimers. Although 
the formation of multimers or protein-protein contacts are inevitable consequences of 
protein crystallisation (Carugo and Argos, 1997), there is some evidence of 
dimerization in solution (Huang et al., 2005) and as discussed below NS5A-targeting 
compounds are speculated to act on a NS5A dimer (Bartenschlager et al., 2013). The 
first crystal structure of a NS5A domain 1 construct consisting of residues 25 to 215 
from genotype 1b, revealed it consist of two subdomains and to contain a novel fold 
with a stabilising disulfide bond. Additionally the asymmetric unit comprised a dimer 
with a intermolecular interface of approximately 830 Å
2
, which forms a large groove 
with the appropriate dimensions to accommodate single- or double-stranded RNA 
 59 
 
(Tellinghuisen et al., 2005) - this dimer has served as the basis for the working model 
of the NS5A domain 1. Crystallisation of NS5A domain 1 construct from the same 
genotype and subtype containing residues 33 to 202 resulted in higher resolution 
structures and showed the NS5A domain 1 to form an alternative dimer with a 910 Å
2
 
dimeric interface. The two dimers may be a result of the different crystallization 
conditions such as protein concentration, however these dimers may represent 
different oligomeric snapshots of NS5A. Through combining the two dimers, it was 
postulated how a NS5A superhelical array could form that tether viral RNA to 
intracellular membranes and shield it from degradation and being sensed by pattern 
recognition receptors (Love et al., 2009). The first crystal form does not seem to be 
reproducible and soaks of the second crystal form with compounds has yet to yield 
structures of ligand-bound complexes (unpublished data from Arrow Therapeutics 
Ltd.). Recent GST pull-down experiments with NS5A constructs provided 
biochemical evidence that dimerization of NS5A occurs through domain 1 of NS5A. 
This dimerization was found to be unaffected by the presence of NS5A inhibitors 
whereas the presence of Zn
2+
 assisted dimerization and the four cysteines forming the 
zinc-binding motif were critical for dimerization (Lim et al., 2012). 
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Important regions of NS5A include the IFN-sensivity-determining region (ISDR) 
sequence which inhibits IFN-induced RNA-dependent protein kinase (PKR) (Gale et 
al., 1997). The ISDR sequences from different HCV genotypes have been associated 
with different responses to interferon treatment (Yen et al., 2008), however whether 
mutations within the ISDR are linked with different responses to treatment remains 
controversial (Munoz de Rueda et al., 2008). The C-terminal portion of NS5A 
contains a sequence that acts as a nuclear localization signal (NLS) (Ide et al., 1996). 
 
 
 
Figure 1.12 Schematic structure of NS5A with putative functional regions. Zinc motif, 
hyperphosphorylation sites, ISDR, polyproline motif, NLS. Domain 1 contains a N-terminal 
amphipathic helix, the structure of which has been solved by NMR spectroscopy (Penin et al., 2004). 
Crystal structures exist for the rest of domain 1 which contains a zinc motif (shown in the cartoon as a 
sphere coordinated by the Cys 39, 57, 59, 80 side chains shown as sticks) essential for NS5A structural 
integrity and replicon viability (Tellinghuisen et al., 2005; Love et al., 2009), and RNA-binding 
properties (Huang et al., 2007). Residues Cys 142 and 190 (shown as sticks) are observed to form a  
disulfide bond (Tellinghuisen et al., 2005). Residues 222, 225, 229, and/or 232 in the linker region 
between domains 1 and 2 are hyperphosphorylated (Tanji et al., 1995). Numbering according to HCV 
1b Con1. Figure structures created from PDB IDs 1R7C and 1ZH1. 
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Subcellular Localization of NS5A 
 
NS5A is mostly localized in the cytoplasmic and perinuclear compartments of the cell 
(He et al., 2006). NS5A associates with the endoplasmic reticulum (ER) or ER-
derived compartments through its N-terminal AH when expressed alone or in the 
context of the entire HCV polyprotein (Brass et al., 2002) forming part of the 
membranous web (Gosert et al., 2003). NS5A colocalizes with the core protein on 
lipid droplets to potentially regulate viral assembly (Shi et al., 2002; Miyanari et al., 
2007). Recent work using pulse-chase imaging to investigate the dynamics of NS5A 
showed that newly synthesized NS5A to be localized to foci before maturation to sites 
of HCV replication and viral assembly. Additionally the same study, NS5A was found 
to transient interactions with HCV core protein and its transport was microtubule-
dependent (Eyre et al., 2014).  
 
A putative nuclear localization signal (NLS) sequence consisting of aa 354-362 as 
PPRKKRTVV (Ide et al., 1996). NS5A remains localised to the cytosol due to an 
NLS-masking sequence at aa 27-38 (Song et al., 2000), however truncated forms of 
NS5A may be transported to the nucleus by the NLS and regulate cellular gene 
transcription as fusions with the NS5A C-terminus function as transcriptional 
activator (Kato et al., 1997). A confocal microscopic analysis of HCV replicating 
cells showed that N-terminally truncated NS5A fragments are localised within the 
nucleus which may represent a mechanism of the virus to regulate its replication by 
removal of essential factors such as c-Raf, from the replication complex (Sauter et al., 
2009). 
 
Phosphorylation States of NS5A 
 
NS5A exists in basally phosphorylated (56 kDa) or hyperphosphorylated (58 kDa) 
forms (p56 and p58) but the precise phosphorylation sites are not yet fully mapped 
(Macdonald and Harris, 2004; Tellinghuisen et al., 2008a). The phosphorylation of 
NS5A is complex and the multiple kinases involved are thought to be highly regulated 
and coordinated (Huang et al., 2007). Different phosphorylation patterns may exist 
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across HCV genotypes, for example genotype 1 isolates contain hyperphosphorylated 
NS5A whereas HCV genotype-2a strains do not (Hirota et al., 1999) - such altered 
phosphorylation states may explain differences in viral pathogenesis and virological 
features between genotypes. Through comparing in vivo and in vitro NS5A 
phosphopeptide profiles, several mammalian kinases (PKA, AKT, p70S6K, MEK1, 
MKK6, and CK II) are thought to be responsible for NS5A phosphorylation (He et 
al., 2006). The phosphorylation sites of NS5A occur predominantly on serine 
residues, with a minor fraction on threonine residues. Basal phosphorylation of NS5A 
occurs within domains 2 and 3 (Tanji et al., 1995) whereas a number of serine 
residues (222, 225, 229, and/or 232) in the central region of NS5A were found to be 
important for hyperphosphorylation (Figure 1.12). In a recent effort to understand 
NS5A phosphorylation sites and their regulatory function, mass spectrometry was 
used to identify the phosphorylation sites of NS5A purified from a JFH-1 subgenomic 
replicon (Ross-Thriepland and Harris, 2014). This study provided unambiguous 
biochemical evidence that serines 146, 222, and 225 and threonine 348 were 
phosphorylated. Further phenotype profiling showed phosphorylation at S146 to be 
involving in regulating NS5A hyperphosphorylation. In addition 
hyperphosphorylation of NS5A is thought to be dependent on other HCV non-
structural proteins, such as the association of NS4A, the presence of NS3-4A protease 
activity in cis, as well as mutations within NS4A and NS4B which do not affect 
polyprotein processing but affected p58 production (Neddermann, 2009). Such results 
suggest the complicated NS5A phosphorylation patterns are regulated by the context 
of the replication complex. NS5A interacts with human vesicle-associated membrane 
protein-associated protein A (hVAP-A) to form the replication complex (Tu et al., 
1999) allowing for HCV RNA replication. Cell culture adaptive mutations which 
block hyperphosphorylation prevent NS5A interacting with hVAP-A and 
considerably reduce RNA replication (Evans et al., 2004) suggesting a model where 
NS5A hyperphosphorylation negatively regulates RNA replication. Additionally 
genetic mapping of JFH-1 NS5A phosphorylation sites revealed a conserved casein 
kinase II (CKII) phosphorylation site containing serine 457; substitution of serine 457 
by aspartic acid reduced RNA replication but had no effect on viral assembly, 
implicating phosphorylation of serine 457 of NS5A as a transitional switch between 
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RNA replication and viral assembly (Tellinghuisen et al., 2008a), suggesting NS5A to 
play a pivotal role in regulation of the replication complex.  
 
RNA-binding properties of NS5A 
 
The essential role of NS5A in HCV RNA replication and its ability to ability to 
associate with the RdRp NS5B prompted researchers to probe NS5A for functions 
related to RNA replication. NS5A was discovered to be a novel structural class of 
RNA-binding proteins. The full length protein was found to bind to the 3′ ends of 
HCV plus and minus strand RNA showing a preference for uridylate- and guanylate-
rich RNA and binding was not dependent upon NS5A phosphorylation (Huang et al., 
2005). Further work established the minimal binding domain of NS5A to consider of 
residues 33 to 249 and a cross-linking experiment showed that an NS5A dimer is 
involved in binding RNA(Hwang et al., 2010). Mapping of the residues involved in 
the cross-linking showed a pattern which is consistent with the groove present in the 
Tellinghuisen dimer (Tellinghuisen et al., 2005). It was later shown that domain 3 
showed low in vitro RNA binding capacity and more importantly that domains 1 and 
2 of NS5A form a specific interaction with the 3′ end of UTR RNA (Foster et al., 
2010). This suggests NS5A could function in regulating a switch from translation of 
the genome to replication of the HCV genome and in recruiting replicase components 
to the HCV RNA. 
 
NS5A as a Regulator of HCV Replication 
 
NS5A was first suspected to play an important role in HCV RNA replication due to 
many cell culture adaptive mutations mapping to domain 2 of the protein (Krieger et 
al., 2001). Indeed deletion mutagenesis studies showed domain 2 of NS5A to be 
essential for HCV RNA replication (Tellinghuisen et al., 2008b). Some adaptive 
mutation sites within the domain 2 of NS5A correlated with phosphorylation sites 
suggesting NS5A phosphorylation to have a function in RNA replication (He et al., 
2006). As mentioned, adaptive mutations in NS5A blocked its dissociation with 
hVAP-A resulting in an increase in HCV RNA replication activity – leading to a 
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proposed model whereby the phosphorylation state of NS5A provides a molecular 
switch in HCV RNA replication with the hyperphosphorylation of NS5A leading to 
its dissociation with replication complex components such as hVAP-A and reduced 
viral RNA replication (Evans et al., 2004). This model was further supported by the 
inhibition of the formation the NS5A-p58 with kinase inhibitors resulting in decreased 
viral RNA replication activity (Neddermann et al., 2004). Expression of a wild-type 
NS5A in NS5A-adapted replicons resulted in an inhibition of their replication 
suggesting hyperphosphorylated NS5A down-regulates HCV RNA replication with a 
dominant negative effect (Graziani and Paonessa, 2004). 
 
Inhibitors of cyclophilins (Cyps), which catalyse the cis/trans isomerisation of proline 
residues at peptide bond linkages, cause an anti-HCV effect. The cyclophilin known 
as CypA is thought to be the main mediator of this inhibition of HCV replication 
(Kaul et al., 2009). Domain 2 of NS5A was shown to be substrate of CypA (Hanoulle 
et al., 2009a) and the interaction of CypA with NS5A was shown to stimulate NS5A 
domain 2 RNA binding activity exploiting this host cell mechanism to enhance the 
replicative ability of the virus (Foster et al., 2011). 
 
NS5A has multiple interactions with other HCV replicase components. NS5A binds 
NS5B to regulate its RdRp activity (Shirota et al., 2002) and exhibits high affinity to 
the 3′ ends of HCV plus- and minus-strand RNAs (Huang et al., 2005; Hwang et al., 
2010). Domain 3 of NS5A appears to be dispensable for RNA replication and is 
involved in the assembly of HCV particles through interactions with the core protein 
(Appel et al., 2008; Hanoulle et al., 2009b). The precise role of NS5A is further 
complicated by the many interactions it forms with host proteins. 
 
NS5A in HCV Assembly 
 
The membranous web is considered to represent the site of viral assembly in addition 
to HCV RNA replication as the HCV non-structural proteins and nascent viral RNA 
are all present in these structures (Moradpour et al., 2007) with assembly proposed to 
take place on lipid droplets. NS5A is essential for the assembly of infectious HCV 
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particles (Appel et al., 2008) and it could regulate HCV virus assembly through its 
interaction with the HCV core protein (Goh et al., 2001). The hyperphosphorylation 
of NS5A is speculated to serve as a switch between HCV RNA replication and virion 
assembly (He et al., 2006) and domain III of NS5A is thought to play a role in virion 
production as mutations in this domain impair production of infectious virions 
(Tellinghuisen et al., 2008a). The phosphorylation status of serine residues near the 
C-terminus of NS5A appears to regulate viral assembly (Gao et al., 2004) and 
experiments with viruses containing chimeric NS5A show this to lie within a C-
terminal serine/threonine cluster in domain 3 of NS5A (Kim et al., 2011). Recently it 
was shown that other phosphorylated sites of NS5A such as serine 222 regulate NS5A 
hyperphosphorylation and could be involved in the regulation of viral assembly. It is 
speculated that the phosphorylation status of NS5A could drive a conformational 
switch between NS5A dimeric species explaining its multiple roles in the viral 
lifecycle (Ross-Thriepland and Harris, 2014). 
 
NS5A and Cellular Pathways 
 
In addition to roles in viral replication and assembly, NS5A has a plethora of putative 
interaction partners (Table 1.1) and is implicated in the modulation of the host 
interferon response, the host cell cycle, apoptosis and stress-responsive pathways 
(Macdonald and Harris, 2004). 
 
NS5A is known to disrupt the host interferon response system through ISG regulation. 
NS5A stimulates IL-8 production which results in attenuation of ISG expression. In 
addition, NS5A binds protein kinase R (PKR) through its ISDR (Gale et al., 1997) 
leading to PKR inhibition and allowing HCV to evade the translational-suppressive 
actions of IFN and the PKR-dependent signalling processes of the interferon response 
(Gale and Foy, 2005). Recently it was shown that the NS5A C-terminus bound to the 
STAT1, a signal transducers and activators of transcription, and disrupted its 
phosphorylation leading to decreased levels of P-STAT1, ISRE signaling, and ISG 
transcription (Kumthip et al., 2012) explaining a possible mechanism of increased 
resistance to IFN treatment. 
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Protein 
 
Protein category 
 
Function of interaction 
 
PKR Cellular antiviral kinase Repression of PKR and downstream 
pathways 
Grb2 Cell signaling adaptor protein Disruption of downstream mitogenic 
signaling 
p85 PI3K Cellular kinase Up-regulation of PI3K/AKT survival 
pathway 
Hck, Lck, Lyn, Fyn Cellular Src family kinases Possible regulation of NS5A 
phosphorylation 
ApoA1 Cellular apolipoprotein Colocalization in the Golgi apparatus 
hVAP-33/hVAP-A Cellular membrane protein HCV RNA replication complex 
p53 Cellular transcription factor Inhibition of transcriptional transactivation 
by p53 
Bax Cellular pro-apoptotic protein Inhibition of apoptosis 
Cdk1 Cell cycle control protein Cell growth and cell cycle perturbations 
FBL2 Cellular geranylgeranylated 
protein 
Involved in HCV replication 
CKII Cellular CMCG family kinase NS5A phosphorylation 
PTX1 Cellular homeodomain protein Perturbation of IFN response 
hTAF(II)32/(TFIID) Transcriptional coactivator Inhibition of transcriptional transactivation 
by p53 
TBP Cellular transcription factor Inhibition of transcriptional transactivation 
by p53 
Jak1 Cellular IFN signaling kinase STAT3 activation 
STAT1 Signal transducer and activator 
of transcription 
Perturbation of IFN response 
 
 
Table 1.1 Some cellular proteins known to interact with NS5A. Table adapted from (Macdonald and 
Harris, 2004). 
 
NS5A contains three polyproline motifs which allow it to interact with numerous 
proteins containing SH3 domains including Grb2, amphiphysin II and members of the 
Src tyrosine kinase family: Hck, Lck, Lyn and Fyn. These interactions are implicated 
in the regulation of signalling pathways such as the Ras/Erk MAPK pathway 
(Macdonald et al., 2005) and may have roles in the regulation of HCV RNA 
replication through the regulation of cellular kinase activity (Gretton et al., 2010).  
 
The pivotal role of NS5A makes it an ideal target for inhibition. Recently compounds 
which target NS5A such as Daclatasvir (DCV) have shown to have strong anti-HCV 
activity against several genotypes in both replicon and infectious cell culture systems 
and in clinical trials DCV shows a rapid decline in HCV RNA levels with no signs of 
adverse side effects (Gao et al., 2010). Future HCV combinatorial drug regimens are 
likely to contain NS5A inhibitors.  
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1.2.8.9 NS5B 
 
The 591 amino acid NS4B (65 kDa) protein is the RNA-dependent RNA Polymerase 
(RdRp) of HCV (Rosenberg, 2001). The NS5B polymerase, similar to other RdRps 
and the HIV reverse transcriptase, lacks an exonuclease or proofreading domain and 
has a low fidelity - misincorporating nucleotides with an estimated error rate of 10
-4
 to 
10
-5
 per nucleotide per round of replication (Margeridon-Thermet and Shafer, 2010). 
NS5B is part of the class of membrane proteins designated tail-anchored proteins as it 
is associated to membranes via a 21 aa C-terminal transmembrane domain which 
posttranslationally targets NS5B to the cytosolic side of the ER (Moradpour et al., 
2004). The crystal structure of the 531 N-terminal aa of NS5B reveal its cytosolic 
catalytic domain to be folded in the classic right hand fingers, palm, and thumb 
subdomain structure of other polymerases (Bressanelli et al., 1999) (Figure 1.13). 
Extensive interactions between the fingers and thumb subdomains result in a fully 
enclosed catalytic site for the synthesis of positive- or negative-strand HCV RNAs 
and de novo initiation is the most plausible mode of RNA synthesis as nucleotide 
binding causes minor structural changes (Ranjith-Kumar and Kao, 2006). Another 
atypical feature of NS5B is a beta-hairpin in the thumb subdomain which is proposed 
to interfere with NS5B binding to double stranded RNA (Hong et al., 2001) or to 
position the 3′ terminus of the viral RNA to ensure correct initiation (Ranjith-Kumar 
and Kao, 2006). In addition the C-terminus is thought to have a direct role in the 
regulation of RNA synthesis activity in vivo (Lee et al., 2004b). 
 
Furthermore the C-terminus of NS5B interacts with the N-terminus of hVAP-33 – 
perhaps to serve an important function in the formation of the HCV replication 
complex (Gao et al., 2004) and NS5A binds NS5B to regulate its RdRp activity 
(Shirota et al., 2002). 
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Figure 1.13 Crystal structure of NS5B in complex with the non-nucleoside inhibitor IDX375. Figure 
created from PDB ID 4EAW (to be published). 
 
1.2.9 Treatment of HCV 
 
Despite the historic lack of effective treatments for HCV, it remains one of a few 
chronic diseases where a cure is possible (Rice, 2011). Following the eradication of 
the virus (serum HCV RNA levels below the limit of detection of at least 50 IU/ml) 
from a course of HCV treatment, it was often found that a virologic relapse would 
occur - where the virus would again become detectable after cessation of treatment. 
The sustained virological response (SVR), which is defined as serum HCV RNA 
levels below the limit of detection 24 weeks after the completion of treatment is 
considered ‘tantamount to a cure’ as almost all patients who achieve it remain 
aviremic for over a decade (Dieterich et al., 2009). Outcome to treatment is dependent 
on a number of host and viral factors. Patients infected with the more widespread 
HCV genotype 1 are the less responsive to past standards of treatment than those with 
genotype 2 or 3 strains (Manns et al., 2001). 
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1.2.9.1 Peginterferon-alpha and Ribavirin 
 
Before the identification of HCV as the aetiological agent of NANBH, early antivirals 
such as acyclovir were used in its treatment unsuccessfully (Pappas et al., 1985). Due 
to the success of interferon in the treatment of Hepatitis B, Interferon-alpha (IFN-α) 
was used to treat NANBH and showed early promise albeit only partial efficacy 
(Hoofnagle et al., 1986). Optimisation of the dosage and length of IFN-α treatment 
allowed the obtainment of SVR rates of approximately 16% from 6%. Subsequent 
studies in the 1990s showed that combining IFN-α with ribavirin (RBV) raised SVR 
rates to about 42% (Strader and Seeff, 2012). Finally the PEGylation of IFN-α 
improved the half-life of the unmodified biologic and further improved SVR rates to 
about 55% (Zeuzem et al., 2000; Strader and Seeff, 2012) with the combination of 
peginterferon-alpha and RBV - which has remained the backbone of HCV treatment 
and Standard of Care for more than a decade.  
 
The peginterferon-alpha and RBV (PEG IFN-α/RBV) is considered inadequate due to 
its long duration of treatment of 48 weeks, the requirement for the interferon to be 
administered through a subcutaneous injection, and its adverse side effects including 
influenza-like symptoms, fatigue, nausea, anaemia and depression (Fried, 2002). 
Furthermore the treatment only succeeds about 50% of the time leaving non-
responders and relapsers to the mercy of the virus or the poorer prospects of 
retreatment with success rates below 20% (Schlütter, 2011). 
 
Response to the past standards of treatment to HCV consisting of PEG IFN-α/RBV 
treatment has long known to have had a genetic component, since the probability of 
patients’ SVR was linked with their ethnic origins. The discovery of polymorphisms 
in the IL28B gene, encoding interferon-lambda-3 (IFN-lambda-3) explained this 
change in the response of patients to treatment and provided an accurate predictor of 
an individual’s response, hence delivering on a decade-old promise of genomics to 
serve the clinic (Ge et al., 2009). 
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1.2.9.2 Current HCV Treatment 
 
In 2011, the first direct-acting antivirals (DAAs) were approved for treatment of 
HCV, consisting of the PIs Telaprevir (Vertex Pharmaceuticals) or Boceprevir (Merck 
& Co.). The PIs target the HCV genotype 1 nonstructural 3/4A protease and 
significantly lower HCV RNA levels. However resistance mutations soon develop in 
monotherapy, hence the PIs must be used in combination with peginterferon-alpha 
and RBV. This new standard of care for HCV offers increased SVR rates of both 
treatment-naïve patients and non-responders, but the treatment is associated with an 
increase in side-effects, is limited to treat HCV genotype 1 infections and still leaves 
many patients without a cure (Schlütter, 2011). Hence there remains an urgent need 
for better interferon-free HCV treatment in the form of combination therapies. 
 
1.2.9.3 HCV Treatments in Development 
 
In addition to second generation PIs – which have pan-genotype specificity and a 
higher barrier to drug resistance, there are novel PIs in development which target NS3 
through a different MOA (Saalau-Bethell et al., 2012). The next major class of HCV 
DAAs in the drug development pipeline target the RdRp NS5B and can be divided 
into nucleoside/nucleotide analogue inhibitors (NIs) – which compete with natural 
nucleotides to terminate viral RNA synthesis, and non-nucleoside analogue inhibitors 
(NNIs) – which bind at allosteric sites (Powdrill et al., 2010). The emergence of 
NS5A as an attractive antiviral target will be discussed in the next section.  
 
Non-traditional targets for antivirals include the host proteins such as cyclophilin – 
which is an essential host factor in the HCV lifecycle (Hopkins et al., 2012), and 
cellular caspases - inhibitors of which could mitigate the negative effects of chronic 
HCV infection (Masuoka et al., 2009). Other potential targets include host receptors 
(Syder et al., 2011), NS4B (Dvory-Sobol et al., 2010) – which include inhibitors of 
NS4B interacting with RNA or the membrane, and p7 (Luscombe et al., 2010) – 
inhibitors of which include amantadines and rimantadine, two well-characterised 
inhibitors of the influenza A virus M2 ion channel. 
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With compounds targeting multiple aspects of the HCV lifecycle, HCV combination 
therapies are expected to form the new standards of care. The first all-oral HCV 
therapies are close to approval (Tse, 2013), new treatment regimens offer the 
possibility of treating all HCV genotypes (Schlütter, 2011)  and there are reports of 
100% SVR rates in trials with some combination treatments. Inhibitors targeting 
NS5A are likely to form an important part of future combination therapies. 
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1.3 NS5A as a HCV Antiviral Target 
 
For a long time NS5A was not considered as a drug target as it has no known 
enzymatic activity. Much interest arose in NS5A however after pharmaceutical 
companies utilised forward chemical genetics approaches efforts to identify anti-HCV 
compounds which targeted HCV RNA replication with new MOAs – whereby drug 
targets are identified through the phenotypic screening of chemical libraries 
(Stockwell, 2000). Whole cell screening found new hit compounds which appeared 
not to affect traditional targets such as the NS3 protease and NS5B polymerase and 
the generation of resistance mutants indicated NS5A is affected. NS5A is an attractive 
antiviral target due to its pivotal role in the HCV RNA replication with interactions 
with viral and host factors and its capacity to bind RNA, and that there are no 
sequence homologues within eukaryotic genomes (Tan and He, 2011). How these 
molecules affect and/or inhibit NS5A is still under speculation and investigation. 
 
Several NS5A inhibitors are in development and are characterised by exceptional 
(picomolar) potencies (Table 1.2). Most of the chemical structures of these 
compounds are not disclosed, however patent literature suggests they are generally 
similar to Daclatasvir (DCV, formerly BMS-790052), allowing it to serve as an 
archetype molecule for NS5A inhibitors (Belda and Targett-Adams, 2012). DCV has 
EC50 values of 9 pM and 50 pM against HCV genotype 1b and 1a replicons 
respectively and a therapeutic index (CC50/EC50) of at least 100,000 (Gao et al., 2010) 
making this class of HCV inhibitor the most potent antiviral molecules ever 
discovered. 
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Compound Company In vitro EC50 (pM) Phase 
Genotype 1b Genotype 1a  
BMS-790052 
(Daclatasvir) 
Bristol–Myers 
Squibb 
9 50 III 
GS-5885 
(Ledipasvir) 
Gilead 4 34 II 
ABT-267 Abbott 5 14 II 
GSK-2336805 GlaxoSmithKline 8 44 II 
ACH-2928 Achillion 2-3 46 I 
ACH-3102 Achillion 4 10 I 
PPI-461 Presidio 10 210 I 
PPI-668 Presidio 10 100 I 
IDX719 Idenix 3 8 I 
EDP-239 Enanta/Novartis 4 34 PC 
MK-8742 Merck 3 4 PC 
 
 
Table 1.2 NS5A-targeting molecules in clinical development. Adapted from (Belda and Targett-
Adams, 2012) who collated data from conference presentations. 
 
1.3.1 Development of DCV 
 
Using a chemical genetics approach, researchers at Bristol-Myers Squibb screened 
over 1 million compounds on an HCV genotype 1b replicon system in Huh-7 liver 
cells. Compounds from libraries were screened in parallel in a BVDV replicon system 
and with naïve Huh-7 to eliminate non-HCV-specific and cytotoxic compounds 
respectively. Active inhibitors were further triaged to discard inhibitors of unrelated 
viruses and established HCV targets such as the NS3 protease, NS3 helicase and 
NS5B polymerase. This project resulted in the identification of a novel-class of HCV 
inhibitors with the discovery of BMS-858 (Bristol-Myers Squibb, Wallingford, CT, 
USA), a weak but specific inhibitor of HCV RNA replication (Gao et al., 2010). 
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Resistance mapping studies revealed the antiviral activity to be mapped to the NS5A 
N-terminus and the genotypes of these resistant mutants were validated by reverse 
genetics (Lemm et al., 2010) giving the first indications that these compounds might 
be interacting with NS5A. BMS-858 was found to undergo oxidation and structural 
rearrangement events in the DMSO present in the cell culture medium. Bioassays of 
HPLC fractions determined the active compound which was determined to be dimeric 
with a stilbene core by NMR and mass spectrometry (Romine et al., 2011). This 
symmetry was established as a key factor in the antiviral activity of these compounds 
targeting NS5A, particularly with respect to pan-genotype inhibition (Lemm et al., 
2011). Subsequent SAR profiling and structural refinements lead to the identification 
of Daclatasvir (DCV), a symmetrical homodimeric biphenyl-based compound (Figure 
1.14), with high potency against HCV NS5A from genotypes 1a and 1b (Belda and 
Targett-Adams, 2012; St Laurent et al., 2012; Belema et al., 2013; Lopez et al., 2013; 
St Laurent et al., 2013). 
 
1.3.2 Clinical Trials with NS5A inhibitors 
 
The efficiency of DCV as an HCV antiviral was evaluated in phase I clinical trials 
which showed the drug to be nontoxic at concentrations significantly exceeding that 
required to express antiviral activity in replicons. A single 100-mg dose of DCV was 
associated with a 3.3 log10 reduction in mean viral load measured 24 h post-dose. 
Furthermore, virus sequencing of samples prior to dosing, and at 24 and 144 h showed 
the evolution of HCV variants with M28T, Q30H/R, L31M and Y93H mutations -
providing clinical validation of NS5A inhibitors (Gao et al., 2010). In addition NS5A 
inhibitors have a low genetic barrier to resistance and combination therapy with other 
DAAs or IFN will be required to suppress the virus successfully.  
 
In phase II clinical trials different doses of the drug were compared with a placebo 
control arm. DCV in conjunction with PEG IFN-α/RBV and up to 90% of patients 
achieved SVR. In IFN-free regimens combining DCV with either the HCV RdRp 
inhibitor Sofosbuvir or the NS3 protease inhibitor Asunaprevir, high SVR rates were 
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achieved, 100% of some cohorts achieving a SVR (Lee, 2013) and represent the first 
time that a PEG IFN-α/RBV-free regimen has cured HCV infection. 
 
In summary, studies with HCV NS5A inhibitors have shown this class of antivirals to 
be generally well tolerated, have high in vitro potency, inhibit multiple genotypes and 
have high efficacy at low doses. Due to a low genetic barrier to resistance, the NS5A 
inhibitors will have used in combination therapy and have the potential to cure HCV 
infection without the use of PEG IFN-α and/or RBV. 
  
1.3.3 Evidence NS5A is the Target of DCV 
 
There are no biophysical data of compounds binding to NS5A nor a biochemical 
assay for NS5A function, so the widely accepted premise that NS5A is the target of 
DCV and other ‘NS5A inhibitors’ rely on indirect evidence (Belda and Targett-
Adams, 2012). 
 
Resistance Mutations Map to the NS5A N-terminus 
 
Resistance selection studies identified drug resistant mutations in the N-terminus of 
NS5A. In genotype 1b, the key resistance mutations generated were L31F/V, P32L, 
and Y93H/N. In genotype 1a, the additional primary resistance mutations M28T, 
Q30E/H/R, L31M/V, P32L, and Y93C/H/N were identified, with resistance mutations 
in genotype 1a conferring higher levels of resistance. Studies with replicons 
containing hybrid genotype 1b/1a NS5A showed the N-terminus to be responsible for 
the genotype-specific responses (Fridell et al., 2010). Similar resistant profiles have 
been reported in vivo (Wang et al., 2013) and are generated in response to treatment 
with structurally related compounds including BMS-766 (Bristol-Myers Squibb), 
Ledipasvir/GS-5885 (Gilead Sciences), GSK2336805 (GlaxoSmithKline) as well as 
PPI-461 (Presidio, structure not disclosed)
1
. Resistant mutants have reduced fitness 
 
                                                 
1
 Data from conference presentations archived at www.NATAP.org 
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(Lemm et al., 2010) and do not prevent binding of RNA in vitro (Targett-Adams et 
al., 2011). AZD-2836 and AZD-7295 (AstraZeneca/Arrow Therapeutics) represent 
distinct chemotypes that only weakly inhibits genotype 1a HCV (Figure 1.14). 
Additional evidence for direct interaction of NS5A with inhibitors came from 
chimeric replicon studies using compounds with differing inhibitory activities. For 
example replacing the first 76 amino acids of NS5A in a genotype 1a replicon with 
those present in genotype 1b resulted in an increase in inhibitory potency to 
compounds such as DCV which show higher potency towards genotype 1b  (Lemm et 
al., 2010). 
 
 
However although resistance associated with AZD-2836 and AZD-7295 mapped to 
NS5A, no resistance phenotype could be restored using reverse genetics (Desai and 
Meanwell, 2013), suggesting the compounds to operate through some cellular 
compound. Indeed testing of AZD-2836 on selected phosphatidylinositol kinases 
revealed the target of this class of these compounds to be the host factor type III 
phosphatidylinositol 4-kinase α (PI4KIIIα) rather than NS5A (Bianco et al., 2012). 
 
Immunoprecipitation Assays 
 
There is no evidence of an HCV inhibitor directly bound to NS5A in vitro possibly 
due to the difficulties in reconstituting NS5A with the appropriate conformation for 
compound recognition. Incubation of biotin-tagged active structurally-related 
compound resulted in the immunoprecipitation of NS5A-containing complexes 
whereas incubation with biotin-tagged inactive derivatives did not, suggesting NS5A 
to be involved in the MOA of these compounds (Gao et al., 2010). Binding of 
compounds only occurred with preincubation of the replicon cells – there was no 
binding with replicon cell lysates or purified NS5A protein. Furthermore only 
minimal binding occurred with expression of NS5A alone, suggesting the interaction 
of compounds with NS5A requires the formation of functional replication complexes 
(Targett-Adams et al., 2011). These requirements suggest compounds may target a 
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transitorily accessible binding site of NS5A in the context of the replication complex 
during the viral lifecycle (Belda and Targett-Adams, 2012). 
 
Compounds Alter NS5A Subcellular Localisation 
 
In the context of the HCV replicon, NS5A is sequestered in replication complexes, 
and without the presence of other HCV proteins, accumulates at the surface of lipid 
droplets (Miyanari et al., 2007). At the onset of replication inhibition from treatment 
of replicons with NS5A inhibitors, NS5A simultaneously redistributes from the ER to 
lipid droplets. A confocal microscopy study utilizing click chemistry verified the 
colocalization of an NS5A replication complex inhibitor with the NS5A protein 
(Jones et al., 2011). This could be hypothetically due to inhibitors locking NS5A into 
a conformation preventing it from being incorporated into replication complexes 
(Targett-Adams et al., 2011). This compound mediated redistribution of NS5A is 
likely to be a phenotype rather than a cause of NS5A inhibition but reaffirms the 
involvement of NS5A in the MOA of the compounds (Belda and Targett-Adams, 
2012). 
 
Compounds Inhibit NS5A Hyperphosphorylation 
 
Hyperphosphorylation is suggested to act as a regulatory mechanism of NS5A 
function in the HCV lifecycle (Evans et al., 2004). Treatment of replicons with NS5A 
inhibitors results in inhibition of the production of the p58 isoform of NS5A. 
Inhibition of p58 formation by inhibition of human kinases has been shown to cause 
sustained HCV RNA synthesis (Neddermann et al., 2004), with a correlation 
demonstrated between hyperphosphorylation of NS5A and inhibition of replicon 
replication (Lemm et al., 2010). In addition treatment with PIs also inhibited p58 
formation (Lemm et al., 2010), suggesting hyperphosphorylation inhibition to be a 
phenotypic consequence of NS5A inhibition rather than vice versa. 
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Dimeric Compounds and NS5A Dimers 
 
The establishment of a dimeric pharmacophore of compounds such as DCV as a key 
factor in their exquisite potencies (Gao et al., 2010) has led to speculation that they 
act on a physiological dimer present in NS5A domain 1 crystal structures. The 
features of DCV complement the symmetry of the NS5A dimers at the primary 
clinical resistance sites (Figure 1.15). Such compounds do not appear to inhibit NS5A 
dimerization or multimerisation (Lim et al., 2012), suggesting they could 
hypothetically act transiently on NS5A dimers or by over-stabilizing NS5A 
dimerization (Lemm et al., 2011).  
 
 
Figure 1.15 Models of DCV bound in the NS5A Domain 1 dimers (A) from Love (PDB ID 1R7C) 
and (B) Tellinghuisen (PDB ID 1ZH1) (Tellinghuisen et al., 2005; Love et al., 2009). The residues 
associated with primary clinical resistance mutations (amino acid residues 28, 30, 31, 93) are shown in 
orange. Images reproduced from (Desai and Meanwell, 2013).  
 
1.3.4 Speculated MOAs of Anti-NS5A Compounds 
 
NS5A-targeting compounds are marked by their exquisite potencies - typically in the 
picomolar range. It has been calculated that at inhibitory concentrations only 6 DCV 
molecules are present per replicon cell as opposed to approximately 60,000 NS5A 
molecules per replicon cell (Gao, 2010). HCV DAAs such as protease inhibitors and 
polymerase inhibitors at their IC50 values are usually present at similar concentrations 
(low nanomolar) and 1:1 stoichiometry with their targets in HCV replicon cells. How 
1 DCV molecule could be affecting 10,000 NS5A molecules has been referred to as 
the ‘potency paradox’ of NS5A inhibitors (Belda and Targett-Adams, 2012). 
A B 
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Whatever the MOA of NS5A inhibition, it is clear it does not operate via the 
sequestration of active NS5A molecules by the inhibitor. There are several 
possibilities for an MOA which are not necessary mutually exclusive. 
 
Inhibition by Concerted Allostery 
 
A single NS5A inhibitor could potentially distort the conformation of a NS5A 
molecule or dimer and this distortion could be communicated throughout a NS5A 
replication network. This concerted allostery could result in the complete inhibition of 
the replication complex by a dominant-negative MOA (Gao, 2010; Belda and Targett-
Adams, 2012). 
NS5A Inhibitors Target Multiple Stages of the Viral Lifecycle 
 
The high potency of NS5A inhibitors may be due to them acting synergistically on 
multiple NS5A-dependent stages of the viral lifecycle hence amplifying inhibitory 
effects. Indeed recent modelling studies show that the NS5A inhibitor DCV has two 
modes of action acting at the HCV RNA synthesis and viral assembly stages (Guedj et 
al., 2013). In addition there is evidence for a possible interaction of NS5A inhibitors 
at the polyprotein-processing stage, as treatment of replicons with DCV leads to the 
accumulation of the NS4B-NS5A polypeptide (Qiu et al., 2011) 
 
NS5A Inhibitors Target Active NS5A 
 
NS5A has multiple roles and potentially multiple tertiary and quaternary structure 
conformations during the HCV lifecycle (Love et al., 2009). NS5A inhibitors may 
target a conformation of NS5A actively involved in a crucial stage of the viral 
lifecycle that is present as a small fraction of the total NS5A molecules (Belda and 
Targett-Adams, 2012). The fact binding of compounds has been shown to only occur 
with preincubation of the replicon cells suggests the compounds only interact with a 
one particular conformation of NS5A in functional replication complexes (Targett-
Adams et al., 2011). 
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Amplification of Inhibition through Host Factor 
 
NS5A inhibitors may be indirectly acting on NS5A through an unknown host factor 
present at lower concentrations than NS5A. Such a host factor may be responsible for 
the regulation of NS5A multimers, disruption of which would explain the apparent 
dominant negative effect of NS5A inhibitors (Belda and Targett-Adams, 2012). For 
example the 4-anilino quinazoline class of HCV inhibitor was recently shown to 
mediate its effects on NS5A via type III phosphatidylinositol 4-kinase α (PI4KIIIα) 
(Bianco et al., 2012). 
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1.4 Aims of Project 
 
HCV NS5A represents a unique and important protein in the HCV. NS5A is 
implicated in many roles in the viral lifecycle (Macdonald and Harris, 2004), however 
the precise functions of NS5A have proven to be enigmatic. A better understanding of 
how NS5A works would elucidate the processes of HCV viral replication, host 
modulation and viral assembly, shedding light on the biology of this important 
pathogen. NS5A now represents an important target of a new class of anti-HCV 
compound. Resistance mutations to these compounds are generated within domain 1 
of NS5A; however the MOA of these how compounds affect NS5A is as perplexing 
as the physiological role of NS5A (Belda and Targett-Adams, 2012). There is no 
biophysical evidence of these compounds interact with NS5A. The potency of these 
compounds depends on their two-fold symmetry (Gao, 2010) suggesting they may be 
acting on a potentially physiological dimer present in genotype 1b NS5A domain 1 
crystal structures (Tellinghuisen et al., 2005; Love et al., 2009). However the other 
important genotype 1a shows lower sensitivity than the 1b genotypes with 
symmetrical compounds. 
 
In this light, we aim to determine the structure of genotype 1a NS5A domain 1 by 
NMR or X-ray crystallography. The examination at a structural level may show how 
these compounds affect the genotype 1a NS5A domain 1 differently to the genotype 
1b. This will involve the creation and isolation of 1a NS5A domain 1 suitable for 
structural characterisation. Additionally, we aim to find some biophysical evidence 
for these compounds interacting with NS5A. NMR is a highly sensitive technique and 
we suspect no compound interactions have been reported with NS5A constructs as 
they lack the N-terminal amphipathic helix which contains sites for the resistance 
mutations (Fridell et al., 2010; Gao et al., 2010). We intend to produce constructs 
which include the amphipathic helix for structural analysis and interaction studies by 
NMR. In addition to validating NS5A as a target of these compounds, we hope this 
approach will help explain a MOA. Furthermore knowledge of the MOA of these 
compounds will in turn give insights into the role of NS5A. 
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Chapter Two 
 
Structural Biology Techniques 
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2.1 Introduction 
 
Macromolecules are key molecules of life with proteins forming the essential 
machinery of the majority of biological phenomena. Structural biology seeks to 
provide a comprehensive understanding of the functions of biological 
macromolecules through determining their architectures at the molecular and atomic 
levels. As one of the early pioneers, James Watson, succinctly put it in 1964, 
“Unfortunately, we cannot accurately describe at the chemical level how a molecule 
functions unless we know first its structure” (Liljas et al., 2009). 
 
As biological macromolecules are too small (1-100 nm) to be visualized with light 
microscopy, structural biology utilises a variety of direct and indirect techniques to 
attain structural information. Despite recent advances in structure prediction, it is still 
necessary to determine the structures of biological macromolecules experimentally. 
Macromolecular crystallography, NMR spectroscopy and cryo-electron microscopy 
are the only techniques able to determine three-dimensional structures of biological 
macromolecules at atomic resolution. In practice, electron microscopy is mainly used 
in determining the structures of large macromolecular complexes at medium 
resolution. This chapter consists of a short overview of the relevant aspects of NMR 
spectroscopy and X-ray crystallography which serve as complementary techniques 
(Yee et al., 2005). 
 
2.2 Nuclear Magnetic Resonance 
 
In the 1950s, magnetic resonance spectroscopy had become a valuable tool in 
chemistry and the first low resolution NMR studies of proteins had begun. The 
determination of macromolecular structures by NMR required the development of 
new NMR techniques, in addition with powerful computational tools to generate three 
dimensional molecular models from structural data (Wüthrich, 2001). The first protein 
solved by NMR was proteinase inhibitor IIA from bull seminal plasma (Strop and 
Wüthrich, 1983). 
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Today NMR contributes to more than 10% of the structures present in the PDB. 
Although X-ray crystallography has an advantage over NMR in that it generally 
obtains higher resolution structural data and does not have an upper size limit
2
, NMR 
has the advantages of not requiring crystals and allows for studies of weakly 
interacting systems and the molecular dynamics of macromolecules in a variety of 
solution conditions, without crystal packing artefacts. The theory of protein NMR is 
well documented (Keeler, 2005; Cavanagh et al., 2007). This section will outline the 
basis of routine NMR experiments used in this project. 
 
2.2.1 Nuclear Spin Theory 
 
Atomic nuclei containing an odd number of protons and/or of neutrons are NMR 
active as they possess a quantum mechanical property known as a nonzero spin and 
have an associated intrinsic magnetic moment. The spin of a particular nucleus is 
empirically determined and nuclei with a spin of 
1
/2 are NMR useful with 
1
H (proton), 
13
C and 
15
N most often being used in solution NMR experiments. 
 
2.2.2 Nuclei in a Magnetic Field and the Resonance Phenomenon 
 
An NMR spectrometer is comprised of a high-field-strength superconducting magnet 
around the sample, a radio-frequency source that can generate pulses in any desired 
combination and a receiver coil detector. 
 
In quantum mechanics, the angular momentum and spin states of nuclei are quantized. 
A nucleus with spin 
1
/2 such as a proton can exist in one of two spin states, m = -
1
/2 or 
1
/2 respectively. In an external magnetic field of strength, B0, the spin states 
correspond to different energy levels with an energy difference, ΔE = ℏγB0 where γ is 
the gyromagnetic ratio and ℏ is the reduced Planck constant. Transitions between the 
 
                                                 
2
 The current size limit of NMR for uniformly labeled protein is around 35 kDa (Clore and 
Gronenborn, 1998) 
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two spin states constitute resonance and resonant absorption occurs if electromagnetic 
radiation of the exact frequency of the precession of the magnetic moments, known as 
the Larmor frequency, is absorbed – which corresponds to the radio frequency range 
for most NMR magnets (Figure 2.1A). The energy absorbed by the nuclear spins 
decays as the nuclei return to equilibrium inducing a voltage in the receiver coil to 
allow the detection of an absorption energy spectrum (Figure 2.1B). In practice the 
many nuclei in a magnetic field will follow a Boltzmann distribution with a small 
population bias towards the lower energy state resulting in an inherent low sensitivity 
for NMR spectroscopy. The number of nuclei in the lower energy state and hence the 
sensitivity can be increased by increasing the magnetic field strength, or the total 
number of nuclei by increasing the volume or concentration of the sample (taking care 
not to cause molecular aggregation). 
 
Treating the spins in terms of magnetisation allows for a classical description of 
NMR. The placement of a nucleus with a spin magnetisation vector in a magnetic 
field, B0, causes it experience a torque and undergo Larmor precession about the B0 
magnetic field at the same Larmor frequency in the quantum mechanical description. 
The application of a radio pulse, B1 perpendicularly to the main magnetic field, B0, 
has the effect of rotating the net magnetization vector away from B0. The angle 
rotated by the magnetic vector is determined by the power and duration of the 
irradiation by B1, - when the angle is 90°, it is termed a 90° pulse (Figure 2.1C). After 
the pulse the net magnetization vector will precess perpendicularly around the 
magnetic field, B0, before returning to equilibrium (Figure 2.1D). The rotating 
magnetic field will induce voltage, the decay of which is measured in the receiver 
coil. 
 
The process of the nuclear spin population coming back to equilibrium involves 
exchange of energy between the spin system and its surroundings and is characterised 
by the spin-lattice relaxation time, T1. The spins also exchange energy between 
themselves, resulting in the net magnetization vector returning to the non-precessing 
field as the precessing nuclei fall out of alignment with each other. This process is 
characterised by the spin-spin relaxation time, T2. The value of T2 is the observed 
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decay time of the observed NMR signal, also known as the free induction decay 
(FID), and governs the width of peaks in NMR spectra. 
 
2.2.3 Chemical Shift 
 
Not all nuclei have the same energy levels and hence nor do they resonate at the same 
frequency. Electrons in the molecular orbitals also have spin and produce a magnetic 
field opposite to that produced the nucleus, resulting in electronic shielding of the 
external magnetic field at the nucleus and reducing the difference between energy 
difference and hence the frequency required to achieve resonance (Figure 2.2A). This 
shielding effect is highly dependent on the local electronic environment of each 
  
Figure 2.1 NMR spectroscopy of Spin-1/2 nuclei. (A) In the quantum mechanical description of NMR, 
nuclei align in parallel or antiparallel to a magnetic field, B0. A radio frequency pulse causes a 
transition from low energy level to the high energy level allowing the detection of (B) an absorption 
energy spectrum. (C) In the classical mechanical description of NMR, the net magnetization vector lies 
parallel to the magnetic field, B0 (in the z-axis by convention). A 90° radio pulse, B1, applied 
perpendicularly to B0 causes the net magnetization vector to precess in the xy plane. (D) After the pulse 
the net magnetization vector returns to equilibrium. The induced voltage of the decay can be measured 
in a receiver coil allowing for detection of the energy spectrum shown in B. 
A B 
C D 
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nucleus in the molecule which enables NMR to probe the chemical structure of 
molecules (Figure 2.2B). Chemical shift δ is typically expressed in parts per million 
(ppm). 
 
The shielding (or deshielding) effect depends on the orientation of molecules with 
respect to the external field (B0) – this effect is known as chemical shift anisotropy 
(CSA). In solution CSA is averaged out by rapid molecular tumbling. However larger 
molecules and aggregated molecules have slower tumbling times resulting in the 
broadening of spectral peaks. This has implications in the size limitations of 
molecules which can be studied by NMR and the use of spinning at the magic angle 
spinning in solid-state NMR. 
 
 
 
Figure 2.2 Chemical shift of protons. (A) The energy levels of nuclei differ depending on their 
chemical environments resulting in the (B) corresponding shifts in a NMR spectrum. 
B 
A 
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2.2.4 Pulsed Nuclear Magnetic Resonance 
 
In continuous wave spectroscopy an NMR spectrum can be generated by slowly 
sweeping the radio frequency range but in practice better resolution and sensitivity in 
NMR is achieved with pulsed Fourier transform techniques. 
 
In Fourier-Transform Nuclear Magnetic Resonance (FT-NMR), a short strong RF 
pulse is used to simultaneously excite all nuclei to the higher spin state. This 
corresponds to tilting the net magnetization vector to be perpendicular to the external 
magnetic field. The out-of-equilibrium magnetization vectors rotate in the plane 
perpendicular to the external magnetic field at their respective Larmor frequencies. 
This nuclear magnetization decreases with time as it gets out of phase and the vector 
returns to equilibrium. This oscillating magnetization vector induces a signal with 
fluctuating declining amplitude in the receiver coil known as the free induction decay 
(FID). A Fourier transform is used to convert this time-domain signal into a 
frequency-domain NMR spectrum (Figure 2.3).  
 
 
 
 
 
Figure 2.3 A Fourier transform converts the measured decay signal to the frequency domain. 
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2.2.5 One Dimensional Proton NMR Spectroscopy (1D 1H NMR) 
 
A 1D NMR experiment consists of a preparation and a detection stage (Figure 2.4). 
During the preparation, the spin states of the sample reaches equilibrium before a 90° 
pulse is applied in the x-y plane. After this pulse each spin state precesses at its own 
Larmor frequency around the z-axis and the FID is recorded. The FIDs from multiple 
experiments are normally averaged to increase the signal to noise ratio before being 
fourier transformed to yield the final 1D spectrum. 
 
 
Figure 2.4 Scheme of a 1D NMR experiment. A 90° pulse is applied to the nuclei before detection of 
the FID. 
 
A typical 1D 
1
H spectrum of a protein is a plot of NMR absorption intensity vs. NMR 
frequency (Figure 2.5). Although macromolecule structural determination by NMR is 
mostly accomplished by 2D and 3D NMR spectroscopy, 1D 1H (proton) NMR 
spectroscopy is useful preparatory technique as it yields a variety of information. For 
example spectra with good dispersion are a good indication of folded proteins suitable 
for further structural characterisation (Page et al., 2005). 
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Figure 2.5 Example of a 1D 1H spectrum of a protein. 
1
H chemical shifts are due to chemical 
environment within each residue and an additional contribution due to secondary or tertiary structure. 
The marked regions correspond to the characteristic chemical shifts of different types of protons. A 
folded protein will typically show good dispersion with methyl peaks in the negative ppm range and 
amide peaks out near 10 ppm. 
 
 
2.2.6 Two Dimensional NMR Spectroscopy 
 
1D NMR spectra of proteins are generally too complex for interpretation as most of 
the signals overlap heavily, allowing only for gross statements about the secondary 
and tertiary structure. The introduction of additional spectral dimensions allows these 
spectra to be simplified – in a 2D NMR spectrum, absorption intensity is plotted as a 
function of two NMR frequencies. 
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A 2D NMR experiment consists of four stages (Figure 2.6): As in a 1D NMR 
experiment, the sample is first prepared by allowing its spin states to reach 
equilibrium before a 90° pulse is applied in the x-y plane. The resulting magnetization 
is then allowed to evolve for the first time period, t1, according to their chemical 
shifts. During the mixing time, a further pulse transfers the magnetization to another 
nucleus via scalar coupling or dipolar interaction (NOE). In the detection stage, a FID 
is collected at end of the experiment. A number of experiments are performed in 
succession with incremented values of the evolution period t1 to generate a data 
matrix, which can then be Fourier transformed to yield a 2D NMR spectrum. 
Similarly experiments with more elaborate pulse signals and mixing allow this 
approach to can be extended to higher dimensions. 
 
2.2.7 Heteronuclear Single Quantum Coherence (HSQC) 
 
An HSQC (Heteronuclear Single Quantum Coherence or Correlation) experiment 
correlates chemical shifts of two different types of directly bound nuclei. In a 
1
H,
15
N-
HSQC experiment the chemical shifts of a nitrogen atom of an 
15
NHx group are 
correlated with that of directly bound protons resulting in the direct detection of the 
proton chemical shifts (
1
H) in one dimension and the indirect determination of the 
15
N 
nuclei chemical shifts the in another dimension. Each signal in an 
1
H,
15
N-HSQC 
spectrum shows a proton that is bound to a nitrogen atom. Hence every peak 
 
Figure 2.6 Basic scheme for all 2D-NMR experiments. The experiment consists of a preparation 
period, an evolution period, a mixing period and a detection period. 
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represents an amino acid residue of a protein since each contains an amide proton. 
Prolines (which contain no amide proton) and the N-terminal residue do not show 
associated peaks and the NH2 peaks from the sidechains of asparagine and glutamine 
residues display additional doublets peak. An 
1
H,
15
N-HSQC spectrum shows 
unambiguously if a sample is well folded and a good candidate for structural 
characterisation (Figure 2.7) and is useful in studying which residues of a protein are 
involved in interactions. The peaks of a protein 
1
H,
15
N-HSQC can be assigned to their 
respective amino acids through the use of backbone assignment NMR experiments. 
 
 
Figure 2.7 1H–15N HSQC spectrum of unfolded and folded proteins. Each peak in the spectrum 
represents an H-N pair. The 
1
H,
15
N-HSQC spectra of the folded protein shows increased dispersion in 
both the 
15
N and especially the 
1
H dimensions compared with the unfolded protein. 
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2.3 X-ray Crystallography 
 
The study of crystals began in the 17
th
 century with observations of their symmetry by 
Johannes Kepler. However the internal structure of crystals commenced after 1912 
when Max von Laue proved X-rays were electromagnetic radiation as they were 
diffracted by crystals. The father-and-son team, William Henry and William 
Lawrence Bragg recognized the potential of X-ray crystallography to “solve” 
(determine) the atomic structures of molecules and minerals. The first crystal 
structures solved were simple salts, followed by those of progressively bigger organic 
molecules. The first biological macromolecules solved were sperm whale myoglobin 
and hemoglobin by John Kendrew and Max Perutz respectively, who shared the 
Nobel Prize in Chemistry in 1962. X-ray crystallography has evolved with technology 
to become an almost automated methodology using powerful synchrotron radiation 
sources with future fourth generation sources potentially being based on free electron 
lasers (Dauter, 2006). 
 
X-ray crystallography allows for the determination of structures of a higher resolution 
than with NMR without a theoretical upper size limit, and has become a routine 
method for analysis of macromolecular structures at atomic resolution: As of 
September 2013, 82998 biological macromolecules have been solved by X-ray 
crystallography and reposited in the PDB making up more than 80% of its total
3
. The 
theory of X-ray crystallography is well documented (Blundell and Johnson, 1976, 
Glusker et al., 1994, Drenth, 1999, Rhodes, 2000, Blow, 2002). This section will 
outline the basic theory and concepts routinely used in macromolecular structure 
determination by X-ray crystallography. 
 
 
 
 
                                                 
3
 Data from http://www.rcsb.org/pdb/statistics/holdings.do 
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2.3.1 Crystals 
 
A crystal is a solid state of matter consisting of a periodic arrangement of atoms or 
molecules, to form an ordered three-dimensional array. At a macroscopic levels, 
crystals often are recognizable by their geometrically regular form with symmetrically 
arranged flat faces (Tilley, 2006). 
 
2.3.1.1 Crystallisation of Biological Molecules 
 
In general, biological macromolecules or proteins have not evolved to crystallise, 
indeed they may have evolved to not crystallise (Doye et al., 2004) hence the 
bottleneck in macromolecular structure determination by X-ray diffraction often lies 
in the production of well-ordered single crystals of the macromolecule under study. 
Protein crystals are much more fragile than salt or small molecule crystals as they are 
held together by weaker forces, primarily through hydrogen bonds between hydrated 
protein surfaces. In addition, due to the molecular variations between different 
proteins, if a protein will crystallise, it will often be in only a unique condition. Hence 
crystallographers will screen many different conditions to obtain a successful 
crystallization. There are several techniques available for growing macromolecular 
crystals (Figure 2.8). In each technique, the protein is slowly taken to a state of 
controlled precipitation from aqueous solution under conditions that do not denature 
the protein often with the use of a precipitant. In a phase diagram, dependent on the 
protein and the conditions, crystal formation is dependent on two stages, nucleation 
and growth (shown in phase diagrams in Figure 2.8). Nucleation involves the 
formation of a molecular aggregate of the protein from which an ordered crystal can 
grow. Thus the screening and optimisation  of conditions for the growth of well-
ordered crystals is delicate balance between amorphous precipitation and controlled 
aggregation of the protein. In sparse matrix screens, a wide range of buffers and 
precipitants are accessed at various temperatures. Once crystalline material is found, 
the conditions are optimised to produce high quality, well-ordered crystals suitable for 
X-ray diffraction experiments. 
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Figure 2.8 Different techniques used in protein crystallisation with their respective crystallisation 
phase diagrams. The most common method used is vapour diffusion crystallisation, where a protein 
sample is mixed with a precipitant solution and sealed in a well containing the same precipitant 
solution in a reservoir. This results in a diffusion gradient between the drop and the well solution due to 
a higher concentration of precipitant being present in the reservoir. In an ideal condition, the protein 
concentration will increase to a point of nucleation in its phase diagram before returning to a region of 
controlled growth. Batch crystallisation entails screening various concentrations of the protein and 
precipitate to determine a point in a phase diagram where nucleation of crystallisation will occur. In 
dialysis crystallisation, the precipitant solution is free to diffuse in or out of a capillary to gradually 
bring the protein to a nucleation region of its phase diagram. 
 
2.3.1.2 Crystal Lattice and Symmetry 
 
Crystals are conceptually built up from a repeating unit designated the unit cell and a 
space lattice exhibiting long-range order and symmetry. The unit cell is defined by six 
parameters, three unique edges, a, b, c, and three unique angles α, β, γ (Figure 2.9). 
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Within a crystal, the unit cells stack in a three-dimensional array with the axes 
defining the vectors a, b and c denoted by x, y and z respectively. 
 
 
Figure 2.9 Diagram representing a unit cell from a crystal lattice. The vectors a, b and c describe the 
lengths of the unit cell against the cell axis x, y and z respectively. The unique angles defining the cell 
axis are α, β, γ. 
 
W. L. Bragg showed that the diffraction of X-rays by a crystal can be treated as if it 
were reflections from sets of parallel planes of atoms within the crystal. An infinite 
number of these lattice planes exist which are designated by three integers, the lattice 
or Miller indices denoted as h, k and l, which describe how often the planes cut the 
relevant axis in the unit cell (Figure 2.10). Thus three indices hkl can be used to 
identify a particular set of equivalent, parallel planes. 
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Figure 2.10 Examples of lattice planes with different Miller indices in a unit cell. 
 
 
For any particular lattice, four different arrangements of lattice points in a unit cells 
are possible. Each lattice points represents the positions occupied by atoms in the unit 
cell. The cell should be the smallest possible one that contains the highest symmetry 
of the atomic arrangement of the crystal. The primitive cell designated (P), is the 
simplest, containing no additional symmetry and just one lattice point, while non-
primitive cells comprise of more than one lattice point in each cell. A C-face centred 
(C) contains an additional lattice point on one face or at ½, ½, 0. A body-centered 
contains an additional lattice point in the centre of the unit cell at ½, ½, ½. A face-
centred lattice (F) contains additional lattice points at each face or at ½, ½, 0; ½, 0, ½; 
and 0, ½, ½. 
The macromolecular structures within the unit cell may be related to one another 
through symmetry operations. A crystal lattice can only contain 2, 3, 4 or 6 fold 
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rotational symmetry creating seven possible lattice systems (International Tables for 
Crystallography, Volume I, 1974). Coupling each of the 7 lattice systems with the 4 
types of unit cell gives rise to the 14 Bravais lattices (Figure 2.11), which represent 
the translational and rotational symmetry of the crystal. 
 
 
Figure 2.11 The Bravais lattices. The combination of the 7 lattice systems with the 4 unit cell types 
leads to the 14 Bravais lattices, due to equivalent combinations. Black dots at vertices represent lattice 
points. 
 
Combining the Bravais lattices with the other symmetry operations; screw axes, 
mirror planes, glide planes and inversion centres leads to unique pattern of 230 
possible space groups. However due to the chirality of biological molecules the only 
other possible operation is screw axis symmetry (consisting of a combination of a 
translation and a rotation). This results in the 65 possible space groups for protein 
crystals (Table 2.1). Within the unit cell is the asymmetric unit, which represents the 
smallest unit from which the crystal structure can be generated using the 
crystallographic symmetry operations of the space group. 
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Bravais  Lattice Point group 
(International 
notation) 
Space groups  
(international short symbol) 
Symmetry 
Order 
aP 1 P1 2 
mP 2 P2, P21 4 
mC C2 4 
oP 222 P222, P2221, P21212, P212121 8 
oC C2221, C222 8 
oI I222, I212121 8 
oF F222 8 
tP 4 P4, P41, P42, P43 8 
422 P422, P4212, P4122, P41212, 
P4222, P42212, P4322, P43212 
16 
tI 4 I4, I41 8 
422 I422, I4122 16 
hR 3 R3 6 
32 R32 12 
hP 3 P3, P31, P32 6 
32 P312, P321, P3112, P3121, 
P3212, P3221 
12 
6 P6, P61, P65, P62, P64, P63 12 
622 P622, P6122, P6522, P6222, 
P6422, P6322 
24 
cP (pcc) 23 P23, P213 24 
432 P432, P4232, P4332, P4132 48 
cI (bcc) 23 I23, I213 24 
432 I432, I4132 48 
cF (fcc) 23 F23 24 
432 F432, F4132 48 
 
Table 2.1 The 65 possible space groups for protein crystals. The symmetry order represents the number 
of different but equivalent arrangements of the lattice. 
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2.3.2 X-ray Diffraction by a Crystal 
 
When X-ray photons collide with electrons in matter, the oscillating electric field of 
the radiation causes the electrons to oscillate with the same frequency as the incident 
radiation. The electrons returns to their original energy state by emitting an X-ray 
photons in all directions of equivalent energy to the incident photon - this coherent 
scattering forms the majority of scattering in an X-ray crystallographic experiment. 
 
In 1912, Max von Laue discovered the diffraction of X-rays by crystals and showed 
that the two waves diffracted by atoms in a lattice translation must be in phase in 
order to observe diffraction. W. L. Bragg (1913) similarly explained this phenomenon 
by modelling a crystal as a discrete set of parallel planes with index hkl and 
interplanar spacing dhkl, and that incident beam would only produce a reflection when 
the path difference between diffracted beams were equal to an integer multiple of the 
wavelength (Figure 2.12). 
 
 
             
Figure 2.12 Bragg’s law. When incident radiation, k0 of wavelength λ interferes with the lattice plane 
hkl with a lattice spacing of dhkl at an angle θ to produce reflected radiation, k at the same angle θ, the 
path difference between diffracted radiation is 2dhkl sin θ. In order to produce constructive interference 
this path difference must equal an integer, n multiple of the wavelength. 
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Through rotating a crystal, different sets of planes will be in the correct orientation to 
satisfy their Bragg’s law, generating new reflections. An X-ray crystallographic 
experiment involves the collection of reflections from the diffraction of atoms within 
the crystals. Each set of parallel planes (hkl) in the crystal produces the reflection hkl 
of the diffraction pattern. The distance between hkl reflections are the reciprocal 
lengths of the unit cell vectors a, b and c (represented as a*, b* and c*). Hence the X-
ray diffraction pattern of a crystal can also be treated as a reciprocal lattice with 
dimensions a*, b*, c* and each reciprocal lattice point is assigned the index (hkl) 
from the real space plane it is derived from. Due to the relationship between real and 
reciprocal space, as the crystal (lattice) is rotated, so does the reciprocal lattice. Paul 
Peter Ewald interpreted Laue's results in terms of reciprocal lattices with the now 
called Ewald sphere (Figure 2.13). The Ewald sphere is a geometric construction that 
 
Figure 2.13 The Ewald sphere construct. In this two-dimensional model the incident radiation, k0 is 
shown passing through the crystal at the centre of the sphere (C), with radius 1/λ, and exiting through 
the origin of the reciprocal lattice origin (O). A reciprocal lattice point (hkl) in the shell of the sphere 
(P) which satisfies Bragg’s law, produces reflected radiation, k. The reciprocal lattice point represents 
the real lattice plane (hkl). Rotating the crystal results in reciprocal lattice points coming into and out of 
contact with the shell of the sphere. 
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demonstrates all the possible points where planes (reflections) could satisfy the Bragg 
equation. 
 
Each X-ray reflection results from contributions of scattering from the electron clouds 
of all the atoms present in the crystal. The amplitude of a reflection (hkl) is dependent 
on the density of electrons in the lattice plane (hkl) and each wave has an individual 
phase angle. Reflections can be considered as a complex wave and a Fourier series 
can represent the amplitude and phase, shown in the structure factor equation: 
      ∑   
                 
 
      
  
  
 
   
 
Where n represents the number of atoms contained in the unit cell. The first 
exponential component of the equation describes a three dimensional periodic 
function with frequencies h, k and l in the x, y, z dimensions. The xj, yj, zj terms are 
the co-ordinates of the atoms in the unit cell, expressed as a fraction of the unit cell 
length, establishing the phase of their contribution. fj is the scattering factor of atom j 
which determines the amplitude of the wave. The second exponential in this equation, 
the Debye-Waller function, describes the effects of thermal and crystal lattice disorder 
and is termed the B-factor. The quantity B represents the extent of divergence, with 
B=8π2(ū2) Å2, where ū is the root-mean-square deviation of atom j from its rest 
position. λ is the wavelength of the incident and diffracted beams. Another way of 
calculating structure factors is to use a continuous function of electron density, 
ρ(x,y,z): 
      ∭         
             
   
   
       
 
Where V is the volume of the unit cell. This Fourier transform of the electron density 
is integrated over 0 to 1 in each of x, y and z as to extend it over the whole unit cell. 
The exponential term describes the phase information. Knowledge of the structure 
factor amplitudes and phases allows one to calculate the positions of atoms within the 
unit cell through a Fourier series – the electron density equation: 
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The finite number of terms in this Fourier series are determined by the number of 
reflections collected and hence the resolution. Each term in this series represents one 
reflection in reciprocal space with indices hkl.│Fhkl│and iαhkl represent the amplitude 
and the phase contributions of the structure factor Fhkl. 
 
In an X-ray diffraction experiment the intensities (I) of the reflections are measured 
on a detector, where Ihkl = │Fhkl│
2
. Indexing the reflections allows determination of 
the unit cell dimensions. However, there is no technology to measure the phase of the 
reflections and this information is lost. In order to determine a structure from 
diffraction data, this so-called phase problem must be solved (Section 2.3.4). 
 
2.3.3 Data Collection and Processing 
 
2.3.3.1 Data Collection 
 
The aim of data collection is to measure the structure factor amplitudes with as much 
accuracy as possible. In an X-ray diffraction experiment, a crystal is mounted in the 
X-ray beam and the reflections are collected by a detector. Protein crystals used to be 
routinely mounted in thin walled glass capillaries containing crystallisation buffer. In 
the 1990s, Hakon Hope and Ada Yonath pioneered cryo-crystallography, whereby 
protein crystals are soaked in a solution of cryo-protectants before being flash cooled 
in a cryogen such as liquid nitrogen or a stream of nitrogen at 100K. 
 
In an X-ray beam at these temperatures, the effects of radiation damage to the crystal 
such as deterioration due to the formation of free radicals and heating of the crystal 
are greatly reduced – which results in a significant improvement of resolution in data 
collection. During an X-ray diffraction experiment, the crystal is rotated in the beam 
(normally around one axis) so that the intensity of every unique reflection can be 
measured. Rotation of the crystal causes the various reciprocal lattice points to come 
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into reflecting positions. The crystal symmetry dictates the the extent of rotation 
required for all the unique reflections to be measured (Table 2.1). In every exposure 
the crystal is oscillated around the axis of rotation, usually through an angle between 
0.1 and 2° allowing the collection of all the Bragg reflections within  the chosen 
oscillation angle. Reflections may be fully recorded reflections generated within one 
image and others will be partially recorded reflections measured over two or more 
images. 
 
2.3.3.2 Auto-indexing and Integration of Reflections 
 
After collecting diffraction data, programs such as HKL-2000 (Denzo/Scalepack), 
MOSFLM and XDS have functions that can auto-index reflections and quickly 
determine unit cell dimensions and the Laue symmetry. The coordinates of each 
Bragg diffraction spots measured during an experiment, are related to the reciprocal 
lattice index (hkl) using an orientation matrix. Indexing uses a few images, usually 
spread over 90° (dependent on the symmetry of the crystal), and determines a list of 
potential space groups with their corresponding unit cell dimensions, symmetries and 
penalties. In general, a space group and cell dimensions with high symmetry and a 
low penalty are selected for integration across all of the image frames with the 
intensity of each measured reflection integrated through profile fitting and assigned to 
a reciprocal lattice point (hkl). 
 
2.3.3.3 Scaling and Truncation of Data 
 
Within a diffraction pattern, reflections are related by symmetry and equivalent due to 
the symmetry of crystals. However because of variations in beam intensity, 
illuminated crystal volume and disparities within the detector, these equivalent 
reflections are not of equal intensity. In scaling, a scale factor is applied to normalise 
the intensities of each image. Symmetry related and multiple recordings of the same 
reflections are then averaged. The CCP4 programme SCALA can be used to scale 
together multiple observations of reflections, and merge these observations into an 
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average intensity. However reflections with intensities in poor agreement with the 
average intensity might be rejected.  
 
The resolution of a dataset depends on the quality of the quality of the data in the 
highest resolution range or shell (the highest diffraction angle). This quality can be 
determined by the agreement between symmetry related reflections by referring to the 
statistics Rmerge (when merging datasets from multiple crystals), Rpim (which reflects 
the increasing precision of intensities as more and more observations are merged) or 
Rsym (when scaling within the same crystal): 
 
     
∑ ∑ (                  )    
∑ ∑ (       )    
 
 
Where Imean is mean intensity of all reflections with these indices. In addition when 
the statistic Imean/σImean falls to 2, is used to decide the resolution cut-off of the data. 
 
2.3.4 Obtaining Phase Information 
 
In order to solve a crystal structure from diffraction data, it is essential to know the 
phase relationships of the reflections as they dictate the accuracy of the final electron 
density map more than the experimentally recorded amplitudes. Three main 
techniques, alone or in combination with one another, are used to calculate these 
phases: molecular replacement, anomalous dispersion and isomorphous replacement. 
The Patterson function is a central concept to all these methods, which can be used to 
obtain positional information from the experimentally measured amplitudes, and thus 
calculate phase information. 
 
2.3.4.1 The Patterson Function 
 
The Patterson represents the Fourier transform of the intensities rather than the 
structure factors: 
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The peaks in a Patterson density map correspond to the interatomic distance vectors, 
with each vector starting at the origin of the Patterson unit cell and the map always 
having centrosymmetry. 
 
2.3.4.2 Molecular Replacement 
 
In molecular replacement, phase information is derived for the diffraction data using a 
previously solved protein structure which shows high homology to the unknown 
structure. A model derived from the known structure is placed in every possible 
position and orientation in the unit cell and structure factor amplitudes are calculated 
and compared with those from the diffraction pattern. The Patterson function allows 
this process to be separated into distinct rotational and translational searches. 
The rotational search uses the fact that the Patterson function is not dependent on the 
choice of origin in the molecule. The Patterson map of the unknown structure can be 
compared with Patterson maps derived from our known homologue structure in 
different orientations. As the searches are conducted in three-dimensions, rotations are 
described by the Euler angles φ, θ and ψ. The fit of an orientation is scored with the 
highest scores being obtained when the unknown and model structures are in similar 
orientations being used for the translational searches. Programs like Phaser use 
maximum likelihood-based algorithms which allow for better discrimination of 
correct solutions from noise. 
 
With the model known correctly oriented, the translational function searches through 
the correct co-ordinates of the molecule by translating it within the unit cell for a 
number of candidate rotations. The translational search uses the Patterson function so 
phase information is not required. After the rotation and translation have been applied 
to the data a list of possible solutions are produced and can be scored by R-factors 
and/or correlation coefficients (CC). 
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Where │Fobs│and│Fobs│ are the measured and calculated structure factor amplitudes 
respectively, and the scaling factor k puts the calculated structure factor amplitudes on 
the same scale as the observed structure factor amplitudes. When the correct rotation 
and translation have been identified, phases can be calculated from the model as an 
estimate for each reflection in the dataset.  
 
2.3.4.3 Anomalous Dispersion 
 
Phase determination by anomalous scattering uses the phenomenon that small 
differences in diffraction are caused by some atoms. As stated before, when X-rays 
impinge on an atom, the electrons vibrate at the same frequency causing scattering in 
all directions. Friedel’s law states that the pair of reflections Fhkl and F-h-k-l have the 
same amplitude but the phase angles of the waves are opposite (Figure 2.14). 
 
However when an X-ray with energy close to a transitional energy of a specific atom 
(able to bring the atom to an excited state), the electronic vibration goes out of phase 
with the X-ray photons and resulting in a reduction in the intensity of the coherent 
scattering and the secondary radiation beam having an altered phase violating 
Friedel’s law. This effect is called anamalous scattering. Anomalous scattering occurs 
close to atomic absorption edges corresponding to different electron shells (K, L , M, 
etc.). In practice, the absorption edges for light atoms, such as carbon, nitrogen and 
oxygen, behave as normal scatters as they are not near the wavelength of X-rays used 
in protein crystallography. However elements, such as sulphur and phosphorous and 
non-covalently bound metals, are within the K edge range and in addition a sample 
can be labelled with selenium methionine to provide anomalous scatters. Programs 
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such as Phaser, SOLVE (Terwilliger, 2004) and SHELXD (Sheldrick, 1998) can be 
used to determine the phases from anomalous dispersion dataset(s).  
 
2.3.4.4 Isomorphous Replacement 
 
Isomorphous replacement involves the comparison of a native crystal with a 
derivative crystal which contains one or more strong scattering elements. The native 
and derivative crystals should have the same unit cell dimensions, symmetry and 
crystal packing. Deriviative crystals are typically prepared by soaking native crystals 
in solutions of heavy metal ions such as Hg, Pb or Pt. The successful incorporation of 
heavy atoms into a native crystal will cause measurable changes to some reflection 
intensities.  
 
After the collection of native and derivative datasets, the contributions of the heavy 
atoms to the amplitudes can be calculated allowing the heavy atoms to be located 
within the unit cell. Knowledge of the phase contributions of the heavy atoms allows 
the phases of the reflections in the native dataset to be calculated. However there will 
be a phase ambiguity associated with each reflection, which can be resolved by 
collecting more data from other isomorphous derivatives. The errors in phase 
 
Figure 2.14 Argand diagram describing Friedel’s law. Friedel’s law states that a pair of reflections 
related by an inversion through the origin are equal in amplitude (│Fhkl│=│F-h-k-l│) but with opposite 
phases (α). 
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estimations can also be reduced with the collection of the anomalous scattering data 
of the heavy atoms in combination with isomorphous replacement, such as in SIRAS 
and MIRAS (single/ multiple isomorphous replacements with anomalous scattering) 
experiments. 
 
2.3.5 Model Refinement 
 
The electron density equation (in Section 2.3.2) can be used to construct an initial 
electron density map when model phases have been determined. This map can contain 
significant errors because of badly estimated phases, although if it is good enough to 
allow fitting of the macromolecular structure, the model can be refined through 
optimising the co-ordinates and B-factors of the atoms in an attempt to minimise the 
difference between the observed and calculated structure factor amplitude. This 
refinement is an iterative process, whereby each improved model contains more 
accurate phase estimates, hence the calculated structure factor amplitudes fit the 
observed structure factor amplitudes better, leading to a more informative electron 
density map to allow for further model improvement.  
 
2.3.5.1 Cross-validation 
 
The R-factor (in Section 2.3.4.2) is used during the refinement of a crystallographic 
model as a measure of how well the refined structure predicts the observed data. 
However, using the R-factor, it is possible to overfit the diffraction data to create an 
incorrect model. To overcome this model bias, the free R factor is used, which 
excludes a small portion of the reflections (5-10%) and omitted in all refinement 
calculations. These are then used to calculate Rfree, which is used exclusively to 
monitor the progress of refinement. 
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2.3.5.2 NCS Refinement 
 
In non-crystallographic symmetry (NCS) refinement, each monomer of the 
asymmetric unit is assumed to correspondent perfectly. This has the effect of reducing 
the number of parameters in model by the number of monomers in the asymmetric 
unit leading to less bias in models during the refinement process.  
 
2.3.6 Manual Modelling 
 
Model bias can arise in an electron density map as the phases are calculated directly 
from the model. By subtracting the observed structure factor amplitudes from the 
calculated structure factor amplitudes allows the creation of difference maps, such a 
Fo-Fc, 2Fo-Fc or 3Fo-2Fc map. These maps can be viewed with modelling programs 
such as Coot (Emsley and Cowtan, 2004), allowing manual inspection and 
manipulation of the models to match the electron density. With correct interpretation 
of the electron density, protein residues and side chains in addition with waters and 
ligand molecules can be built into the electron density. 
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Chapter Three 
 
Materials and Methods 
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3.1 Materials 
 
The full-length 1a (isolate H77) NS5A gene DNA template was codon optimised and 
synthesised by Life Technologies (Paisley, UK). DNA oligonucleotides were 
purchased from Invitrogen (Paisley, UK). Phusion polymerase kit, T4 DNA Ligase, 
restriction enzymes, restriction enzyme buffers, calf alkaline phosphatase, 6× DNA 
loading dye, 100 bp DNA ladder, 1 kb DNA ladder were purchased from New 
England BioLabs (Hitchin, UK). UltraPure™ DNase/RNase-Free Distilled Water, 
SYBR Safe and SYPRO orange dye were purchased from Life Technologies. T4 
DNA Polymerase, dATP, pET32ekLIC were contained in the Ek/LIC Cloning Kit 
purchased from Novagen (Nottingham, UK). The pBAT vectors; pHAT4 (Peränen et 
al., 1996) and pGAT3 (Peränen and Hyvönen, unpublished) were a generous gift from 
Dr. Marko Hyvonen. GeneJET Plasmid Miniprep, PCR Purification and Gel 
Extraction Kits were purchased from Thermo Scientific (Runcorn, UK). E. coli 
competent cells XL1 Blue and BL21(DE3),  BugBuster reagent and lysonase were 
purchased from Novagen. Lysogeny broth (LB) was prepared from tryptone, yeast 
extract and sodium chloride purchased from Melford Laboratories Ltd. Aprotinin, 
leupeptin, pepstatin, phenylmethanesulfonylfluoride, agarose and nonfat dry milk 
powder were purchased from Melford Laboratories (Ipswich, UK). Nitrocellulose 
membrane and western blotting kit were purchased from Life Technologies. M9 
minimal media and Monoclonal Anti-polyHistidine Peroxidase Conjugate was 
purchased from Sigma-Aldrich. An Amersham ECL Plus Western Blotting Detection 
System purchased from GE Healthcare was used for the detection of conjugated 
antibodies. HisTrap FF Crude, GSTrap FF, HiPrep 26/10 Desalting and Superdex 75 
16/60 column had been purchased from GE Healthcare. C-18 ZipTips were purchased 
from Millipore. Additive Screens were purchased from Hampton Research. TEV 
protease was expressed and  according to established protocols (Tropea et al., 2009). 
The amphipathic helix of genotype 1a NS5A 1-31 containing the amino acid residues, 
SGSWLRDIWDWICEVLSDFKTWLKAKLMPQL was synthesised by and a 
generous gift from Christopher Douse (Department of Chemistry, Imperial College 
London). The viral RNA (20rU) was provided by Arrow Therapeutics. Daclatasvir 
(DCV) was provided by Bristol-Myers Squibb.  
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3.2 Methods 
 
3.2.1 Bioinformatic Analysis 
 
The 1a NS5A sequence from isolate H77 (accession number AF009606) was 
retrieved from the Los Alamos HCV Database 
(http://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html) where it was used to 
find only HCV NS5A genotypes using the BLAST HCV facility 
(http://hcv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html). The BVDV 
and GBV-B homologues of NS5A were identified using BLASTP (NCBI) and 
alignments were made using ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/). 
JPRED was used to make secondary structure predictions (Cole et al., 2008). 
AmphipaSeeK (Sapay et al., 2006) was used to predict in-plane amphipathic helices. 
 
3.2.2 Molecular Biology Techniques 
 
3.2.2.1 Transformation of E. coli 
 
1 µl of plasmid or ligation mixture at 50 ng/µl was mixed with 50 µl competent cells 
(XL1 Blue or BL21(DE3) for cloning or expression respectively) on ice. The mixture 
was then subjected to a heat shock through incubation at 42°C for 45 s before 
incubation back on ice immediately for 2 min. Transformation mixtures containing 
plasmids with ampicillin resistance genes (such as the pBAT family and pET32) 
could be spread immediately on LB-agar plates containing 100 µg/ml carbenicillin. 
Plates were incubated at 37°C for 16 h for inspection of colonies (transformants). 
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3.2.2.2 Plasmid DNA Preparation 
 
Individual colonies were picked from plates and each used to inoculate 10 ml LB 
cultures containing 50 µg/ml kanamycin or 100 µg/ml carbenicillin for pET32 or 
pBAT family plasmids respectively. Cultures were incubated at 37°C for 16 h with 
shaking and then harvested by centrifugation at 4,000 × g and 4°C for 10 min. 
Plasmid DNA was prepared from cell pellets according to the manufacturer’s 
instructions of the GeneJET Plasmid Miniprep Kit. 
 
3.2.2.3 DNA Oligonucleotide Design 
 
DNA oligonucleotide primers were designed to include enough base pairs matching 
the template DNA so that the matching region of each primer had a calculated melting 
temperature of at least 63°C according to the Integrated DNA Technologies 
OligoAnalyzer 3.1 
(http://eu.idtdna.com/analyzer/applications/oligoanalyzer/default.aspx). The primers 
used for creation of NS5A constructs are shown in Table 3.1 and summarised in 
Figure 3.1. DNA oligonucleotides were purchased without any modifications on a 
synthesis scale of 25 nmol with desalted purification from Life Technologies. 
Lysophilised DNA oligonucleotide primers were resuspended in TE buffer (10 mM 
Tris-HCl, 0.1 mM EDTA, pH 8.0) to 1 µg/µl and stored at –20°C. 
 
 
 
Figure 3.1 Schematic of the primers used to create the genotype 1a NS5A constructs. 
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Primer Name Primer Sequence 
1a-f33 5´-atatatccatgggtattccgttcgtatcatgccaac-3´ 
1a-r202 5´-atatatgtcgacttacatagaggtcagaaccgccac-3´ 
1a-r202-ek 5´-atatatgtcgacttacttgtcgtcgtcgtccatagaggtcagaaccgccac-3´ 
1a-tev-f1 5´-atatatccatggaaaacctgtatttccagagcgggtcttggctgcgtg-3´ 
1a-tev-1GST-f1 5´-atatatccatggaaaacctgtatttccagggcagcaccagcgggtcttggctgcgtg-3´ 
1a-tev-2GST-f1 5´-atatatccatggaaaacctgtatttccagggcagcaccggcagcaccagcgggtcttggctg 
cgtg-3´ 
1a-tev-3GST-f1 5´-atatatccatggaaaacctgtatttccagggcagcaccggcagcaccggcagcaccagcgg 
gtcttggctgcgtg-3´ 
1a-tev-4GST-f1 5´-atatatccatggaaaacctgtatttccagggcagcaccggcagcaccggcagcaccggcag 
caccagcgggtcttggctgcgtg-3´ 
1a-tev-5GST-f1 5´-atatatccatggaaaacctgtatttccagggcagcaccggcagcaccggcagcaccggcag 
caccggcagcaccagcgggtcttggctgcgtg-3´ 
1a-tev-f20 5´-atatatccatggaaaacctgtatttccagaaaacctggctgaaagcgaaactg-3´ 
1a-tev-f25 5´-atatatccatggaaaacctgtatttccaggcgaaactgatgcctcaactg-3´ 
1a-tev-1GST-f20 5´-atatatccatggaaaacctgtatttccagggcagcaccaaaacctggctgaaagcgaaactg-
3´ 
1a-tev-1GST-f25 5´-atatatccatggaaaacctgtatttccagggcagcaccgcgaaactgatgcctcaactg-3´ 
1a-tev-ns4b-f229-1 5´-actgtaacccagctcctgaggcgactgcatcagtggataagctcggagtgtaccactccatg 
cagcgggtcttggctgcgtgatatctgggattggatc-3´ 
1a-tev-ns4b-f229-2 5´-atatatccatggaaaacctgtatttccaggcagccgcccgcgtcactgccatactcagcagcc 
tcactgtaacccagctcctgaggcgactgcatcagt-3´ 
1a-tev-ns4b-f229-3 5´-atatatccatggaaaacctgtatttccaggcagccgcccgcgtc-3´ 
1a-lic-f33 5´-gacgacgacaagatgggtattccgttcgtatcatg-3´ 
1a-lic-r202 5´-gaggagaagcccggtttacatagaggtcagaac-3´ 
1a-lic-tev-f33 5´-gacgacgacaagatggaaaacctgtatttccagggcagcggtattccgttcgtatcatg-3´ 
1a- lic-r202-ek 5´-gaggagaagcccggtttacttgtcgtcgtcgtccatagaggtcagaac-3´ 
 
 
Table 3.1 The primers used for the generation of genotype 1a NS5A constructs. 
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3.2.2.4 Polymerase Chain Reaction 
 
The polymerase chain reaction (PCR) was carried out for each construct with the 
following reaction mixture: 
 
Component Volume 
/ µL 
5× Phusion HF Buffer 10 
dNTP mix (2 mM each) 5 
DNA Template (~ 1 ng/µL) 1 
Forward primer (1 µg/µL) 0.5 
Reverse primer (1 µg/µL) 0.5 
UltraPure distilled water 32.5 
Phusion polymerase 0.5 
TOTAL 50 
 
Reaction mixtures were thermocycled with the following program using a 
Mastercycler gradient thermal cycler (Eppendorf): 
 
  5 min 95°C 
 
 
1 min 95°C 
35×  1 min 57°C 
 1 min per 2 kb 72°C 
  5 min 72°C 
  ∞ 4°C 
 
Samples of PCR mixtures were analysed by agarose gel electrophoresis (see section 
3.2.2.5) to confirm they contained a substantial amount of product of the correct size, 
before being purified according to the manufacturer’s instructions of the GeneJET 
PCR Purification Kit. 
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For the creation of the construct 4B_229-5A_202-ek, previous PCR products were 
used as templates with different forward primers 1a-tev-ns4b-f229-1, 1a-tev-ns4b-
f229-2 and 1a-tev-ns4b-f229-3 for successive PCRs. 
 
3.2.2.5 Agarose Gel Electrophoresis 
 
Loading dye was added to each sample. Analysis and gel purification of PCR 
products and inserts (approximately 500 to 1,100 bp) was performed on a 1.6% (w/v) 
agarose gel prepared in TBE (89 mM Tris, 89 mM Boric acid, 2 mM EDTA, pH at 
25°C: 8.0) with 0.1% SYBR Safe using a 100 bp DNA ladder. Analysis and gel 
purification of pBAT and pET32 plasmids (approximately 4–6 kb) was performed 
similarly but using a 0.8% (w/v) agarose gel with a 1 kb DNA ladder. TBE was used 
as a running buffer for electrophoresis using a constant 100 V for 60 min. 
 
3.2.2.6 Restriction Digestion of DNA and Preparation of Inserts 
 
pBAT family vectors and genotype 1a constructs (except constructs made using the 
forward primer 1a-tev-f1) were digested with NcoI-HF and SalI-HF in NEBuffer 4 at 
37°C for 4 h. Constructs made using the forward primer 1a-tev-f1 were digested with 
BspHI and SalI-HF in NEBuffer 4 for 2 h at 37°C. 1 μl of calf alkaline phosphatase 
was added to pBAT vectors during the final 30 min of the digestion reaction. PCR 
products produced using primers with LIC sites (1a-lic-f33, 1a-lic-r202, 1a-lic-tev-f33 
and 1a- lic-r202-ek) were treated with T4 DNA Polymerase and dATP according to 
the Novagen Ek/LIC Cloning Kit protocol. Treated PCR products were loaded into 
agarose gels and subject to electrophoresis (see section 3.2.2.5), bands corresponding 
to the correct size were extracted and purified according to the manufacturer’s 
instructions of the GeneJET Gel Extraction Kit. 
 
3.2.2.7 Ligation of DNA Inserts into Expression Vectors 
 
1.6 μl of restriction-digested and gel-purified DNA insert was added to 2.4 μl 
restriction-digested, alkaline phosphatase-treated and gel-purified vector, 0.5 μl T4 
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DNA Ligase Reaction Buffer (10×) and 0.5 μl T4 DNA Ligase. The reaction mixture 
was incubated at 22°C for 30 min. 
 
For T4 DNA polymerase-treated DNA inserts, 1 μl was added to 0.5 μl Ek/LIC 
Vector and incubated at 22°C for 5 min before addition of 0.5 μl 25 mM EDTA 
according to the Novagen Ek/LIC Cloning Kit protocol.  
 
After ligation 1 μl of each reaction mixture was used to transform XL1 Blue cells (as 
described in section 2.2.2.1). 
 
3.2.2.8 Restriction Analysis of Ligation Transformants 
 
Plasmid DNA was prepared from any ligation transformants (see section 3.2.2.2) and 
a sample was used in the following mixture for restriction digestion: 
 
 µL 
10× NEBuffer 4 0.5 
100× BSA (10 mg/ml) 0.05 
Restriction enzyme 1 0.075 
Restriction enzyme 2 0.075 
Transformant plasmid DNA 4.3 
TOTAL 5 
 
NcoI-HF and SalI-HF were used as restriction enzymes for genotype 1a inserts in 
pBAT family vectors (except constructs made using the forward primer 1a-tev-f1). 
Constructs made using the forward primer 1a-tev-f1 were restriction digested with 
BamHI and SalI-HF. pET32 plasmids were restriction digested with XbaI and XhoI. 
Reaction mixtures were incubated at 37°C for 2 h before analysis by agarose gel 
electrophoresis (see section 3.2.2.5); samples showing a band of the correct size were 
further validated by DNA sequencing by GATC Biotech. Plasmids containing the 
correct sequence were transformed into BL21(DE3) cells (as described in section 
3.2.2.1) for expression. 
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3.2.3 Protein Biochemistry 
 
3.2.3.1 Expression and Solubility Trial Dot Blots 
 
Colonies of BL21(DE3) cells transformed with expression plasmids were grown in 
Lysogeny Broth medium with 100 μg/ml carbenicillin (pBAT expression vectors) or 
50 μg/ml kanamycin (pET32 expression vectors) to an O.D.600nm between 0.6 and 0.8. 
A 1 ml 10% glycerol stock was made, 1 ml was taken for induction with 1 mM IPTG 
(Isopropyl β-D-1-thiogalactopyranoside) and incubation at 3 h at 37ºC, 12 h at 25ºC 
or 20 h at 15ºC. Induced and uninduced empty pET32 vector were used for positive 
and negative controls respectively. The cells from 500 μl of each incubated culture 
were harvested by centrifugation at 16,060 × g for 1 min. Cell pellets were each 
resuspended in 30 μl BugBuster reagent with 2 μl Lysonase per 1 ml BugBuster and 
then incubated for 10 minutes at room temperature. 2 μl of this whole cell lysate (total 
fractions) of the samples, and positive and negative controls were transferred to 
nitrocellulose membrane. In solubility trials, the whole cell lysates were separated by 
centrifugation at 16,060 × g for 3 min before 2 μl of the supernatant (soluble 
fractions) of the same samples and controls were transferred to the membrane. The 
spots were allowed to dry before incubating the membrane in phosphate buffered 
saline with 0.1% Tween-20 (PBST) with 5% (w/v) milk powder for 45 min followed 
by another 45 min incubation with anti-polyHistidine Peroxidase Conjugate in PBST 
and three 10 min washes in PBST. The blot was developed according to the 
instructions of the Amersham ECL Plus Western Blotting Detection System and 
imaged using a FujiFilm LAS-3000 imager. 
 
3.2.3.2 Large-scale Expression and Purification 
 
NS5A constructs in BL21(DE3) cells were grown in Lysogeny Broth medium with 
100 μg/ml carbenicillin and induced with 1 mM IPTG, for 20 h at 15ºC. Cells 
harvested by centrifugation at 5,000 × g for 20 min at 4ºC, and each 1 g of cell pellet 
was resuspended in 10 ml of buffer A containing 100 mM Tris-HCl (pH 8.0), 300 
mM NaCl, 10 mM imidazole (for his-tagged constructs), 10% glycerol, in addition to 
 120 
 
the protease inhibitors aprotinin at 2 µg/ml, leupeptin at 10 µM, pepstatin at 1 µM and 
phenylmethanesulfonylfluoride at 1 mM. A cell disruptor (Constant Systems) running 
at 25 kPSI was used to lyse the cells, before isolation of the soluble fraction by 
centrifugation at 27,000 × g for 50 min at 4ºC. The supernatant was loaded onto a 1 
ml HisTrap FF Crude (for his-tagged constructs) or 1 ml GSTrap FF column (for 
GST-tagged constructs). Columns were washed with 100 ml of buffer A. Bound 
proteins were eluted from Ni-columns or glutathione-columns with a buffer consisting 
of buffer A with either 500 mM imidazole or 15 mM reduced glutathione 
respectively.  
 
Fractions containing protein were desalted using a HiPrep 26/10 Desalting column 
into buffer B consisting of 100 mM Tris-HCl (pH 8.0), 300 mM NaCl, 10% glycerol 
for TEV protease (TEV protease was produced in-house (Tropea et al., 2009)) 
overnight cleavage or 20 mM Tris.HCl (pH 7.5), 100 mM NaCl, 2 mM CaCl2 for 
enterokinase light chain cleavage. After cleavage TEV protease and His-, His-
thioredoxin- or GST-tags were removed by loading onto a Ni-column and collecting 
the flow-through and wash fractions. In the case of the GST-tagged constructs the first 
peak from an elution gradient (from 20 to 500 mM imidazole) was collected. 
Enterokinase light chain and the thioredoxin tag (from pET32ekLIC) were removed 
by loading onto an SP-sepharose-column and collecting the first peak from an elution 
gradient (from 50 to 1 M NaCl). As a final step the protein was loaded onto a 
Superdex 75 16/60 column equilibrated and run with crystallisation buffer consisting 
of 20 mM Tris.HCl, 150 mM NaCl, 10% glycerol, pH 8.0 with or without 5 mM 
DTT; or an NMR buffer consisting of 100 mM KPO4, 1 mM DTT, 100 mM NaCl pH 
7.5. Fractions containing the protein were collected and pooled. 
 
3.2.3.3 Optimisation of Thioredoxin-tagged 1a NS5A D1 Cleavage 
 
The fusion protein was transferred to cleavage buffer containing 100 mM Tris.HCl 
(pH 8.0), 300 mM NaCl, 10% glycerol. The protein was diluted to 2.0 mg/ml and 0.5 
ml was taken for a test digestion. A sample was taken for 0 min and was added to 
denaturing loading dye and boiled. 5 µl of TEV protease (from homemade stocks) at 1 
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mg/ml (5 µg) was added to each tube. Samples were taken from 1 min, 2 min, 5 min, 
15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h and overnight cleavage during incubation at 
25°C and added to denaturing loading dye and boiled, before SDS-PAGE analysis of 
the samples (Shapiro et al., 1967). 
 
3.2.3.4 Thermal Denaturation Assay 
 
Protein samples were transferred in duplicate into a 96-well QPCR plate in addition to 
SYPRO orange dye and buffer or additives to a final volume of 20 µl per well. The 
plate was heated incrementally in steps of 0.1°C from 10°C to 100°C over 2 h and 
SYPRO orange dye fluorescence readings were taken by a Mastercycler® ep realplex 
(Eppendorf) QPCR machine. The plate was gently centrifuged to ensure each droplet 
was mixed properly before each experiment. An optimisation  assay was performed 
varying the protein and SYPRO orange dye concentrations so that the fluorescence 
signal was maximal but within the dynamic range of the QPCR machine; determining 
final concentrations of 10 mM of the construct 33-202-ek with 25× dye for use in 
screening experiments. The raw data were copied to an Excel spreadsheet, which 
calculated the melting temperature (Tm) for each well as the temperature at the 
inflexion point of the S-curve. Buffers and additive conditions used in screens are 
shown in Appendix 7.2.  
 
3.2.4 MALDI-TOF Mass Spectrometry 
 
20 µl of sample was transferred to a buffer consisting of 50 mM ammonium 
carbonate, pH 7.5 using a C-18 ZipTip before mixing the sample in 1:1 dilution with 
matrix solution and loading 1 µl of the mixture on the MALDI plate according to 
standard protocols (Nordhoff et al., 2003). A 4800 nanoLC MALDI TOF-TOF 
System (AB Sciex) was used for the MALDI-TOF analysis. 
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3.2.5 Crystallization of 1a NS5A D1 
 
Protein was concentrated to 8 mg/ml as determined by a NanoDrop 1000 (Thermo 
Scientific). To remove any precipitation samples were subject to centrifugation at 
16,060 × g for 2 min. Crystals were grown using the sitting drop method of vapour 
diffusion. Conditions for crystal growth were determined through commercial sparse 
matrix screens labelled as ICL1-14 corresponding to the screens; Crystal Screen HT 
(Hampton Research), Wizard I (Emerald BioSystems), PEG/Ion Screen (Hampton 
Research), HR2-144 (Hampton Research), SaltRx HT (Hampton Research), 
MemStart and MembSys screen (Molecular Dimensions), PACT Suite (Qiagen), 
JCSG+ Suite (Qiagen), MemGold (Molecular Dimensions), Wizard III (Emerald 
BioSystems), JBScreen Cryo HTS (Jena Bioscience), ProPlex (Molecular 
Dimensions), MORPHEUS protein crystallization screen (Gorrec, 2009) and PGA-
LM (Molecular Dimensions) with 100 nl reservoir solution added to 100 nl protein 
with a mosquito crystallisation robot (TTP LabTech) before sealing and incubation of 
the plates at 4°C. The largest crystals were grown using microseeding with the 
crystals from the original condition containing 0.1 M MES pH 6.5, 1.6 M MgSO4  
which were crushed and used as a seeding stock for an optimisation plate consisting 
of sitting drops of 2 µl of the protein solution with 2 µl reservoir using a cat whisker 
to streak the seeding solution over equilibrated drops. After 30 days incubation at 4°C 
crystals were visible and grew to a full size of up to approximately 150 µm after 60 
days. Crystal soaks were performed in reservoir buffers with daclatasvir (DCV) at 1 
and 2 mM for 1 min, 1 h and 24 h. 
 
3.2.6 X-ray Data Collection and Structure Determination 
 
Crystal hits were fished out of the solution in 0.1-0.2 mm cryoloops (Hampton), 
before being immersed briefly in a buffer consisting of the reservoir solution with 
30% glycerol, and then flash frozen in liquid nitrogen. Native data sets were collected 
using a PILATUS 6M detector at the microfocus beamline I24 at Diamond Light 
Source. Data were processed using MOSFLM (Leslie and Powell, 2007), scaled with 
SCALA (Evans, 2006) and structure factor amplitudes derived using TRUNCATE 
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(French and Wilson, 1978) within the CCP4 suite of programmes. After determining 
the correct space group data were reprocessed using xia2 (Winter, 2009) and phases 
were calculated with Phaser (McCoy et al., 2007) using the genotype 1b NS5A 
domain 1 structure (Protein Data Bank code 1ZH1) as a search model. The process of 
refinement using Phenix.refine with NCS restraints (Afonine et al., 2012) and model 
building was iterated. Validation and Ramachandran analysis of the model were 
carried out using Molprobity (Davis et al., 2007). Bured solvent accessible surface 
area, rotation angles and distances between centres of masses of the dimers were 
calculated with Chimera (Pettersen et al., 2004). Amino acid conservation at dimer 
contact sites was determined by 95% conservation from 25 sequences from genotypes 
1 to 6 from the Los Alamos database (Kuiken et al., 2005). Figures were made using 
PyMOL (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, 
LLC.). 
 
3.2.7 Protein Nuclear Magnetic Resonance 
 
3.2.7.1 Isotopic Labelling of Recombinant Proteins 
 
The recombinant proteins were expressed in Minimal media with 
15
NH4Cl as the only 
nitrogen source with the same protocol as Section 3.2.3.2. 
 
3.2.7.2 NMR Data Acquisition 
 
NMR experiments were performed on a Bruker 600 MHz NMR Spectrometer 
equipped with a cryoprobe at the cross-Faculty NMR Centre at Imperial College 
London. All experiments for NS5A domain 1 constructs were run at 298K for optimal 
spectral properties without causing precipitation of samples. All one-dimensional 
1
H 
NMR experiments were recorded using a Hahn-Echo with water pre-saturation or 
Excitation Sculpting with gradient water suppression. 1D NMR data were processed 
using Topspin software (Bruker Biospin Ltd) and 2D NMR data were processed using 
NMRPipe software and analysed in NMRView (One Moon Scientific). In NMR 
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titrations Daclatasvir (DCV) was dissolved at 15 mM in DMSO before adding this to 
NMR samples at a volume of 10% of the sample volumes. 
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Chapter Four 
 
Cloning of HCV Genotype 1a NS5A and 
Isolation of a Domain 1 for Structural 
Characterisation 
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4.1 Bioinformatics 
 
We conducted a bioinformatic analysis of the NS5A protein from different genotypes 
to highlight any structurally conserved regions. Different genotypes of 1a NS5A were 
identified using the Los Alamos HCV Database and BVDV NS5A was identified 
using BLASTP (NCBI) (Table 4.1). NS5A shows a high degree of conservation of 
between 62.3-80.6% identity within the HCV genotypes. The pestivirus BVDV-1 
from the only known genus of virus other than HCV known to contain a protein 
homologous to NS5A (Stapleton et al., 2011) and GBV-B show a somewhat different 
primary sequence with various small insertions and deletions and a lower sequence 
identity of 10.9% and 21.2% respectively when aligned with 1a HCV NS5A (data not 
shown). 
 
Genotype Isolate Accession Number % Identity to 
1a 
1a H77 AF009606 N/A 
1b Con1 AJ238799 80.6% 
2a HCVQ4 DQ859969 62.3% 
3a RF20C7 EU826223 72.1% 
4a Eg3 DQ988074 73.4% 
5a SA13 AF064490 70.8% 
6f THCM-L2/08 HM042094 73.2% 
GBV-B N/A NC_001655.1 21.2% 
BVDV-1 N/A NC_001461.1 10.9% 
 
 
Table 4.1 Sequences of Flaviviridae NS5A genotypes used for bioinformatic analysis. The Sequence 
identity to 1a NS5A varys from 62.3% to 80.6% (1b NS5A). Sequence identity of BVDV-1 NS5A to 
1a NS5A is a much lower 10.9%. 
 
A multiple sequence alignment of the HCV NS5A sequnces was created using 
ClustalW2 and this identified an evolutionarily conserved N-terminus, with high 
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conservation between residues 1 and 243 of NS5A (Figure 4.1). JPRED analysis of 
the 1a NS5A sequence predicted this N-terminus to consist of a helix at the N-
terminal with the rest of the conserved domain 1 consisting of beta-sheets folded most 
likely in similar way to the 1b NS5A D1 structure (Tellinghuisen et al., 2005; Cole et 
al., 2008; Love et al., 2009). Use of the amphipathic helix (AH) program 
AmphipaSeeK (Sapay et al., 2006) predicted the genotype 1a NS5A N-terminal AH 
to lie in-plane in a membrane bilayer (data not shown). We performed disorder 
predictions for the genotype 1a NS5A using RONN (Yang et al., 2005). Regions 189-
252, 334-444, 446-446 of the protein were predicted to be disordered (Figure 4.2) 
which corresponds with the linker region between domains 1, 2 and 3, and domain 3, 
which have been shown empirically to be intrinsically unstructured region of the 
protein (Liang et al., 2007; Hanoulle et al., 2009b). 
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                   JPRED           ---HHHHHHHHHHHHHHHHHHHHHH-----------EE-------EEE--EEEEEE---- 
                   1a_NS5A         SGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYRGVWRGDGIMHTRCHCG 60 
                   1b_NS5A         SGSWLRDVWDWICTVLTDFKTWLQSKLLPRLPGVPFFSCQRGYKGVWRGDGIMQTTCPCG 60 
                   4a_NS5A         ANSWLWEVWDWVCTVLSDFKTWLKAKLLPRMPGIPFLSCQRGYRGEWRGDGVMHTTCPCG 60 
                   5a_NS5A         DGTWLRAIWDWVCTALTDFKAWLQAKLLPQLPGVPFLSCQRGYRGVWRGDGVNSTKCPCG 60 
                   6f_NS5A         ATSWLRDIWDWVCTVLSDFKTWLKAKITPSLPGIPFLSCQRGYRGTWRGDGVCHTTCPCG 60 
                   3a_NS5A         SGDWLRDIWDWVCTVLSDFKTWLSAKIMPALPGLPFISCQKGYKGVWRGDGVMSTRCSCG 60 
                   2a_NS5A         SGSWLRDVWDWVCTILTDFKNWLTSKLFPKMPGLPFISCQKGYKGVWAGTGIMTTRCPCG 60 
                                      **  :***:*  *:*** ** :*: * :**:**.***:**:* * * *:  * * ** 
 
                   JPRED           -EEEEEEE--EEEEE----HHHH-----E-----------------HHEEEEE----EEE 
                   1a_NS5A         AEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYKFALWRVSAEEYVE 120 
                   1b_NS5A         AQITGHVKNGSMRIVGPRTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVE 120 
                   4a_NS5A         AELAGHIKNGSMRITGPKTCSNTWHGTFPINAYTTGPGVPIPAPNYKFALWRVSAEEYVE 120 
                   5a_NS5A         ATISGHVKNGTMRIVGPKLCSNTWHGTFPINATTTGPSVPAPAPNYKFALWRVGAADYAE 120 
                   6f_NS5A         ASIAGHVKNGTMKIIGPRTCSNIWHGTFPINATTTGPSVPIPSPNYRRALWRVAAEEYVE 120 
                   3a_NS5A         ASIAGHVKNGSMRLAGPRTCANMWYGTFPINEYTTGPSTPCPPPNYTRALWRVAANSYVE 120 
                   2a_NS5A         ANISGNVRLGSMRITGPKTCMNTWQGTFPINCYTEGPCMPKPAPNFKTVIWRVAASEYAE 120 
                                   * ::*::: *:*:: **: * * * ******  * **  * *.**:  .:***.* .*.* 
 
                   JPRED           EEE---EEEEEE-----EEE-------HH-H----EEEEE------------EEEEE--- 
                   1a_NS5A         IRRVGDFHYVSGMTTDNLKCPCQIPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLH 180 
                   1b_NS5A         VTRVGDFHYVTGMTTDNVKCPCQVPAPEFFTEVDGVRLHRYAPACKPLLREEVTFLVGLN 180 
                   4a_NS5A         VRRVGDFHXVTGVTQDNIKCPCQVPAPEFFTEVDGVRLHRHAPKCKPLLREEVSFSVGLN 180 
                   5a_NS5A         VRRVGDYHYITGVTQDNLKCPCQVPSPEFFTELDGVRIHRYAPPCNPLLREEVCFSVGLH 180 
                   6f_NS5A         VVRHGDYHYVVAATSDNLKCPCQVPSPEFFTEVDGVRLHRYAPACRPLLRDEITYSVGLS 180 
                   3a_NS5A         VRRVGDFHYITGATEDELKCPCQVPAAEFFTEVDGVRLHRYAPPCKPLLRDEITFTVGLN 180 
                   2a_NS5A         VTQHGSYSYITGLTTDNLKVPCQLPSPEFFSWVDGVQIHRFAPTPKPFFRDEVTFCVGLN 180 
                                   : : *.:  : . * *::* ***:*:.***: :***::**.**  .*::*:*: : ***  
 
                   JPRED           -EE-----------HHHHHHHH--------HHHHHHHH---------------------- 
                   1a_NS5A         EYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSMASSSASQLSAPSLK 240 
                   1b_NS5A         QYLVGSQLPCEPEPDVAVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLSAPSLK 240 
                   4a_NS5A         SFVVGSQLPCEQEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSLASSSASQLSAPSLK 240 
                   5a_NS5A         SFVVGSQLPCEPEPDVTVLTSMLSDPAHITAETAKRRLDRGSPPSLASSSASQLSAPSLK 240 
                   6f_NS5A         TYLIGSQLPCEPEPDVAVLTSMLTDPAHITAETAGRRLARGSPPSLASSSASQLSAPSLK 240 
                   3a_NS5A         SYAIGSQLPCEPEPDVSVLTSMLRDPSHITAETAARRLARGSPPSEASSSASQLSAPSLK 240 
                   2a_NS5A         SFVVGSQLPCDPEPDTDVLMSMLTDPSHITAEAAARRLARGSPPSEASSSASQLSAPSLR 240 
                                    : :******: ***. ** *** **:*****:* *** ****** *************: 
 
                   JPRED           -------------EEHHHHHHHHH-----EEE-----EEEEE--------- -------- 
                   1a_NS5A         ATCTANHDSPDAELIEANLLWRQEMGGNITRVESENKVVILDSFDPLVAEE-DEREVSVP 299 
                   1b_NS5A         ATCTTRHDSPDADLIEANLLWRQEMGGNITRVESENKVVILDSFEPLQAEE-DEREVSVP 299 
                   4a_NS5A         ATCTARHDSPGTELLETNLLW----GSAATRVETDEKVIILDSFEPCVAEPGDDREVSVA 296 
                   5a_NS5A         ATCTTQGHHPDADLIEANLLWRQCMGGNITRVEAENKVVILDSFEPLKADD-DDREISVS 299 
                   6f_NS5A         ATCTTADRHPDAELIEANLLWRQEVGGNITRVESENKIIVLDSFDPLVAET-DDREISVA 299 
                   3a_NS5A         ATCQTHRPHPDAELVDANLLWRQEMGSNITRVESETKVVILDSFEPLKAET-DDAELSVA 299 
                   2a_NS5A         ATCTTHGKAYDVDMVDASLFM----GGDVTRIESESKVVVLDSLDPMAEER-SDLEPSIP 295 
                                   *** :     ..:::::.*:     *.  **:*:: *:::***::*   :  .: * *:. 
 
Figure 4.1 JPRED secondary structure prediction and ClustalW2 multiple sequence alignment. JPRED 
secondary structure prediction of the 1a NS5A D1 residues shown at the top of the sequences with –, H 
and E representing predicted random coil, alpha helix and beta sheet respectively. The N-terminal 
amphipathic helix is shown. The consensus of the aligned residues of the HCV sequences is shown 
below the ClustalW2 multiple sequence alignment with *, : and . representing identical amino acids, 
conserved and semi-conserved substitutions respectively. 
Amphipathic helix 
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Figure 4.2 RONN Disorder prediction for genotype 1a NS5A. Amino acid residues 189 – 252 and 334 
– 446 were predicted to be disordered regions of the protein. 
 
4.2 Molecular Biology 
 
4.2.1 Determination of Constructs 
 
HCV genotype 1 NS5A constructs included domain 1 with and without the whole or 
partial N-terminal AH with N-terminal His-tag, thioredoxin tag, glutathione S-
transferase tag, or maltose-binding protein tag fusions. The region of genotype 1a 
NS5A without its N-terminal AH was chosen to include amino acid residues 33 to 202 
as these mapped to the same residues used in a genotype 1b construct successfully 
isolated for structural studies (Love et al., 2009). Additionally the construct 4B_229-
5A_202-ek extended the N-terminus to include an AH of the NS4B coding region 
(Figure 4.3).  
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4.2.2 Amplification of NS5A DNA by PCR 
 
The DNA used for the template for the genotype 1a NS5A constructs was codon-
optimised - containing the preferred codons AUA, AGG, AGA, CUA, CCC, CGG, 
and GGA for expression in E. coli (Burgess-Brown et al., 2008). 
 
Figure 4.3 The different genotype 1a NS5A expression products. Shown are their construct names on 
the left. Open rectangles indicate His (His6 tag),  TRX (thioredoxin tag), GST (glutathione S-
transferase tag), MBP (maltose-binding protein), TEV (TEV protease cleavage site), and ek 
(enterokinase, light chain cleavage site at C-terminus); solid bars, NS5A coding region.  ‘Link’ marks 
glycine, serine, threonine linker repeats. Small numbers below the lines show amino acid positions in 
the NS5A protein. Overlapping sections of the constructs are aligned above each other.  
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4.2.2.1 Generation of Genotype 1a NS5A Constructs 
 
The PCR products of constructs 33-202, 33-202-ek, LIC 33-202, LIC 33-202-ek, LIC 
tev-33-202-ek, tev-1-202-ek, 1GST-1-202-ek, 2GST-1-202-ek, 3GST-1-202-ek, 
4GST-1-202-ek, 5GST-1-202-ek, 20-202-ek, 25-202-ek, 1GST-20-202-ek, 1GST-25-
202-ek and 4B_229-5A_202-ek were amplified successfully as shown by the agarose 
gel analysis (Figure 4.4). 
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Figure 4.4 1.6% Agarose gels of PCR products of genotype 1a NS5A constructs. (A) Successful PCR 
products of constructs 33-202, 33-202-ek, LIC 33-202, LIC 33-202-ek, LIC tev-33-202-ek and tev-1-
202-ek with expected sizes of 536, 551, 543, 558, 582 and 650 bp respectively. (B) Successful PCR 
products of constructs 1GST-1-202-ek, 2GST-1-202-ek, 3GST-1-202-ek, 4GST-1-202-ek and 5GST-1-
202-ek with expected sizes of 659, 668, 677, 686 and 695 bp respectively. (C) Successful PCR products 
of constructs 20-202-ek, 25-202-ek, 1GST-20-202-ek and 1GST-25-202-ek with expected sizes of 575, 
560, 584 and 569 (D) Successive PCR products to create an NS4B-NS5A construct from NS4B residue 
229 to NS5A residue 202 with a C-terminal ek site (4B_229-5A_202-ek). PCR mixtures 1, 2 and 3 
contain products of expected sizes of 696, 761 and 761 bp respectively. 
 
4.2.3 Digestion of pBAT Vectors 
 
Restriction-digested and alkaline phosphatase-treated pBAT family expression 
vectors (non-commercial vectors, see appendix 8.1) were successfully gel-purified 
(Figure 4.5) in preparation for cloning NS5A constructs into them. 
A B 
C D 
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Figure 4.5 0.8% Agarose gel of NcoI and SalI-digested pBAT family expression vectors. Vectors are 
approximately of their expected sizes of 4480, 5146 and 5599 bp. 
 
4.2.4 Ligation 
 
Before expression trials, we confirmed plasmid to contain an insert by restriction 
analysis and further verified the correct sequence and reading frame of the constructs 
by DNA sequencing. 
 
4.2.4.1 Ligation of 1a NS5A Constructs into Expression Vectors 
 
Successful ligation of genotype 1a NS5A constructs 33-202 into pHAT4 (His-33-
202), 33-202 into pGAT3 (GST-33-202), 33-202-ek into pHAT4 (His-33-202-ek), 33-
202 into pET32 (TRX-33-202), 33-202-ek into pET32 (TRX-33-202-ek), tev-33-202-
ek into pET32 (TRX-tev-33-202-ek), tev-1-202-ek into pHAT4 (His-tev-1-202-ek), 
tev-1-202-ek into pGAT3 (GST-tev-1-202-ek), tev-1-202-ek into pMAT10 (MBP-tev-
1-202-ek), 1GST-1-202-ek into pMAT10 (MBP-Link1-1-202-ek), 2GST-1-202-ek 
into pMAT10 (MBP-Link2-1-202-ek), 3GST-1-202-ek into pMAT10 (MBP-Link3-1-
202-ek), 4GST-1-202-ek into pMAT10 (MBP-Link4-1-202-ek), 5GST-1-202-ek into 
pMAT10 (MBP-Link5-1-202-ek), 20-202-ek into pMAT10 (MBP-20-202-ek), 25-
202-ek into pMAT10 (MBP-25-202-ek), 1GST-20-202-ek into pMAT10 (MBP-
Link1-20-202-ek), 1GST-25-202-ek into pMAT10 (MBP-Link1-25-202-ek) and 
4B_229-5A_202-ek into pMAT10 (MBP-4B_229-5A_202-ek) were accessed by 
restriction analysis (Figure 4.6). The correct sequences and reading frames of the 
constructs in each expression vector were confirmed by DNA sequencing. 
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Figure 4.6 1.6% Agarose gels of restriction analysis of genotype 1a NS5A constructs ligated into 
expression vectors. (A) Successful ligation of NS5A constructs 33-202 into pHAT4, 33-202 into 
pGAT3, 33-202-ek into pHAT4, 33-202 into pET32, 33-202-ek into pET32 and tev-33-202-ek into 
pET32 with expected sized bands from restriction analysis of  536, 536, 551 bp (each with NcoI and 
SalI), and 1104, 1119, 1143 bp (with XbaI and XhoI) respectively. (B) Successful ligation of NS5A 
constructs tev-1-202-ek into pHAT4, pGAT3 and pMAT10 with expected sized bands from restriction 
analysis with NcoI and SalI of 684, 684 and 654 bp respectively. (C) Successful ligation of NS5A 
constructs 1GST-1-202-ek, 2GST-1-202-ek, 3GST-1-202-ek, 4GST-1-202-ek, 5GST-1-202-ek, 20-
202-ek, 25-202-ek, 1GST-20-202-ek, 1GST-25-202-ek and 4B_229-5A_202-ek into pMAT10 with 
expected sized bands from restriction analysis with NcoI and SalI of 659, 668, 677, 686, 695, 575, 
560, 584, 569 and 761 bp respectively. 
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4.3 Protein Biochemistry 
 
Constructs suitable for structural determination should show high expression, 
solubility, stability and monodispersity. 
 
We attempted to express and purify 1a NS5A D1 with the intents of optimizing our 
yields of soluble, stable, folded protein for structural analysis. A range of tags were 
used including His6-tag (pHAT4), GST-tag (pGAT3), thioredoxin-tag (pET32ekLIC), 
as well as enterokinase , light chain (ek) protease and TEV protease cleavage sites. 
 
4.3.1 Expression and Solubility Trials of 1a NS5A Domain 1 
 
We first assayed genotype 1a NS5A domain 1 33-202 for soluble expression with a 
N-terminal His-tag fusion (contained in the pHAT4 vector), a N-terminal glutathione 
S-transferase (GST) fusion (contained in the pGAT3 vector) and His-thioredoxin 
fusion (contained in the pET32 vector) in a BL21(DE3) cells. BL21(DE3) strains 
were used in the expression of genotype 1b NS5A domain 1 constructs (Tellinghuisen 
et al., 2004; Love et al., 2009) and contain the T7 RNA polymerase expression 
system allowing for overexpression of recombinant proteins, and the constructs were 
codon-optimised for expression in E. coli removing the need to use BL21 derivatives 
which supply rare tRNAs such as Rosetta 2(DE3). Although inclusion bodies are easy 
to isolate and can be useful to obtain high yields of protein (Rudolph and Lilie, 1996), 
we choose to purify protein that was folded in vivo, making it more likely to be folded 
natively. To increase soluble expression, we experimented with lowering the 
temperature before induction and increasing the period of induction, thus decreasing 
the rate of protein synthesis, a traditional approach used to increase solubility 
(Baneyx, 1999). 
 
We assessed the expression and solubility of the His-tagged, GST-tagged and His-
thioredoxin-tagged genotype 1a NS5A domain 1 constructs from small scale 
expression cultures at different temperatures with a dot blot (Figure 4.7). All fusion 
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proteins appeared to express equally well at all temperatures from comparing the 
induced samples against the positive expression control. However little soluble 
expression of the fusion proteins was observed at 37ºC compared with the soluble 
expression at lower temperatures and the positive soluble expression control. 
Therefore we opted to perform slow expression of NS5A domain 1 constructs at 15ºC.  
 
 
Figure 4.7 Anti-polyHistidine dot blot of expression and solubility trials of genotype 1a NS5A Domain 
1. The top three rows show expression of His-tagged, GST-tagged and His-thioredoxin-tagged 1a 
NS5A 33-202 in columns 1 to 3 respectively at all temperatures; 3 h at 37ºC, 12 h at 25ºC or 20 h at 
15ºC. The bottom three rows show low soluble expression of 1a NS5A 33-202 in each vector at 37ºC 
but apparent soluble expression at 25ºC and 15ºC. Column 4 shows positive (expressed empty pET32 
vector) and negative (uninduced empty pET32 vector) controls in total (rows 1 and 2 respectively) and 
soluble (rows 4 and 5 respectively) fractions. 
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4.3.2 Purification of His-tagged 1a NS5A D1 
 
We first attempted to isolate 1a NS5A 33-202 through purification of the His-tagged 
fusion protein (Figure 4.8). His-tagged 1a NS5A 33-202 could be used for further 
studies, however the large (35 aa) N-terminal tag makes the fusion construct a poor 
candidate for in depth structural characterization. TEV cleavage and isolation of 1a 
NS5A 33-202 without the His-tag lead to average yields of about 1.2 mg/litre culture 
(data not shown). 
 
 
Figure 4.8 Purification of His-tagged 1a NS5A 33-202. Shown are the total fraction (whole cell 
lysate), the soluble fraction, the Ni column flow-through (FT), the flow-through collected during 
washing, and the flow-through collected from elution. The elutants show soluble His-tagged NS5A 
constructs 33-202 (22 kDa) shown at red arrow. 
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4.3.3 His-GST-tagged 1a NS5A D1 
 
In an attempt to increase the yield of pure NS5A 33-202, we expressed it with a N-
terminal GST tag. Expression produced high levels of soluble 1a NS5A D1 (Figure 
4.9A), however ~50% of the protein consisted of GST-tag alone – possibly due to the 
fusion protein breaking apart in the cells or during lysis. Use of a Ni-column with an 
imidazole gradient (Figure 4.9C) to remove the his-tagged GST-tag, his-tagged TEV 
protease and any uncleaved fusion protein allowed 1a NS5A D1 to be isolated to high 
purity (Figure 4.9B). Nevertheless the purified 1a NS5A D1 was still present in low 
yields < 1mg/litre culture. 
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Figure 4.9 Purification of GST-tagged 1a NS5A construct 33-202. (A) SDS-PAGE analysis of the 
glutathione-column fractions. Shown are the soluble fraction, the glutathione-column flow-through, the 
flow-through collected during washing, the flow-through collected from elution, sample after O/N 
cleavage. (B) SDS-PAGE analysis of the Ni-column fractions. Shown are the completed cleavage 
reaction, the Ni column flow-through, the flow-through collected during washing and the first major 
peak from the imidazole gradient. (C) Chromatogram of the Ni-column imidazole gradient. 1a NS5A 
construct 33-202 and its peak are shown with red arrows. 
33-202 
GST-33-
202 
 
GST-tag 
33-202 
33-202 
A B 
C GST-tag 
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4.3.4 His-thioredoxin-tagged 1a NS5A D1 
 
Purification of the His-thioredoxin-tagged 1a NS5A 33-202 (Figure 4.10) resulted in 
high purity and high yields of the protein of 25-35 mg/litre culture after the desalting 
step. In the first preparation, approximately 30-40% of the fusion protein was lost 
during the desalting step which was possibly from precipitation in the elution buffer. 
In future purifications, we desalted the elution fractions immediately to minimize 
exposure to imidazole. 
 
 
 
 
  
Figure 4.10 Purification of His-thioredoxin-tagged 1a NS5A construct 33-202. Shown are the total 
fraction, the soluble fraction, the Ni column flow-through, the flow-through collected during washing, 
the flow-through collected from elution and desalted fraction. The eluate and desalted fractions show a 
high yield of soluble His-thioredoxin-tagged 33-202 (36 kDa) marked by red arrow. 
 
TRX-33-202 
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4.3.5 Optimisation of TEV Cleavage of His-thioredoxin-tagged NS5A D1 
Constructs 
 
Fusion tags can be useful in helping to obtain soluble tagged protein. Their caveat is 
they can mask the characteristics of the construct and upon the tag’s removal the 
construct can revert to original properties. In the case of cleaving the thioredoxin tag 
from the 1a NS5A D1, this lead to 100% precipitation of protein. Care has to be 
therefore taken to cleave the fusion protein in an environment amiable to the 
construct. Initial work cleaving His-thioredoxin-tagged 33-202 resulted in very poor 
yields of < 1 mg/litre culture of the tag-less 1a NS5A 33-202 construct. Experiments 
done to vary the amount of protease, concentration of the fusion protein, temperature 
of incubation and time incubated had no effect on yields. In addition, when we 
attempted to concentrate the purified 1a NS5A 33-202 construct, it showed further 
instability and would only concentrate to an approximate limit of 6 mg/ml before 
severe losses of the protein occurred, presumably via precipitation. To test that this 
was not due to enterokinase protease was not unintentionally digesting the construct, 
we inserted a TEV protease site before the construct. Digestion of this new construct 
with TEV resulting in the same construct instability, suggesting that this was caused 
by the properties of the construct itself rather than any unspecific digestion. The 
addition of the C-terminal ek site that was present in the homologue constructs 
(Tellinghuisen et al., 2005; Love et al., 2009) were found to be more than just surplus 
amino acids. The inclusion of a C-terminal ek site in 1a NS5A domain 1 constructs 
dramatically improved their properties, allowing 1a NS5A 33-202-ek to be 
concentrated 40-50 mg/ml after separating it from its tag. No precipitation occurred 
during TEV protease cleavage so long as the fusion protein His-thioredoxin-tagged 
33-202-ek concentration was diluted to a maximum concentration of 2 mg/ml. We 
went on to determine that 1 mg of TEV protease was sufficient to digest 100 mg of 
His-thioredoxin-tagged 33-202-ek during a cleavage reaction overnight at room 
temperatures (Figure 4.11). 
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4.3.6 Expression and Purification of 1a NS5A 33-202-ek 
 
Expression of His-thioredoxin-tagged 33-202-ek in BL21(DE3) cells resulted in 
yields of 30-40 mg/litre culture of His-thioredoxin-tagged 33-202-ek after the 
desalting step. After cleaving the protein, we decided to use a second Ni-column to 
remove the TEV protease, the His-thioredoxin as well as any impurities that bound to 
the first Ni-column. This should give highly pure sample as in theory everything that 
bound to the first Ni-column pre-cleavage should bind to it again except the 1a NS5A 
33-202-ek construct as it was dissociated from the His6-tag. This worked out to result 
in obtaining pure 33-202-ek in practice, although the protein was diluted in the flow-
through and 1st wash of the 2nd Ni-column (Figure 4.12). The dilute sample 
 
Figure 4.11 TEV protease cleavage time-course of His-thioredoxin-tagged 33-202 at 22°C. Shown are 
SDS-PAGE analysis of samples from incubation of 1 mg of His-thioredoxin-tagged 33-202 at 2 mg/ml 
for digestion with 5 µg TEV protease (1:200 (w/w) protease-fusion protease ratio). 80-90% of His-
thioredoxin-tagged 33-202 appears to be digested after overnight incubation. 
 
TRX-33-
202-ek 
 
TRX-tag 
33-202-ek 
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necessitated a concentration step taking between 8 to 24 hours before we subjected 
the sample to size exclusion chromatography into either crystallization or NMR 
buffers as a final polishing step (Figure 4.13A). The pooled fractions corresponding to 
the peak appeared to contain the 1a NS5A 33-202-ek construct to high purity (Figure 
4.13B). We were able to obtain yields of 4.5 mg/litre culture using the His-
thioredoxin-tagged 1a NS5A 33-202-ek.  
 
 
 
  
Figure 4.12 Purification of 33-202-ek from the expressed His-thioredoxin-tagged 33-202-ek fusion 
protein. Shown are the soluble fraction, the Ni-column flow-through, the flow-through collected during 
washing (lane 3), the flow-through collected from elution, the desalted fraction, TEV digestion of His-
thioredoxin-tagged 33-202-ek, collection of 33-202-ek from the flow-through and first wash from the 
2
nd
 Ni-column, the second wash from the 2
nd
 Ni-column and elution from the 2
nd
 Ni-column. The 
desalted fraction shows a high yield of soluble His-thioredoxin-tagged 33-202-ek (36 kDa) marked by 
red arrow. Furthermore the flow-through and first wash from the 2
nd
 Ni-column contain a high yield of 
pure 1a NS5A 33-202-ek. 
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tagged 33-202-ek 
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Figure 4.13 Size exclusion chromatography of 1a NS5A 33-202-ek. (A) Chromatograph of Superdex 
75 16/60 filtration with 25 mM Tris-HCl (pH 8.0), 150 mM NaCl as the running buffer. The expected 
elution volumes from calibration with molecular mass standards Blue Dextran, Conalbumin, 
Ovalbumin, Ribonuclease A and Aprotinin, are marked with the black arrows. (B) SDS-PAGE 
analysis of the 1 ml fractions A1 to A13 representing the elution volume 65.7 ml to 77.7 ml. The sizes 
of band (shown at red arrow) in these fractions correspond to 33-202-ek (20 kDa). 
 
4.3.7 MALDI-TOF Mass Spectrometry of 1a NS5A 33-202-ek 
 
For quality control we verified the purity of the 1a NS5A 33-202-ek construct with 
Matrix-assisted laser ionization Time-of-flight (MALDI-TOF) Mass spectrometry 
A1   A3   A5   A7  A9  A11 A13A15B14 B12B10 B8  B6 
A 
B 
Blue Dextran 2000 
V0 = 46.1 ml 
Conalbumin (Mr = 75 kDa) 
Ve1 = 55.0 ml 
Ovalbumin (Mr = 44 kDa) 
Ve2 = 60.9 ml 
Ribonuclease A (Mr = 13.7 kDa) 
Ve3 = 78.6 ml 
Aprotinin (Mr = 6.5 kDa) 
Ve4 = 91.6 ml 
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(Figure 4.14). We determined the protein to be of sufficient purity (more than 95%) 
for structural studies and its crystallisation. 
 
 
Figure 4.14 MALDI-TOF Mass spectrum of purified 1a NS5A 33-202-ek. The spectrum indicates 33-
202-ek to be qualitatively greater than 95% pure. The major species of 19702 Da is smaller than 33-
202-ek’s theoretical molecular weight of 19806 Da - this discrepancy might be due to calibration of the 
MALDI-TOF mass spectrometry machine or the loss of an amino acid. Peaks at 39529, 59346 and 
79009 Da result most likely from MALDI-induced multimerisation. 
 
4.3.8 Thermal Denaturation Assay 
 
Obtaining high yields of soluble NS5A D1 is not the only challenge in its isolation for 
structural studies. NS5A D1 is highly susceptible to precipitation, particularly when 
concentrated to concentrations > 1 mg/ml. To circumvent or restrict this problem we 
used a fluorescence-based thermal shift experiment (Zhang and Monsma, 2010) to 
identify stabilizing buffer components for NS5A D1. In general, buffers, compounds 
or additives which stabilize a protein will cause it to unfold or melt at a higher 
temperature resulting in melting temperature (Tm) shift (Figure 4.15A). The full list of 
the conditions tested with construct 33-202-ek is shown in appendix 7.2. 
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4.3.8.1 Effect of Buffers and pH on 33-202-ek Denaturation 
 
24 different buffers which pH values from 3.0 to 10.0 were assayed for any stabilizing 
effect on genotype 1a NS5A construct 33-202-ek (Figure 4.15B). The buffer observed 
to have the most stabilizing effects contained phosphate. Further experiments showed 
that the cation of the phosphate buffers, either sodium or potassium, made no 
difference to the stability of 33-202-ek (data not shown). However the phosphate 
buffer appeared to stabilize 33-202-ek the most at a pH of approximately 7.5 (Figure 
4.15C).  
 
It is known for phosphate anions to stabilize proteins against denaturation particularly 
in proteins known to bind phosphate (Ahmad and Bigelow, 1986): As NS5A domain 
1 is a known RNA-binding protein (Hwang et al., 2010), it might be that the 
phosphate ions are stabilizing construct 33-202-ek in place of a ribonucleic acid 
backbone. 
 
4.3.8.2 Glycerol Stabilizes 33-202-ek 
 
From the screen of conditions, most of the additives do not have a significant 
stabilizing effect (data not shown), including perhaps surprisingly the addition of zinc 
or other divalent cation salts – as the structural integrity of NS5A domain 1 is 
dependent on binding zinc (Tellinghuisen et al., 2004), we should assume it is fully 
saturated. 
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Figure 4.15 Phosphate buffers stabilize genotype 1a NS5A construct 33-202-ek. (A) Fitted melting 
curves of 33-202-ek samples in control (the crystallisation buffer consisting of 20 mM Tris.HCl, 150 
mM NaCl, 10% glycerol, pH 8.0), sodium acetate and phosphate buffers with melting temperature 
(Tm) shifts indicated. (B) Summary of Tm shifts relative to control. Phosphate buffers can have a 
stabilizing effect on 33-202-ek. Error bars indicate the standard deviation (n=4). (C) Average Tms of 
phosphate buffers at different pHs. Phosphate buffers have the greatest stabilizing effect at a pH of 
approximately 7.5. Error bars indicate the standard deviation (n=8). 
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The notable exception is glycerol, from fitting the melting curves of 1a NS5A 
construct 33-202 with and without glycerol, the Tm increased from 42°C to 44°C 
indicating it to have a stabilizing effect on the 1a NS5A construct 33-202-ek (data not 
shown). Glycerol has long been used as a cosolvent to stabilize proteins in aqueous 
solutions and prevent their aggregation (Vagenende et al., 2009). Henceforward we 
used 10% (v/v) glycerol in all the purification buffers to minimise loss of NS5A 
domain 1 constructs due to precipitation. Concentration experiments have shown this 
allows construct 33-202-ek to be concentrated to 40 mg/ml. 
 
We followed-up this result and tested the effect of glycerol stabilization over a range 
of concentrations: Glycerol has a substantial effect on the thermal stability of 33-202-
ek with an addition of concentrations of 55% (v/v) or more increasing the Tm by 10°C 
(Figure 4.16). Such concentrations may be useful to allow higher temperatures for 
NMR and less aggregation, assuming the decreased signal-to-noise because of the 
increased viscosity is mitigated. 
 
 
Figure 4.16 Average melting temperatures (Tms) of 33-202-ek with different concentrations of glycerol. 
Note the control (SEC buffer) already has 10% glycerol. The presence of glycerol highly stabilizes 
construct 33-202-ek with Tms increasing from 42°C to 52°C but plateauing after about 55% glycerol. Error 
bars indicate the standard deviation. 
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4.4 NMR of 1a NS5A 33-202-ek 
 
With a general purification protocol established to isolate pure 33-202-ek, we could 
move on to its structural analysis. NMR allows us to immediately study the protein in 
solution in addition to giving us better information on the construct’s suitability for 
further structural studies. 
 
4.4.1 1D NMR of 33-202-ek 
 
An initial 1D 
1
H spectrum of a 1a NS5A 33-202-ek was performed using a phosphate 
buffer at pH 7.5 (Figure 4.17) as determined by the previous stability screens using 
the thermal denaturation assays. The 1D 
1
H spectrum shows 1a NS5A 33-202-ek to be 
well folded and a suitable construct for further structural characterisation. 
 
 
Figure 4.17 1D 1H spectrum of a 1a NS5A 33-202-ek. Buffer consists of 100 mM KPO4 (pH 7.5), 100 
mM NaCl at 298K. 33-202-ek shows a good dispersion with methyl peaks in the negative ppm range 
and amide peaks out near 10 ppm indicating it to be folded. 
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To examine the tertiary structural environment of 33-202-ek, we performed a 1D 
NMR experiment (Figure 4.18). The spectrum shows a range of additional methyl 
peaks suggesting the protein is folded or at least partially folded. Without reducing 
agent present, the amplitude of these peaks has decreased slightly after 1 day’s 
incubation at 298K and their amplitude has decreased 3-fold after 4 days incubation at 
298K. The inclusion of 5 mM TCEP reducing agent resulted in only a small reduction 
in the methyl peak amplitude during the 298K incubation – probably by preventing 
aggregation through inhibiting intermolecular sulphite bond formation. 
 
We used reducing agent in our attempts to make a peptide backbone assignment of 
33-202-ek at higher concentrations, however the signal from was much lower 
paradoxically than that from lower concentrations of 33-202-ek. In an attempt to 
rectify this, we concentrated 33-202-ek further, only to result in a further decrease in 
signal. This is probably due to the propensity of 33-202-ek to aggregate at higher 
concentrations (Tellinghuisen et al., 2005). This dilution of concentrated samples 
resulted in an increase in 33-202-ek signal, showing the aggregation effect was at 
least somewhat reversible (Figure 4.19). The optimal concentration – highest 
  
Figure 4.18 Stability of construct 33-202-ek. 33-202-ek at 220 µM in 100 mM KPO4 (pH 7.5), 100 
mM NaCl at 298K (A) without and (B) with 5 mM TCEP at day 0 (shown in red), at day 1 (shown in 
red) and at day 4 (shown in green). At the start of the 298K incubation both spectra showed 33-202-ek 
to have a dispersion of methyl peaks and hence be well folded. With the reducing agent, the amplitude 
of most of the peaks of 33-202-ek remained the same, the exception being a large peak at 0 ppm. 
Without reducing agent all the peaks’ amplitudes were substantially reduced over the 298K incubation.  
 
A B 
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concentration without aggregation - of 33-202-ek for NMR experiments was 
determined to be approximately 200 µM. However this concentration would not 
bestow enough signal for structural assignment experiments. 
 
 
Figure 4.19 Reversible aggregation of 33-202-ek at high concentrations. Buffer conditions consist of 
100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K. Spectra from top to bottom show 33-
202-ek at 544 µM (yellow), at 400 µM (purple), at 300 µM (green), at 250 µM (red), and at 200 µM 
(blue). At higher concentrations of 33-202-ek, the methyl signal of 33-202-ek decreases, probably as a 
result of non-disulfide-linked aggregation of 33-202-ek.  
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Although glycerol had a stabilizing effect on NS5A domain 1 (see 4.3.8.2), deuterated 
glycerol resulted in a distortion in the NMR spectra (Figure 4.20) ruling out its 
inclusion in NMR buffers despite its stabilising and anti-aggregation effects. However 
it should be noted that concentrations of glycerol below 10% (v/v) results in only 
minor distortions in NMR spectra and inclusion at these levels may be useful when a 
slight stabilising is required in NMR experiments of NS5A domain 1. 
 
 
Figure 4.20 Effect of deuterated glycerol on NS5A 33-202-ek 1D spectrum. Buffer conditions consist 
of 100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K, in addition with either 50% (v/v) 
glycerol (shown in red), 40% glycerol (shown in green), 30% glycerol (shown in purple), 20% glycerol 
(shown in yellow), 10% glycerol (shown in orange) and 0% (shown in blue).  
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4.4.2 2D NMR of 33-202-ek 
 
At relatively low concentrations of 33-202-ek we were able to performed a 2D NMR 
1
H,
15
N-HSQC experiment to better observe its tertiary structural environment (Figure 
4.21). The peaks of the 
1
H,
15
N-HSQC are reasonably well dispersed and most of the 
individual peaks can be distinguished. 
 
 
Figure 4.21 1H,15N-HSQC spectrum of 33-202-ek. 33-202-ek is at 55 µM in 100 mM KPO4 (pH 7.5), 
100 mM NaCl 10 mM TCEP at 298K. The spectrum shows a good dispersion of peaks suggesting the 
33-202-ek construct to be well folded. The 154 counted peaks corresponds well with the 171 peaks 
predicted to be visible suggesting the majority of the construct is folded. 
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The construct 33-202-ek contains 178 amino acid residues; 17 of which were prolines 
which do not show up on the 
1
H,
15
N-HSQC spectrum, at least 3 flexible N-terminal 
residues left from TEV site, at least 5 flexible C-terminal residues from the 
enterokinase site which should not be expected to appear on the spectrum and in 
addition 33-202-ek contained 3 glutamines and 5 asparagines which show an extra 
doublet peak per amino acid residue – this gives a predicted amount of 171 peaks 
which should be visible. Approximately 154 residues could be counted on the 
spectrum which gives an indication that 33-202-ek is overall well folded and 
monomeric. 
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4.4.3 Titrations 
 
There have been no reports of any NMR interaction studies of NS5A with NS5A 
inhibitors so we attempted an 
1
H,
15
N-HSQC titration of 33-202-ek with Daclatasvir 
(DCV). A one point titration was followed with a 15-fold concentration of DCV to the 
construct 33-202-ek (Figure 4.22). There was no obvious change to the 
1
H,
15
N-HSQC 
of 33-202-ek in the presence of DCV suggesting there no interaction. 
 
 
Figure 4.22 1H,15N-HSQC spectra of a titration of 33-202-ek with DCV. Buffer conditions consist of 
100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K. The 33-202-ek with DCV at 1.5 mM 
(shown in green) does not have any chemical shifts in peaks relative to 33-202-ek without DCV 
(shown in red). In both spectra, 33-202-ek is at 125 mM. 
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Similarly, we repeated this interaction study with a 20 repeat poly-uracil (20rU) 
resembling viral RNA to investigate the RNA-binding properties of the domain. There 
were no obvious peak shifts and hence no interaction of 33-202-ek with the viral RNA 
(Figure 4.23). We surmise this lack of interaction is due the full RNA-binding region 
of NS5A not being present in the construct 33-202-ek (Hwang et al., 2010). 
 
 
 
Figure 4.23 1H, 15N-HSQC spectra of a titration of 33-202-ek with RNA. Buffer conditions consist of 
100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K. The 33-202-ek with RNA (20rU) at 2 
mM (shown in green) does not cause any shifts in peaks than 33-202-ek without RNA (shown in red). 
In both spectra, 33-202-ek is at 50 mM.  
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In another titration of 33-202-ek, we investigated if there was an interaction of the 
amphipathic helix (AH) with the construct. A synthesised amphipathic helix (AH) 
from genotype 1a consisting of the amino acids residues SGSWLRDIWD 
WICEVLSDFK TWLKAKLMPQL, was used for the titration. Some shifts in peaks 
were observed (Figure 4.24), however these shifts were small, indicating a very weak 
interaction of AH with 33-202-ek. 
 
 
 
Figure 4.24 1H,15N-HSQC spectra of a titration of 33-202-ek with AH. Buffer conditions consist of 
100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K. The 33-202-ek with AH at 1 mM 
(shown in green) causes slight perturbations (marked at red arrows) in the peak positions of 33-202-ek 
without AH (shown in red) however not enough to indicate a strong interaction. In both spectra, 33-
202-ek is at 125 mM. In both spectra, 33-202-ek is at 100 mM. 
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4.5 Chapter Summary 
 
After a bioinformatics analysis, we successfully cloned constructs of domain 1 of the 
HCV genotype 1a (isolate H77) NS5A with and without its N-terminal AH and 
ligated them into the expression vectors pHAT4, pET32, pGAT3 and pMAT10 which 
are N-terminally his-tagged, thioredoxin-his-tagged, GST-tagged and MBP-tagged 
respectively.  
 
After testing expression of genotype 1a NS5A construct without its N-terminal AH 
(33-202-ek) with a N-terminal His-tag and GST-tags, we established a purification 
protocol which gave maximal yields of the construct after expression and isolation 
with a thioredoxin-tag. Our 33-202-ek purification protocol yields approximately 4.5 
mg/litre culture of pure protein. We optimised a NMR buffer for 33-202-ek to consist 
of 100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP. NMR spectroscopy showed 
the construct to be well-folded. Interactions of 33-202-ek with viral RNA, DCV or the 
amphipathic helix (AH), could not be detected by NMR.  
 
As the key resistance mutations to NS5A inhibitors such as DCV arise in the AH 
(Fridell et al., 2010; Gao et al., 2010), we surmise the inclusion of the AH in NS5A 
constructs is necessary to establish an interaction with DCV. In Chapter 5, we attempt 
to rectify this by isolating NS5A domain 1 constructs containing the AH or at least 
part of the AH. 
 
Reversible aggregation of 33-202-ek occurred at concentrations over 200 µM 
hampering its structural determination by NMR. However we used 33-202-ek in 
crystallisation trials and were able to solve its structure by X-ray crystallography 
(Chapter 6). 
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Chapter Five 
 
Isolation of Genotype 1a NS5A Constructs with 
the Amphipathic Helix 
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5.1 Protein Biochemistry 
 
As the amphipathic helix (AH) contains key resistance mutations to NS5A-targeting 
compounds (Gao et al., 2010) we attempted to create constructs which included these 
residues.  
 
5.1.1 Expression of Genotype 1a NS5A 1-202-ek Fusion Proteins 
 
There are no reports of NS5A constructs which include the AH in the literature and 
constructs typically have the N-terminal AH removed to obtain soluble protein 
(Marcotrigiano and Tellinghuisen, 2009) as inclusion of the AH abolishes expression. 
We attempted to circumvent this by including a large N-terminal fusion tag before the 
genotype 1a NS5A domain 1 which included the AH consisting of the construct 
NS5A 1-202-ek. A glutathione S-transferase (GST) tag was able to revive expression, 
however the expressed protein was not soluble. A maltose-binding protein (MBP) tag 
produces soluble 1a NS5A 1-202-ek fusion with the most soluble protein appearing to 
be expressed at 25°C (Figure 5.1). 
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Figure 5.1 Anti-polyHistidine dot blot of expression and solubility trials of genotype 1a NS5A 1-202-
ek. The top three rows show expression of N-terminally His-tagged, GST-tagged and MBP-tagged 1a 
NS5A 1-202-ek in columns 1 to 3 respectively at all temperatures; 3 h at 37ºC, 12 h at 25ºC or 20 h at 
15ºC. The bottom three rows show low soluble expression of 1a NS5A 1-202-ek in each vector at 37ºC 
but apparent soluble expression at 25ºC and 15ºC. Column 4 shows positive (expressed empty 
pMAT10 vector) and negative (uninduced empty pMAT10 vector) controls in total (rows 1 and 2 
respectively) and soluble (rows 4 and 5 respectively) fractions. 
 
5.1.2 Purification of MBP-tagged 1-202-ek 
 
The MBP-tagged construct 1-202-ek could be isolated but not cleaved from its MBP-
tag (Figure 5.2) presumably due to the hydrophobic residues of the AH inferring with 
TEV protease activity. 
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Figure 5.2 Attempted purification of 1-202-ek from the expressed MBP-tagged 1-202-ek fusion 
protein. Shown are the soluble fraction, the Ni-column flow-through, the flow-through collected during 
washing, the flow-through collected from elution, the desalted fraction, incubation with 1 mg TEV 
protease per 100 mg fusion protein for 16 h, and a further incubation with an additional 10 mg TEV 
protease per 100 mg fusion protein for an additional 16 h. The desalted fraction shows a high yield of 
soluble MBP-tagged 1-202-ek fusion protein (57 kDa) marked by red arrow. Incubation with TEV did 
not result in any cleavage of the fusion protein. 
 
 
5.1.3 Expression and Purification of 1a NS5A (Link 1-5) 1-202ek 
Constructs 
 
To permit cleavage of the MBP-1-202-ek fusion, we created a series of constructs 
with 1 to 5 Gly-Ser-Thr linker repeats (Link) between the TEV cleavage site and the 
AH.  The Gly-Ser-Thr linker repeats provide an extended linker region to introduce 
additional space for TEV protease to access its cleavage site, potentially relieving the 
steric occlusion. As this amino acid sequence is known to be unstructured (PJ 
Simpson, unpublished results) it should not contribute any ordered structure to the 
construct, which could potentially interfere with later structural studies. The 
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constructs were expressed, purified and incubated with TEV protease. The (Link1) 1-
202ek construct was not successfully cleaved, suggesting that this linker is 
insufficient to provide space for TEV protease to access its cleavage site, whereas 
longer linkers in the (Link5) 1-202ek construct resulted in an unstable cleavage 
product. Finally we opted for the (Link2) 1-202ek construct as of the successfully 
cleaved constructs it could be cleaved with the shortest Gly-Ser-Thr repeat linker and 
therefore any potential interference from the linker in later structural studies would be 
minimised (Figure 5.3). 
 
 
Figure 5.3 TEV protease cleavage of each of the 1a NS5A (Link 1-5) 1-202ek constructs.  Samples of 
each construct before and after (-/+) overnight incubation at room temperature with TEV protease.  No 
cleavage of the 1a NS5A (Link 1-5) 1-202-ek construct with the shortest linker is seen.  The lanes 
corresponding to 1a NS5A (Link 2-4) 1-202-ek constructs following  overnight incubation with TEV 
protease show a clear decrease in the band at ~ 66 kDa corresponding to the construct fused to the 
MBP tag and the emergence of a band at ~22 kDa, indicating successful cleavage of 1-202ek from the 
tag.  The lanes corresponding to the 1a NS5A (Link 5) 1-202-ek construct are missing the band at ~66 
kDa before cleavage by TEV protease, suggesting that this construct is unstable. 
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5.1.4 Purification of 1-202ek NS5A 
 
Following digestion of the 1a NS5A (Link 2) 1-202-ek construct with TEV protease, 
we used size exclusion chromatography to separate 1-202-ek from the MBP tag.  The 
elution profile (Figure 5.4A) shows two clear peaks corresponding to the void 
volume, which contains proteins and aggregates too big to enter the pores of the 
column matrix, and the MBP tag.  SDS-PAGE analysis of the second peak showed 
that the NS5A construct eluted from the column in a small peak within the tail of the 
MBP elution (Figure 5.4B).  This indicates that there was only a small amount of 1-
202-ek present and therefore that it is likely to be unstable in solution. There was also 
some NS5A construct present in the void volume indicating aggregation of the 
protein. Purifications were also carried out in detergents which did not interfere with 
TEV cleavage including LDAO, DPC and CHAPS. None of these detergents were 
determined to significantly stabilise the 1-202-ek by increasing yields (data not 
shown) and yields could not produce enough 1-202-ek construct for an 1D NMR 
experiment. An attempt was made to stabilise the amphipathic by including an 
additional amphipathic helix at the N-terminus using a construct that extended NS5A 
into NS4B (4B_229-5A_202-ek). This approach was based on the knowledge that 
NS4B-NS5A intermediates exist in vivo (Bartenschlager et al., 1994) and that the C-
terminal amphipathic helix of NS4B may stabilise the N-terminal amphipathic helix 
of NS5A before inserting into the ER and cleavage of the polyprotein. However we 
were unable to express this construct (data not shown). 
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Figure 5.4 Size exclusion chromatography of the HCV 1a (Link 2) 1-202ek. The construct was 
separated from the MBP tag by size exclusion chromatography with a Superdex 75 column.  (A) The 
elution profile shows two clear peaks corresponding to the void volume and the MBP tag. (B) SDS 
analysis of the initial TEV cleavage reaction and of various fractions collected at the elution volumes 
indicated.  The band at ~24 kDa in fractions 61 to 64 ml corresponds to the 1-202-ek NS5A construct,  
present in a small peak within the tail of the larger MBP peak. 
 
 
 
 
 
A 
B 
Fractions taken 
for SDS-PAGE 
analysis
 
MBP-tag 
1-202-ek 
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5.1.5 MBP-tagged (Link2) 1-202ek NS5A is Not Folded 
 
1D NMR spectra of the fusion protein and of MBP alone were recorded and compared 
to a previously recorded spectrum of an NS5A construct without the amphipathic 
helix (Figure 5.5).  The methyl region of the spectrum corresponding to the fusion 
protein closely resembled that of MBP in isolation and was missing several distinct 
peaks seen in the previous NS5A spectrum, suggesting that either the NS5A construct 
is unfolded in solution or has aggregated.  Either scenario hampers the recording of an 
NMR spectrum for this region of the construct. 
 
 
Figure 5.5 Domain 1 is not folded in MBP-tagged (Link2) 1-202ek NS5A. 1D 
1
H NMR spectra of 
NS5A construct without the amphipathic helix (blue), the MBP-NS5A fusion protein (green) and MBP 
alone (red).  Buffer conditions consist of 100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 
298K. The absence of several distinct peaks in the spectrum of the fusion protein that are present in the 
spectrum of the previous NS5A construct (such as the peak shown with the red arrow), indicates that 
the NS5A construct is either unfolded or aggregated.  
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5.1.6 Expression and Purification of Constructs with Partial AH 
 
We created and expressed new NS5A constructs including part of the AH and the AH 
linker, with the objective of creating a NS5A domain 1 construct containing the key 
resistance mutation sites. NS5A constructs 20-202-ek and 25-202-ek were expressed 
and purified with MBP fusions. 20-202-ek could not be digested by TEV protease 
whereas 25-202-ek could be digested and isolated as in 5.1.4 (Figure 5.6). Inclusion 
of a single Gly-Ser-Thr repeat (Link1) in between 20-202-ek and the TEV site 
allowed its digestion and subsequent isolation.  
 
 
Figure 5.6 Purification of 20-202-ek and attempted purification 25-202. Shown are the desalted 
fraction after an initial Ni chromatography step, incubation with 1 mg TEV protease per 100 mg fusion 
protein for 16 h, the flow-through, wash and elution fractions from a further No chromatography step. 
20-202-ek could not be digested and hence isolated. 25-202-ek (22 kDa) marked by red arrow could be 
digested and isolated. 
 
 168 
 
5.2 NMR 
 
5.2.1 NMR of NS5A 20-202-ek and 25-202-ek 
 
1D NMR spectra of the NS5A (Link1) 20-202-ek and 25-202-ek showed the 
constructs to contain the ordered peaks of the NS5A domain 1 suggested they were 
correctly folded (Figure 5.7). Constructs were also subject to digestion and isolated by 
size exclusion chromatography with a Superdex 75 column as the 1a NS5A (Link 2) 
1-202-ek construct (Figure 5.4). Due to the low yields of obtained of isolated (Link1) 
20-202-ek after digestion (less than 0.2 mg/litre culture); we used the shorter 
construct 25-202-ek (yield of 1 mg/litre culture) for further characterisation which 
still contained the key resistance mutation sites. 
 
 
Figure 5.7 Domain 1 is folded in MBP-tagged (Link1) 20-202ek NS5A and 25-202ek NS5A. 1D 
1
H 
NMR spectra showing from top to bottom MBP-1-202-ek (in purple), MBP-Link1-20-202-ek (in 
green), MBP-25-202-ek (in red) NS5A fusions, and NS5A 33-202-ek (in blue). Both constructs with 
the partial AH appear to contain the folded peak of NS5A domain 1 (shown at red arrows). Buffer 
conditions consist of 100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K. 
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5.2.2 2D NMR of 25-202-ek 
 
NS5A 25-202-ek showed a similar 
1
H,
15
N-HSQC spectrum to NS5A 33-202-ek with 
some additional peaks and perturbations of peaks suggesting domain 1 of 25-202-ek 
to be correctly folded and the additional residues N-terminal AKLMPQLP of the 
partial AH region to be structured and interacting with the rest of the domain (Figure 
5.8). The most noticeable peak shift was a tryptophan (due its position in the 
1
H,
15
N-
HSQC) which may be involved in part of a conformation change due to the inclusion 
  
Figure 5.8 1H,15N-HSQC overlay of 33-202-ek over 25-202-ek. 33-202-ek is shown in red. 25-202-ek 
is shown in black. Buffer conditions consist of 100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP 
at 298K. 25-202-ek contains some additional peaks (shown at red arrow) and perturbations of peaks 
(shown at blue arrow – likely to be a tryptophan residue). 33-202-ek is at 125 mM and 25-202-ek is at 
200 mM. 
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of the partial AH region. The NMR signal of 25-202-ek was lower than that of 33-
202-ek as it showed a higher propensity to aggregate. 
 
5.2.3 Titration of 25-202-ek with DCV 
 
Addition of DCV to 25-202-ek showed small but significant changes in a 
1
H,
15
N-
HSQC (Figure 5.9) indicating a weak interaction of DCV with the construct. Due to 
the small shift in the spectrum and the compound being in 7.5-fold excess of the 
construct, this interaction is likely to be in fast exchange. Interestingly, the same 
tryptophan peak which had undergone a shift with the extension of the N-terminus 
undergoes a further shift with the addition of DCV. This suggests this region of the N-
terminus in the extended construct is structured and this additional structure allows 
interaction of DCV with NS5A.  
 
A caveat to note for this result is that we had no DMSO control, as after addition of 
DCV, 25-202-ek is present in 10% DMSO which may be responsible for the peak 
shifts. However as DMSO had no effect on the 
1
H,
15
N-HSQC of 33-202-ek, we 
surmise it has no effect on the 
1
H,
15
N-HSQC of the very similar construct 25-202-ek. 
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Figure 5.9 1H,15N-HSQC overlay of 33-202-ek over 25-202-ek and 25-202-ek with DCV. 33-202-ek 
is shown in black, 25-202-ek is shown in red, 25-202-ek with DCV is shown in green. Buffer 
conditions consist of 100 mM KPO4 (pH 7.5), 100 mM NaCl 10 mM TCEP at 298K. Arrows indicate 
shifts due to addition of DCV to 25-202-ek. The peak marked with the red arrow which has undergone 
a shift with the extension of the N-terminus undergoes a further shift with the addition of DCV.  
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5.3 Chapter Summary 
 
After screening a NS5A domain 1 construct with the AH, 1-202-ek, for expression 
with N-terminal His-tags, GST-tags and MBP-tags, we were able to express a soluble 
fusion with an N-terminal MBP-tag. After optimised its cleavage and isolation from 
the MBP-tag, the construct 1-202-ek was highly prone to precipitation and NMR 
showed it to be poorly folded. 
 
Using the same expression and purification protocol we had established, we purified 
constructs with only part of the AH, constructs 20-202-ek and 25-202-ek. Both 
appeared to be folded, however the yields for construct 25-202-ek were higher (1 
mg/litre culture).  
 
1
H,
15
N-HSQC spectra showed 25-202-ek to be folded similarly to construct 33-202-
ek, however extra peaks were present suggesting additional structure. Furthermore 
inclusion of the AH linker appeared to slightly alter the conformation of the rest of the 
domain. These additional and altered regions may form part of the interaction site 
with NS5A inhibitors such as DCV. A titration of construct 25-202-ek suggests there 
is a weak interaction with DCV. Part of this region interacting with DCV, likely a 
tryptophan due to its position on the  
1
H,
15
N-HSQC spectrum, is also a region of the 
construct 33-202-ek that was altered with inclusion of the AH linker. We propose that 
inclusion of the AH linker alters NS5A domain 1 in such a way to allow an interaction 
with NS5A inhibitors like DCV. 
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Chapter Six 
 
The Crystal Structure of Genotype 1a NS5A 
Domain 1 
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6.1 Crystallisation of 1a NS5A 33-202-ek 
 
The NS5A construct 33-202-ek, which was determined as pure by SDS-PAGE and 
MALDI-TOF Mass spectrometry and well-folded by NMR spectroscopy, was used in 
efforts to determine its structure via X-ray crystallography. 
 
6.1.1 Optimisation of 1a NS5A D1 Concentration for Crystallization 
 
Crystallisation of proteins occurs when the protein is present in a supersaturated phase 
which is dependent on protein concentration and precipitants present in the solution 
(Rhodes, 2006). At too low a protein concentration, no precipitant and hence no 
crystallisation can occur. At too high a protein concentration, too much crystal 
nucleation or amorphous precipitation of the protein will occur. Before the arduous 
process of screening many different precipitant and buffer conditions, it is first 
necessary to optimize the concentration of the protein so that its nucleation and 
crystallisation can occur without an overabundance of precipitate or clear drops. 
 
 
33-202-ek concentration 
(mg/ml) 
Proportion of clear 
drops 
11 5-6% 
9 ~7.5% 
7 ~15% 
6 ~41% 
5 ~41% 
 
 
Table 6.1 Proportion of clear drops on ICL1 sparse matrix screen with varying 33-202-ek 
concentration after incubation for 24 h at 20°C. 
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To optimize the concentration of 33-202-ek, we set up several plates of Hampton 
Research Crystal Screen HT, a sparse matrix protein crystal screen, with different 
concentrations of 33-202-ek (Table 6.1). The aim was to find protein concentrations 
where between 33-50% of the drops in the screen were clear after equilibration was 
reached – which should be within 24 hours incubation time at 20°C. Using this as a 
guideline, we determined that between 5-7 mg/ml would an optimum range of 33-
202-ek concentration to use in crystallisation screens drops. 
 
6.1.2 Crystal Screens of 1a NS5A D1 at 20°C 
 
We used the full range of (14) screens (ICL1 to ICL14) available at the Imperial X-
ray Crystallography facility, a total of 1344 conditions (including redundant 
conditions), to screen 33-202-ek for crystallisation at 20°C. Plates were checked at 4 
days, 1, 2, 3 weeks, 1, 2 and 3 months after setting up the screens. No drops contained 
any crystal hits, only clear drops and a variety of amorphous precipitations. 
 
6.1.3 Crystal Screens of 1a NS5A D1 at 4°C 
 
Temperature can be an important variable in macromolecular molecule crystallization, 
affecting a protein’s propensity to nucleate to crystals and grow by changing its 
solubility and saturation points (Hampton Research, 2001). Indeed the crystallisation 
of the 1b NS5A D1 homologue was achieved at 4°C (Tellinghuisen et al., 2005; Love 
et al., 2009). On this basis the same 14 screens (ICL1 – ICL14) were used to screen 
crystallisation of 33-202-ek at wider concentration range of 6 to 12 mg/ml at 4°C. 
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Crystal hits first appeared visible between one and three weeks incubation at 4°C. 
Hits were of varying morphology and were obtained from several different conditions 
- a full list of the hits is shown in appendix 7.3. The biggest crystals obtained from the 
screens grew in 1.6 M magnesium sulphate with 0.1 M MES pH 6.5 on the ICL12 
screen well H6. The crystals were between 30-40 µm wide and resembled small 
octahedra, an unusual crystal habit for salt crystals (Figure 6.1). Hits also appeared in 
the same conditions present in other ICL screens, indicating the reproducibility of 
growing these crystals, however there was variation in size from each drop. The MES 
buffer was present in two other non-redundant hits, perhaps suggesting its importance 
in the formation of genotype 1a NS5A 33-202-ek crystals. 
 
6.1.4 Optimisation of Crystal Hits 
 
The condition 1.6 M magnesium sulphate with 0.1 M MES pH 6.5 buffer was chosen 
for optimisation. Magnesium sulphate concentration was varied from 0 to 2.2 M in 
increments of 0.2 M and the pH of the 0.1 M MES was varied from pH 5.25 to pH 7.0 
in increments of 0.25 pH units. We used new preparations of 33-202-ek for this 
optimisation screen, with and without 5 mM DTT in the final buffer.  
A 
 
B 
 
Figure 6.1 Crystal hits of 33-202-ek. (A) ICL12 screen drop H6 containing the largest 33-202-ek 
crystals after 5 weeks incubation at 4°C in a sitting drop setup with 100 nl of 33-202-ek at 8 mg/ml in 
20 mM Tris.HCl, 150 mM NaCl, 10% glycerol, pH 8.0 added to 100 nl of the reservoir buffer. The 
reservoir buffer consists of 1.6 M magnesium sulfate and 0.1 M MES pH 6.5. (B) Magnification of 
image from A. Crystals are octahedral with widths between 30-40 µm. 
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After 6 days incubation crystals were observed in two drops; both at pH 6.75, both 
without the reducing agent and at magnesium sulphate concentrations of 1.4 M and 
1.6 M. After 20 days incubation, a spectrum of increasingly smaller and abundant 
crystals merging into amorphous precipitate was observed in the drops (except 
magnesium sulphate concentrations of 1.4 M at pH 5.75 and pH 6.0) with increasing 
concentrations of magnesium sulphate of 1.4 M and above. The 5 mM DTT did not 
present a clear advantage or disadvantage over its absence as there was no trend in 
improving crystals; some wells had bigger crystals with the reducing agent, some 
wells had bigger crystals without the reducing agent. However the best condition after 
20 days incubation consisted of the 33-202-ek with the reducing agent at pH 6.0 with 
1.6 M magnesium sulphate (Figure 6.2A). Interestingly, crystals forming at between 
pH 5.25 and pH 5.75 exhibited a planar form of crystal (Figure 6.2B). 
 
The optimisation screen was repeated but after their equilibration, each drop was 
streaked with a seeding mixture made from crushed crystals from the ICL12 H6 initial 
hit (Figure 6.1). No crystal formation - only amorphous precipitation in the drops was 
observed at 30 days incubation when crystals had already formed in the crystallisation 
experiments without seeding. However at 45 days, crystals were present in one drop 
with conditions of 1.25 M MgSO4 0.1 M MES pH 5.75 with a width of approximately 
100 microns (Figure 6.2C). At 59 days incubation, these seeded crystals were the 
biggest 33-202-ek crystals produced with a width of approximately 140 microns 
(Figure 6.2D). Further attempts to improve crystal growth, including additive screens 
and replacing divalent cations and anions, did not result in any improvement in crystal 
size and quality (data not shown). 
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A 
 
B 
 
C 
 
D 
 
Figure 6.2 Optimisation of crystal hit. The sulphate concentration and 0.1 M MES pH were varied. 
Largest 33-202-ek crystal obtained to date (A) Drop with 1.6 M magnesium sulfate 0.1 M MES pH 
6.0 as reservoir with 5 mM DTT after 20 days incubation at 4°C in a sitting drop setup with 300 nl of 
33-202-ek at 8 mg/ml in 20 mM Tris.HCl, 150 mM NaCl, 10% glycerol, 5 mM DTT, pH 8.0 added to 
300 nl of the reservoir buffer. The reservoir buffer consists of 1.6 M magnesium sulfate and 0.1 M 
MES pH 6.5. (B) Same conditions as A except with pH at 5.75. At pHs below 6.0, planar-type 
crystals are observed. (C) Crystals from A at 59 days incubation at 4°C. This condition showed the 
largest (approximately 80 microns wide) and fewest amount of crystals. (D) The largest 1a NS5A D1 
crystal (approximately 140 microns wide) were produced from microseeding crushed crystals shown 
in Figure 6.1 after 59 days incubation at 4°C. 
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6.2 X-ray Crystallography of 1a NS5A 33-202-ek 
 
We screened several crystals of 33-202-ek from unseeded and seeded plates 
microfocus beamline I24 (Diamond Light Source, Harwell Science and Innovation 
Campus, UK) for their diffraction. Data were collected from several crystals which 
showed diffraction to 4.5 Å however the best diffracting crystal was identified to be 
the largest one produced from microseeding in Figure 6.2D and showing diffraction 
spots beyond 3.0 Å (Figure 6.3). 
 
6.2.1 Data Collection 
 
Data for HCV genotype 1a NS5A 33-202-ek were collected on the microfocus 
beamline I24 with wavelength of 0.97780 Å and crystal to detector distance of 633.67 
mm. Data were collected to 3.0 Å from one crystal at 100K with an oscillation angle 
 
Figure 6.3 Diffraction image from microseeded 33-202-ek crystal. The image shows reflections to 
about 3-3.5 Å. Taken from crystal shown in Figure 6.2D. 
2.7 Å 
3.6 Å 
5.5 Å 
10.8 Å 
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of 0.2˚ per frame, using a Pilatus3 6M detector. A total of 180˚ of data were collected 
over 900 images. 
 
6.2.2 Data Processing and Structural Determination 
 
Initially the data were processed using MOSFLM (Leslie and Powell, 2007), scaled 
with SCALA (Evans, 2006) and structure factor amplitudes derived using the 
programme TRUNCATE (French and Wilson, 1978). Upon indexing the data, a 
primitive tetragonal cell was suggested and processing was carried out in the space 
group P422. Whilst no twinning was detected, the resulting Rmerge of the processed 
data was very high (above 30%) indicating that there were problems with the 
processing and/or data. The data were reprocessed in space groups with lower 
symmetry until processing in P222 resulted in a Rmerge of 0.117. Analysis of the 
systematic absences output from SCALA suggested the true space group to be P212121 
with the dimensions a=100.25, b=101.53, c=148.70 Å. 
 
The Matthews coefficient (Matthews, 1968) and solvent content were calculated 
based on the unit cell dimensions and the molecular weight of the protein molecules 
in the unit cell. It was calculated that with 8, 6, or 4 protein molecules present in the 
asymmetric unit, the Matthews coefficients were 2.38 Å
3
/Da, 3.18 Å
3
/Da and 4.73 
Å
3
/Da, with solvent contents of 48.40%, 61.30% and 73.97% respectively. The data 
was reprocessed using xia2 (Winter, 2009) in P212121 and attempts to calculate phase 
were made with Phaser using a search model consisting of chain A of the genotype 1b 
NS5A domain 1 structure ((Tellinghuisen et al., 2005), Protein Data Bank code 
1ZH1) mutated to contain the genotype 1a NS5A amino acid residues using 
CHAINSAW (Stein, 2008). Phaser could not find a solution with 8 or 6 protein 
molecules in the asymmetric unit but successfully calculated a solution with 4 protein 
molecules in the asymmetric unit. This solution had a final translational Z-score and 
Log likelihood gain of 35.8 and 1926, respectively. The packing of the asymmetric 
unit in the unit cell is shown in Figure 6.4. 
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Figure 6.4 Crystal packing arrangement by 1a NS5A 33-202-ek. Shown in green, pink, blue and red 
are the four asymmetric units that make up the unit cell. 
 
6.2.3 Structural Refinement and Modelling 
 
Refinement of the 1a NS5A 33-202-ek structure was carried out using Phenix.refine 
with non-crystallographic symmetry (NCS) restraints, secondary structure restraints 
and reference model restraints using the mutated 1b NS5A domain 1 structure as a 
reference model (Afonine et al., 2012). The refinement was performed using the full 
resolution range using bulk solvent correction. 2Fo-Fc and Fo-Fc electron density 
maps were calculated by Coot and model building was performed in Coot (Emsley 
and Cowtan, 2004). The initial model had been fitted into the electron density by 
phaser and amino acid residues and side chains were built into the model and removed 
during the model building process. The initial model had a Rwork of 42.83% and Rfree 
of 42.77%. The process of model building and subsequent refinement using Coot and 
Phenix.refine were repeated in an iterative process until the R factors converged. 
After 16 iterations, the model had a Rwork of 22.63% and Rfree of 26.48% and the 
electron density allowed the fitting of aromatic and large side chains (Figure 6.5). 
Data collection and final refinement statistics are summarised in Table 6.2. 
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Figure 6.5 2Fo-Fc electron density map of refined 33-202-ek. Aromatic groups and large side chains of 
amino acid residues could be built into the final refined electron density. Shown with their surrounding 
electron density are residues Arg 112, His 159 and Phe 161 from chain A, and Arg 112 and Phe 161 
from chain B. The map was set at sigma level 1.5. 
 
 
 
 
 
 
 
 
A H159 
A F161 
A R112 
B R112 
B F161 
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Crystal parameters  
Space group P2
1
2
1
2
1
 
Cell dimensions a=100.25 Å    b=101.53 Å 
c=148.70 Å 
Molecules per asymmetric unit 4 
Data collection  
 
Beamline DLS I24 
Wavelength (Å) 0.97780 
Resolution range (Å)
  
51.475-3.5 (3.67-3.5) 
Unique observations* 17168 (1226) 
Rmerge* 0.135 (0.388) 
<I >/ σI * 3.5 (1.9) 
Completeness (%)* 86.0 (87.5) 
Multiplicity*
 
3.4 (3.3) 
  
Refinement  
Rwork  / Rfree (%) 22.49 / 26.64 
Number of protein residues in monomer 159 
RMSD stereochemistry  
 Bond lengths (Å) 
Bond angles (°) 
0.0147 (monomer A) 
2.453 (monomer A) 
  
RMSD of monomers  
 B to A (Å) 
C to A (Å) 
D to A (Å) 
0.412 
0.454 
0.622 
  
  
Table 6.2 Crystal data collection and refinement statistics.  
*Values reported in the format: overall data (last resolution shell). RMSD stereochemistry is the 
deviation from ideal values. 
   
Situated in between monomers A, C and D, there was a large unmodelled region in 
the electron density difference map appearing to be coordinated by nitrogens ε from 
residues Arg 41 and Arg 81 from monomer A and by a nitrogen η from Arg 78 from 
monomer B (Figure 6.6A).  Owing to the presence of these positively-charged side-
chains and the high concentration of sulphate ions in the crystallisation solution, it 
was modelled as SO4
2-
. Arg 41 and Arg 78 are strictly conserved as positive amino 
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acids (>90% Arg or Lys at position 41 and >95% Arg or Lys at position 78), whereas 
Arg 81 shows no conservation (Arg, Ser, Ala, Met or Leu substitutions at position 
81). Another region of unmodelled electron density was adjacent to monomer A with 
possible coordination by Arg 44 from chain C and the backbones of Gly 45 and Met 
72 from chain A. We tentatively propose this region to include an additional sulphate 
ion, however it was not modelled as this region of electron density is less well defined 
(Figure 6.6B).  
 
        
 
Figure 6.6 Sulphate molecules observed in crystals of genotype 1a NS5A domain 1. (A) A sulphate ion 
fits well to electron density difference maps (shown at sigma level 2.0) and appears to be coordinated 
by three arginine residues: Arg 41 and Arg 81 from monomer A, and Arg 78 from chain C. (B) An 
additional bound sulphate ion may be present possibly bound by Arg 44 from chain A and the 
backbones of Gly 45 and Met 72 from chain A. However the unmodelled region in the electron density 
difference (shown at sigma level 1.5) is smaller than that due to the sulphate ion in A, which leaves the 
presence of this sulphate ion at this site more ambiguous or perhaps there is a lower occupancy of 
sulphate ions at this location in the crystal structure. 
 
6.2.4 Model Analysis and Validation 
 
There were no improvements to the model with further refinement or model building, 
so the structure was validated using COOT, MOLPROBITY (Chen et al., 2010) and 
the PDB server. The atoms in the backbone and side chains were surrounded by good 
electron density and orientations of side chain were adjusted by rotamer analysis. Due 
to the low resolution of the data, both the bond lengths and bond angels were tightly 
restrained during refinement to those of theoretical values. No large unmodelled 
A B 
A R41 
A R81 
C R78 
SO4
2-
 SO4
2-
 
A R44 
A M72 
A G45 
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regions of electron density were discovered at this stage which suggested no 
additional ligand or water molecules were present. The Ramachandran analysis 
reported by MOLPROBITY gave 91.1% (562/618) of the residues resident in the 
favoured regions and just 0.6% (4/618) of the residues falling within the disallowed 
regions (Figure 6.7). 
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RMSD stereochemistry  
 Bond lengths (Å) 0.0147 
 Bond angles (°) 2.453 
Ramachandran analysis (%)  
 Residues in outlier regions 4 (Chain A Glu 191, 
chain C Pro 147 Pro 167, 
chain D Val 113) 
 Residues in favoured regions 562 (91.1%) 
 Residues in allowed regions 614 (99.4%) 
 
 
Figure 6.7 Ramachandran plot for the X-ray structure of 1a NS5A 33-202-ek. Residues marked in 
regions with blue borders are most favoured, within purple borders are additionally allowed and outside 
purple borders are disallowed. Ramachandran analysis was carried out using MOLPROBITY (Davis et 
al., 2007). 
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The final model contains four protein chains and one sulphate ion. Amino acid 
residues present in the construct that could not be fitted to any electron density 
include the disordered N- and C-termini of 3-4 residues and 13-16 residues, 
respectively depending on the monomer. Loops between β-strands B7 and B8, and β-
strands B8 and B9 could not be fully modelled in monomer A, in which modelling of 
residue Glu 172, and residues Gly 178 and Leu 179, respectively, had to be omitted. 
 
6.3 Crystal Structure of Genotype 1a NS5A Domain 1 
 
Our crystals of genotype 1a NS5A domain 1 represent a new crystal form. The crystal 
structure consists of four monomers of the genotype 1a NS5A domain 1 arranged into 
T-shaped asymmetric units (Figure 6.8), which are juxtaposed to form large solvent 
channels; explaining the Matthews coefficient of 4.73 Å
3
/Dalton and high solvent 
content of 73.97% and possibly why the crystals diffracted relatively poorly for their 
size. This high solvent content may make this crystal form suitable for ligand soaks, 
however n our genotype 1a crystal structure, similar surfaces of the molecule are 
exposed to the solvent as in the most recent 1b NS5A Domain 1 dimer crystal 
structure (Love et al., 2009). 
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Figure 6.8 The asymmetric unit in the genotype 1a NS5A domain 1 crystal structure. The four 
monomers which make up the asymmetric unit can be considered as two dimeric interfaces forming a 
dimer AB of monomers A and B, and dimer CD of monomers C and D. 
D 
A 
B 
C 
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6.3.1 Asymmetric Unit 
 
The overall fold of each monomer in our model superposes well with the NS5A 
domain structures from genotype 1b (Tellinghuisen et al., 2005; Love et al., 2009) 
with an average Cα RMSD of 0.57 Å between 1a and 1b monomers (Figure 6.9). The 
zinc-binding motif has the same coordination as the genotype 1b NS5A Domain 1 
with an average distance of 2.24 Å between coordinating sulphurs and the zinc atom. 
These bond lengths are slightly less than the ideal distance (2.35 ± 0.09 Å) for 
structural metal zinc-coordination sites and slightly more than the ideal distance (2.08 
± 0.13 Å) for catalytic metal zinc-coordination sites (Alberts et al., 1998). The 
arrangement and proximity of residues Cys 142 and Cys 190 in our model and the 
presence of electron density in between the residues suggests the formation of a 
disulphide bridge, despite the presence of DTT in the crystallisation buffer with a 
distance between the sulphur atoms of 2.0 Å, 2.0 Å, 2.0 Å and 2.5 Å in monomers A, 
B, C and D respectively.  It is not known whether this disulphide bond is 
physiologically important as it is not known to be essential for HCV replication 
(Tellinghuisen et al., 2004). 
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Figure 6.9 The fold of genotype 1a NS5A domain 1 is the same as 1b NS5A domain 1. (A) Secondary 
structure alignment of the genotype 1a NS5A domain 1 structure (shown in green) with Tellinghuisen 
(shown in pink) and Love (shown in blue) structures of genotype 1b NS5A domain 1 (Tellinghuisen et 
al., 2005; Love et al., 2009). (B) 1a NS5A domain 1 shares the same topology organization as 1b 
NS5A domain 1. Taken from (Tellinghuisen et al., 2005). 
A 
B 
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6.3.2 Dimer Interfaces 
 
Two new dimeric forms of NS5A domain 1 are observed from the crystal packing 
shown in the asymmetric unit. Monomers A and B of our structure are related by a 
twofold axis (179.9°) perpendicular to their length. Dimer AB displays a similar 
interface to that previously reported (Love et al., 2009), but one of the monomer’s 
orientation is reversed creating a head-to-tail conformation (Figure 6.10A), rather than 
head-to-head. Dimer AB has a smaller buried solvent-accessible surface area of 870.2 
Å
2
 than that calculated for the Love et al. dimer (957.1 Å2), due to the more detached 
packing of the two molecules - the distance between the centres of mass of the 
monomers in dimer AB is 23.1 Å compared to 21.4 Å in the Love et al. dimer (Figure 
6.10B). The contact surfaces are formed by residues 97-99, 112-115, 149, 160-161. 
Amino acid residues Pro 97, Cys 98 and Thr 99 show low conservation and are in 
contact with the conserved residue Phe 120 of the other dimer. Conserved amino acid 
residues Arg 122, Val 123 Ala 125 and the non-conserved Ser 124 form contacts with 
conserved residues Arg 160 and Phe 161 (which is Tyr or His in other genotypes). All 
of these 10 residues are also included in the contact area of the Love et al. dimer, 
whose contact area also includes an additional 14 residues. Pairs of residues forming 
notable interactions reported in the Love et al. dimer, such as the salt bridge formed 
by conserved residues Glu 148-Arg 112, the backbone hydrogen bond between 
conserved residues Ala 92 and Gly 96, and an electrostatic interaction between 
residues Arg 48 and Glu 116 are not close enough to form in dimer AB. The amino 
acids involved in the interface of the dimer AB are largely conserved in the genotype 
1b NS5A  (shown in red in Figure 6.11) with the identical amino acids present in the 
same positions with the exception of the conservative substitutions Ser 114 Ala and 
Phe 161 Tyr. 
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Figure 6.10 Dimer AB. (A) Monomers A (orange) and B (green) make up dimer AB. (B) A secondary 
structure alignment of monomer A from our genotype 1a crystal structure with monomer B from the 
Love et al. dimer (blue). Dimer AB shares a similar dimer contact face to the Love et al. dimer except it 
is less closely packed and in a head to tail conformation. 
 
 
 
 
A 
B 
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1a_NS5A   SGSWLRDIWDWICEVLSDFKTWLKAKLMPQLPGIPFVSCQRGYRGVWRGDGIMHTRCHCG 60 
1b_NS5A   SGSWLRDVWDWICTVLTDFKTWLQSKLLPRLPGVPFFSCQRGYKGVWRGDGIMQTTCPCG 60 
          *******:***** **:******::**:*:***:**.******:*********:* * ** 
 
1a_NS5A   AEITGHVKNGTMRIVGPRTCRNMWSGTFPINAYTTGPCTPLPAPNYKFALWRVSAEEYVE 120 
1b_NS5A   AQITGHVKNGSMRIVGPRTCSNTWHGTFPINAYTTGPCTPSPAPNYSRALWRVAAEEYVE 120 
          *:********:********* * * *************** *****. *****:****** 
 
1a_NS5A   IRRVGDFHYVSGMTTDNLKCPCQIPSPEFFTELDGVRLHRFAPPCKPLLREEVSFRVGLH 180 
1b_NS5A   VTRVGDFHYVTGMTTDNVKCPCQVPAPEFFTEVDGVRLHRYAPACKPLLREEVTFLVGLN 180 
          : ********:******:*****:*:******:*******:**.*********:* ***: 
 
1a_NS5A   EYPVGSQLPCEPEPDVAVLTSMLTDPSHITAEAAGRRLARGSPPSMASSSASQLSAPSLK 240 
1b_NS5A   QYLVGSQLPCEPEPDVAVLTSMLTDPSHITAETAKRRLARGSPPSLASSSASQLSAPSLK 240 
          :* *****************************:* **********:************** 
 
Figure 6.11 ClustalW Alignment of genotypes 1a and 1b NS5A domain 1. Highlighted in red and 
yellow show residues which form contact surfaces in the dimers AB and CD respectively. 
 
Monomers C and D form a second dimer CD that shows an approximately 2-fold 
(173.6°) symmetry axis, composed of the monomers aligned in a head to head 
conformation (Figure 6.12A). The monomers form a buried solvent-accessible surface 
area of 630.0 Å
2
. The contact surfaces are formed by residues 74-78 and 83-84. 
Residues 74-78 from each molecule appear to form an intermolecular anti-parallel β-
sheet through an extension of β-strand B3 from Val 75 to Arg 78 (Figure 6.12B). The 
formation of this intermolecular β-sheet does not disrupt the β-sheets within each 
molecule. All the residues involved in the intermolecular β-sheet Ile 74 to Arg 78 are 
conserved. Residues 83-84 from each molecule may stabilize the dimer through 
additional van der Waals interactions. Met 83 shows conservation as a hydrophobic 
residue (>99% residues are Met, Thr, Val or Ile) while Trp 84 is highly conserved 
(>95% Trp). The amino acids involved in the interface of the dimer CD are largely 
conserved in the genotype 1b NS5A (shown in yellow in Figure 6.11) with the 
identical amino acids present in the same positions with the exception of the 
conservative substitution Met 83 Thr. In forming the intermolecular β-sheet, the 
refined structure shows intermolecular backbone hydrogen bonds between pairs of 
residues Ile 74 O with Arg 78 NH, and Gly 76 NH with Gly 76 O. 
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Figure 6.11 Dimer CD. (A) Monomers C (orange) and D (green) make up dimer CD. (B) A secondary 
structure alignment of monomer A from the Love et al. dimer (blue) with each monomer C and D 
shows an extension of β-strand B3 from Val 75 to Arg 78. (C) Hydrogen bonds are formed between 
residues Ile 74 O and Arg 78 NH, Gly 76 NH and Gly 76 O, forming a total of 4 hydrogen bonds in the 
dimer CD. 
 
Contacts between asymmetric units in the crystal consist of the same interfaces in 
dimer AB and dimer CD: With monomer A of an asymmetric unit in a head to head 
conformer with a monomer B from an adjacent asymmetric unit in the same 
conformation as dimer CD. Equivalently, monomer C of an asymmetric unit is an 
antiparallel conformation with a monomer D from an adjacent asymmetric unit in the 
same conformation as dimer AB. 
 
 
 
Ile 74 
Ile 74 
Gly 76 
Gly 76 
Arg 78 
Arg 78 
B C 
A 
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6.4 Crystal Soaks of 1a NS5A Domain 1 with DCV 
 
Datasets from 1a NS5A 33-202-ek crystals soaked with daclatasvir (DCV) were 
processed and solved to approximately 4 Å as in Section 6.2 using our structure for 
molecular replacement and two rounds of refinement. No prominent features were 
present in electron density maps suggesting no compound to be bound in the crystal; 
or that it was present in too low an occupancy to be observed; or that the binding 
interface of the protein was not exposed to allow for binding of the compound. 
 
6.5 Chapter Summary 
 
After extensive screening of crystallisation conditions, crystals were obtained for 1a 
NS5A 33-202-ek. Optimal conditions for crystal growth were determined to be 1.25 
M MgSO4 0.1 M MES pH 5.5 to pH 6.5 at 4°C. Microseeding produced the largest 
crystals, which grew to their maximum size of up to 140 µm in their largest 
dimension in 60 days. 
 
The largest 33-202-ek produced the best diffraction allowing the solving of the 
genotype 1a NS5A domain 1 crystal structure. After refinement and validation, the 
crystal structure of genotype 1a NS5A domain 1 was observed to share the same 
structure as genotype 1b NS5A domain 1. However the asymmetric unit of our crystal 
structure contains two new dimeric forms of this domain. Monomers A and B formed 
dimer AB with a head-to-tail conformation and sharing a similar dimer interface to 
that previously reported (Love et al., 2009), but with a more detached packing. 
Whereas monomers C and D are aligned in a head to head conformation to form the 
dimer CD. These dimers represent additional candidates for targets of dimeric 
inhibitors DCV. 
 
The crystal contains large solvent channels making it useful for soaks with large 
compounds. However our preliminary soaks of the genotype 1a NS5A domain 1 
crystals with DCV did not show electron density for compounds bound to NS5A. 
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Chapter Seven 
 
Discussion 
  
 197 
 
HCV is a clinically important human pathogen. Although the exact function of the 
HCV protein NS5A is unclear, it plays a critical role in the virus lifecycle. Future 
treatment regimens of HCV are likely to include compounds which target NS5A. The 
mechanism of action (MOA) of these compounds is unknown, however resistance 
mutant analysis suggests the compounds interact with the NS5A N-terminus (Fridell 
et al., 2010; Gao et al., 2010). It is hoped that further structural analysis of NS5A and 
how compounds interact with it will help explain their MOA and in turn reveal a more 
precise understanding of the role of NS5A in the viral lifecycle. 
 
7.1 Summary of our Findings 
 
We cloned constructs of domain 1 of the HCV genotype 1a (isolate H77) NS5A gene 
and ligated them into the expression vectors pHAT4, pET32, pGAT3 and pMAT10 
which are N-terminally his-tagged, thioredoxin-his-tagged, GST-tagged and MBP-
tagged respectively. Expression and purification protocols have been determined for 
the genotype 1a NS5A constructs 33-202-ek and 25-202-ek. 
 
33-202-ek consists of the genotype 1a NS5A aa 33 to 202 with a C-terminal 
enterokinase light chain site. Our 33-202-ek purification protocol yields 
approximately 4.5 mg/litre culture of pure protein. We established optimal buffers for 
33-202-ek for NMR spectroscopy. NMR spectroscopy showed the construct to be 
well-folded however reversible aggregation occurs at concentrations over 200 µM. 
Interactions of 33-202-ek with viral RNA, daclatasvir (DCV) or the amphipathic helix 
(AH), could not be detected by NMR. After extensive screening of crystallisation 
conditions, crystals were obtained for 1a NS5A 33-202-ek. The crystals of 33-202-ek 
show a different crystal form from the genotype 1b NS5A domain 1, and allowed 
structural determination via X-ray crystallography of the protein to a resolution of 3.5 
Å. Furthermore the 1a genotype NS5A domain 1 structure shows two new dimeric 
forms of this domain.   
 
Experiments to create stable constructs with N-terminal extensions of the 33-202-ek 
construct resulted in NS5A construct 25-202-ek. 25-202-ek consists of the genotype 
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1a NS5A aa 25 to 202 with a C-terminal enterokinase light chain site. 25-202-ek 
contains key resistance mutation sites Met28, Gln30, Leu31 and Pro32 (Fridell et al., 
2010; Gao et al., 2010) to NS5A-targeting compounds within a linker to the AH (the 
AH linker). Our 25-202-ek purification protocol yields about 1 mg/litre culture of 
pure protein. 
 
7.1.1 The AH Linker is Structured in the Context of the N-terminal NS5A 
Region 
 
NMR showed that adding the AH linker to construct 33-202-ek to create the extended 
construct 25-202-ek resulted in additional structure in NS5A domain 1. Furthermore 
inclusion of the AH linker appeared to slightly alter the conformation of the rest of the 
domain. These additional and altered regions may form part of the interaction site 
with NS5A inhibitors such as DCV. 
 
7.1.2 NS5A may show a Weak Interaction with DCV 
 
Our preliminary data suggest there is a weak interaction of the extended N-terminal 
NS5A construct 25-202-ek with DCV. Part of this region interacting with DCV, likely 
a tryptophan due to its position on the  
1
H,
15
N-HSQC spectrum, is also a region of the 
construct 33-202-ek that was altered with inclusion of the AH linker. We suggest 
inclusion of the AH linker alters NS5A domain 1 in such a way to allow an interaction 
with NS5A inhibitors like DCV. 
 
7.1.3 New Crystal Form of NS5A 
 
Our crystals of genotype 1a NS5A domain 1 show a new packing form with very high 
solvent content. The crystal contains large solvent channels and is therefore likely to 
be amenable to soaks with large compounds.  The same contact face of NS5A domain 
1 is buried in the genotype 1a crystal structure as in the Love et al. crystal structure - 
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with which soaks had previously failed to show bound ligand
4
. Although this interface 
in our genotype 1a NS5A domain 1 structure is less extensive and it may be more 
accessible to ligands. However our preliminary soaks of the genotype 1a NS5A 
domain 1 crystals with DCV did not show electron density for compounds bound to 
NS5A. We anticipate with more extensive screening with DCV, other compounds and 
tool compounds, the genotype 1a NS5A domain 1 structure may serve as an additional 
useful tool for the design and development of therapeutics which target NS5A. 
 
The crystal structure of genotype 1a NS5A domain 1 shares the same structure as 
genotype 1b with an average Cα RMSD of 0.57 Å between 1a and 1b monomers. The 
zinc-binding motif of our structure displays an identical coordination as the genotype 
1b NS5A Domain 1 and like the Tellinghuisen et al. structure, the genotype 1a NS5A 
domain 1 structure contains a disulphide bridge between residues Cys142 and Cys190 
(Tellinghuisen et al., 2005). This high degree of resemblance suggests that the tertiary 
structure of NS5A domain 1 is not a good indicator of ligand specificity and does not 
account for the differences in potencies of NS5A-targeting compounds between HCV 
genotypes 1a and 1b. 
 
Monomer A in our crystal structure coordinates at least one and possibly two 
sulphates. A secondary structure alignment of monomer A from our crystal structure 
with the first genotype 1b structure (Tellinghuisen et al., 2005) places the anions in a 
proposed RNA-binding groove and it was possible to manually model an approximate 
position of viral RNA (7rU) in hypothesised RNA-binding groove. 
 
7.1.4 New Dimeric Forms of NS5A domain 1 
 
In the 4 monomers of the asymmetric unit of our crystal structure, two unique NS5A 
domain 1 dimers were observed. Monomers A and B formed dimer AB with a head-
to-tail conformation and sharing a similar dimer interface to that previously reported 
 
                                                 
4
 Disclosure from Arrow therapeutics 
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(Love et al., 2009), but with a more detached packing. Monomers C and D are aligned 
in a head to head conformation to form the dimer CD. The interface of dimer CD 
includes an intermolecular association of anti-parallel β-strands and is smaller than 
the contact interfaces of dimer AB and the other reported NS5A domain 1 dimers 
(Tellinghuisen et al., 2005; Love et al., 2009). 
 
 
7.2 NS5A Domain 1 Dimers as a Target of DCV 
 
Publication of the crystal structure for the HCV genotype 1b Tellinghuisen and Love 
dimers (Tellinghuisen et al., 2005; Love et al., 2009) has caused debate as to which or 
both dimers are biological relevant. Since monomeric inhibitors which target NS5A 
are highly potent against genotype 1b but not 1a (Cordek et al., 2011), it is plausible 
that the NS5A dimers present in genotype 1a infected cells are more relevant to the 
  
   
Figure 7.1 Genotype 1b and 1a NS5A domain 1 crystal structure dimers in ribbon representation. The 
side chain of tyrosine 93, a major resistant mutation is displayed as spheres. Monomers are shown in 
orange and green, and coloured in pastel for genotype 1b dimers. (A) The Tellinghuisen dimer 
(Tellinghuisen et al., 2005) forms a potential RNA-binding pocket. (B) The Love dimer (Love et al., 
2009). (C) Monomers A and B from the genotype 1a NS5A domain 1 crystal structure share the 
interface as the Love et al. dimer shown in B albeit with the monomers arranged antiparallelly (D) 
Monomers C and D form a N-terminal head to head dimer. 
A 
B 
C 
D 
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MOA of these compounds. However assuming that the mechanism of how genotype 
1a NS5A functions does not vary significantly from that of genotype 1b, our results 
provide further candidates for a physiologically-relevant NS5A dimer (Figure 7.1). 
Although as discussed in section 1.3; NS5A targeting compounds may exhibit their 
potency via a host factor. However the current working hypothesis is that these 
compounds act on an NS5A dimer, based on the dimeric nature of DCV and the 
location of NS5A resistance mutations. Recently experiments have isolated a NS5A 
dimer using chemical cross-linking of photoaffinity DCV analogs, providing the first 
direct evidence of compounds interacting with the N-terminal region of NS5A 
(O'Boyle Ii et al., 2013). Due to the size of the compounds targeting NS5A, we deem 
that the head to tail conformation of dimer AB places the two N-termini too far apart 
for the dimensions of DCV, although this does not rule out another physiological role 
for dimer AB. The monomers of dimer CD have adjacent N-termini and this dimer 
could be the biological target of the compound. Although dimer CD has a relatively 
small buried solvent accessible surface area of 315.0 Å2, the inclusion of the N-
terminal amphipathic helix in vivo may further stabilize its formation. Evidence that 
DCV acts directly on a NS5A dimer (O'Boyle Ii et al., 2013) and does not inhibits the 
formation of NS5A dimer (Lim et al., 2012) makes it conceivable that DCV may 
disrupt the HCV lifecycle by stabilizing the formation of a weak dimer such as dimer 
CD.   
 
7.3 RNA or Phosphate Binding Site in NS5A Domain 1 
 
While the bound sulphates may be present in the crystal structure in a stabilizing role 
in crystal formation by bridging side-chains between monomers, a secondary structure 
alignment of monomer A from our crystal structure with the Tellinghuisen genotype 
1b structure (Tellinghuisen et al., 2005) places the anions in the hypothesised RNA-
binding groove. As SO4
2-
 and the phosphate from an RNA background have similar 
conformations and charge, they may be mimicking the natural ligands of NS5A. 
Taking this assumption, it was possible to model in an approximate position of viral 
RNA (7rU) in the proposed RNA-binding groove using the positions of the refined 
sulphates to define the positions of the phosphates of the RNA backbone (Figure 7.2).  
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Figure 7.2 Viral RNA backbone modelled into NS5A domain 1 dimer. A secondary structure 
alignment of monomer A and its associated sulphates from our genotype 1a crystal structure with each 
monomer in the Tellinghuisen et al. dimer places the sulphates in the hypothesised RNA-binding 
groove of the dimer. The sulphates may be mimicking an RNA phosphate backbone (model shown in 
green) allowing the modelling of viral RNA into the dimer. The surface of the dimer is coloured by its 
electrostatic potential (red is negative, gray is neutral, and blue is positive). 
  
 
SO
4
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Another possible role for these binding sites could be in sequestering the 
phosphorylated C-terminus of NS5A. Phosphorylation of NS5A is thought to regulate 
its interaction with a variety of host and viral binding partners, hence regulating HCV 
replication and assembly. Therefore binding of a phosphorylated residue within the C-
terminus would alter NS5A specificity for target host proteins and progression 
through the viral lifecycle, thus explaining how the targeting of NS5A inhibitors to 
NS5A domain 1 would affect phosphorylation in domains 2 and 3, and halting the 
transition from viral RNA replication to virus assembly (Qiu et al., 2011).  This 
regulation of NS5A domains 2 and 3 by domain 1 could explain recent findings that 
have determined that DCV expresses dual MOAs: interfering with the roles of NS5A 
in both viral RNA synthesis and virion assembly (Guedj et al., 2013), with the latter 
being a consequence of NS5A domain 1 dimer destabilization/stabilization. 
 
7.4 Modelling Work by Collaborators  
 
Using the head-to-head CD-dimer from our structure, our collaborators at Bristol–
Myers Squibb identified the cleft between the CD-dimer as a potential binding site for 
DCV through the use of homology modelling, molecular docking, and molecular 
dynamics (manuscript in preparation). DCV was docked into this pocket and subject 
to a molecular dynamic stimulation which showed the CD-dimer/DCV complex to 
remain stably associated. The physical chemical properties and dimensions of the cleft 
between the head-to-head CD-dimer match well with DCV.  For example, the central 
floor region of the cleft is composed of hydrophobic residues Val75, Gly76, and 
Pro77 which lie under the biphenyl core and between the caps of DCV while the 
periphery of the putative binding site contains more polar residues such as His54, 
Arg56, Glu62, His66, Arg73, and Thr79 which are proximal to the cap regions of 
DCV. The N-terminal AH was grafted onto each monomer of the CD-dimer to place 
Gln30 and Leu31 near DCV (Figure 7.3).  
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Figure 7.3 DCV docked into the cleft between the CD-dimer.  The surface of the dimer is coloured by 
its electrostatic potential (red is negative, gray is neutral, and blue is positive.  The N-terminal residues 
are shown in ribbon (C-domain in green, D-domain is gold).  Key resistant positions are shown with 
van der Waals surface. DCV is shown in a ball and stick depiction (carbon: aquamarine, nitrogen: blue, 
oxygen: red, polar hydrogen: white).  (A) Top view of DCV docked symmetrically through the cleft.  
(B) Side view focuses on the cap of DCV docked into the cleft.  Yellow dotted lines indicate the 
hydrogen bond between the DCV valine carbonyl and NS5A Glu 62 backbone amide NH. Leu 31 
packs against the cap valine moiety of DCV. Image used with permission from David Langley (Bristol-
Myers Squibb). 
 
Modelling of DCV with genotype 1b NS5A domain 1 dimers demonstrates that the 
compound could be in direct proximity to key resistance mutation sites Met28, Gln30, 
Leu31 and Tyr93 (Cordek et al., 2011; O'Boyle Ii et al., 2013). In our structure, the 
key resistance mutation Tyr93 is connected to DCV via a communication network 
through Arg56 and Glu62 in the molecular dynamic simulation (Figure 7.4). 
Interestingly, Glu62 is a position that has been associated with resistance but this 
normally arises when linked with the primary Q30R mutation (Sun et al., 2012). 
However this allosteric mechanism of resistance is supported by the recent report that 
binding alone is not sufficient for inhibition (O'Boyle Ii et al., 2013) and implies that 
resistance could occur by the conversion of productive to non-productive binding. 
However, based on the relative strength of the Tyr93His and Glu62Asp resistance we 
cannot rule out that other binding modes are possible. 
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Figure 7.4 Communication network between DCV and Tyr93.  The ribbon depiction of the C and D 
monomers are shown in green and gold respectively.  The Van der Waals surface shows DCV (carbon: 
aquamarine) and the Glu62, Arg56, and Tyr93 communication network (carbon: gray). Image used 
with permission from David Langley (Bristol-Myers Squibb). 
 
7.5 NMR Titrations Support an Interaction of DCV with the 
NS5A N-terminus 
 
The inclusion of the AH results in a slight structural alteration to the rest of NS5A 
domain 1, in particular affecting what is likely to be a tryptophan residue. As this 
same tryptophan residue appears to be involved in an interaction with DCV, we 
propose the AH linker to alter this region of NS5A and forms part of the interaction 
site. Tryptophan residues that could interact with the AH linker include Trp47, Trp84 
and Trp111. Within our dimer CD, Trp47, Trp84 are within range of the AH linker 
(Figure 7.5) and Trp84 is proximal to our proposed binding cleft (Section 7.4). 
Similarly, these one of these tryptophan residues could form part of proposed binding 
in the Tellinghuisen and Love dimers (Cordek et al., 2011; O'Boyle Ii et al., 2013). 
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Figure 7.5 Tryptophan residues at N-termini of the monomers of the CD dimer of 33-202-ek. Trp47 
and Trp84 are within range of the AH linker present in construct 25-202-ek. Either tryptophan residue 
could be involved in forming an interaction site with the AH. 
 
None of these tryptophan residue are sites for resistance mutations (Gao et al., 2010) 
suggesting this site could be involved in allosteric alterations in NS5A from drug 
binding and mutations do not occur as they may be lethal to the virus. 
 
7.6 A NS5A Network Regulates the Replication Complex 
 
We cannot rule out the possibility that all of the genotype 1b or 1a dimers are simply 
crystal packing artefacts and do not represent the physiological dimer. However due 
to the apparent propensity of NS5A to oligomerise, another possible explanation 
would be that NS5A is a promiscuously binding protein and these dimers explain 
some of the multiple interactions of NS5A. The discovery of our new NS5A dimers 
suggests that the formation of an extended multimeric network of NS5A may occur 
through the utilisation of various dimer interfaces. The combination of the two 
genotype 1b NS5A domain 1 dimers allowed the formation of a superhelical array 
that provides an explanation for the oligomerisation of NS5A and NS5A domain 1 
constructs observed in vitro. However, the formation of this higher order oligomer 
into a nonplanar, superhelical array precludes its association with a lipid bilayer (Love 
et al., 2009). By combining the different conformations of the new NS5A domain 1 
dimers present in our crystal structure, one can envisage an array of NS5A molecules 
Trp84 Trp84 
Trp47 
Trp47 
Phe36 at N-terminus 
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that forms a more expansive network that could interact with the membranous web 
(Figure 7.5). NMR experiments of NS5A constructs have shown the protein can 
reversibly aggregate (data not shown), possibly into ordered oligomeric states; such 
complexes could imaginably have roles in the formation of the membranous web, the 
replication complex, and/or the assembly complex on lipid droplets.  
 
 
 
 
Figure 7.5 Two-dimensional NS5A domain 1 network. Combining more than 2 non-overlapping 
different monomer-monomer interfaces allows the creation of a theoretical assembly of NS5A domain I 
proteins. Such a network could potentially form part of the membranous web and explain the 
multifaceted role of NS5A. 
 
Current models propose that NS5A inhibitors disrupt the regulatory role of NS5A in 
the formation and function of the replication complex (O'Boyle Ii et al., 2013). The 
compound-interaction site on the surface of NS5A is thought to be formed or exposed 
only transiently during the HCV life cycle – explaining why interactions with NS5A 
have only been detected using whole replicons and not in vitro (Gao et al., 2010; 
O'Boyle Ii et al., 2013). Alternatively binding of inhibitors to NS5A during 
1a dimer CD 
1b Rice dimer 
1a dimer AB 
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polyprotein processing or replication complex formation could result in a 
conformational alteration to NS5A leading to the formation of non-functional 
replication complexes (O'Boyle Ii et al., 2013). The inability of NS5A to partake in 
the replication complex results in the observed phenotypes of inhibited NS5A 
hyperphosphorylation and altered NS5A subcellular localisation (Lemm et al., 2010; 
Lee et al., 2011). 
 
The structural distortion of NS5A upon ligand binding may result in inhibition of the 
replication complexes through concerted allostery communicated through NS5A 
complexes. In this scenario, a subset of NS5A molecules in an active conformation 
would be the target of inhibition. The isolation of a NS5A dimer via chemical cross-
linking of photoaffinity DCV analogs, provided the first direct evidence of 
compounds interacting with the N-terminal region of NS5A (O'Boyle Ii et al., 2013). 
It also emphasizes the importance of dimerization of NS5A in the HCV life cycle and 
the inhibition of NS5A. Recent work with fluorescently tagged NS5A shows 
compounds disrupt the proximity of adjacent NS5A N-termini in vivo (Bhattacharya 
et al., 2013), possibly reflecting a conformational alteration in a NS5A dimer. This 
disruption occurs with a repositioning domain 3, perhaps due to its regulation by 
domain 1, and leads to large aggregates of NS5A (Bhattacharya et al., 2013). 
 
We propose that NS5A domain 1 represents a multimerisation unit of the protein and 
NS5A inhibitors target a unique NS5A dimer or simultaneously multiple dimers 
within a NS5A network. The NS5A domain 1 multimerisation unit allows multiple 
quaternary structure conformations of NS5A and its arrangement into NS5A network. 
We suggest that the genotype 1b Tellinghuisen and Love dimers, and the genotype 1a 
dimer AB and dimer CD may all be physiologically relevant and involved in the 
formation of this NS5A network. Within the network, a dimer represents the target of 
this class of NS5A inhibitors leading to the disruption of the NS5A network and 
malfunction of the associated replication complexes. We contend that either the 
genotype 1b Tellinghuisen or Love dimers, or the genotype 1a dimer CD serves as the 
unique NS5A dimer target of the NS5A inhibitors. As NS5A has multiple roles and 
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NS5A inhibitors affect viral RNA synthesis and virion assembly (Guedj et al., 2013), 
we suggest this proposed NS5A network also serves a purpose in viral assembly. 
 
7.7 Future Perspectives 
 
The future direction of the project and some potential follow-up work are detailed 
below. 
 
7.7.1 Backbone Assignment of NS5A Domain 1 
 
In order to determine which residues of NS5A domain 1 show slight alterations in 
their structure, we could perform backbone assignment experiments to determine 
which peaks of the HSQC spectra are associated with which residues of the 
constructs. In addition this may allow us to confirm the interaction site of DCV and 
other NS5A targeting compounds. 
 
The construct used would require triple labelling and we would use our optimized 
conditions for a buffer. We suggest using construct 33-202-ek as although it has a 
propensity to aggregate which results in the broadening of NMR spectral peaks, it is 
less prone to aggregation than 25-202-ek however the inclusion of 5-10% deuterated 
glycerol may alleviate some of this aggregation effect. 
 
7.7.2 Mutation of Sites on NS5A 
 
The multimerisation of NS5A and which NS5A dimer compounds target could be 
tested by making mutations in the dimer contact interfaces. The effect of mutations on 
multimerisation could be tested in vitro by a decrease in NS5A aggregation using 
NMR as we have done with the wild-type domain 1; or in vivo by assaying how the 
mutations affect HCV replication and the formation of replication complexes in 
replicon systems. One could test if mutation of Trp84 is lethal to the HCV, or how it 
would affect NS5A function and if our proposed allosteric alterations in NS5A could 
result from drug binding. 
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Additionally we could mutate the RNA or phosphate binding site of NS5A domain 1 
to test if it has any effect on RNA binding using NS5A domain 1 construct with an 
extended C-terminus to include the RNA-binding region (Hwang et al., 2010). 
 
7.8 Implications 
 
Although this work does not solve the puzzle of the role of NS5A, we consider it to 
add further clues in how NS5A could function and how NS5A inhibitors may be 
abolishing this function. An understanding into the role of NS5A in the regulation of 
the viral lifecycle may give insights in viral replication and offer intuitions in how 
other unique components of viral machinery can be targeted. 
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Appendices 
 
Expression Vector Data 
 
pHAT4 
 
 
 
 241 
 
pGAT3 
 
 
 242 
 
pMAT10 
 
 
  
 243 
 
Thermal Denaturation Assay Buffer Conditions 
 
Condition (final concentrations) 
0.1 M Glycine pH 3.0 200 mM NaCl 
0.1 M Citric acid pH3.2 400 mM NaCl 
0.1 M PIPPS pH 3.7 600 mM NaCl 
0.1 M Citric acid pH 4.0 800 mM NaCl 
0.1 M Sodium Acetate pH 4.5 1 M NaCl 
0.1 M Sodium/Potassium Phosphate pH 5.0 400 mM KCl 
0.1 M Sodium Citrate pH 5.5 10 mM CaCl2 
0.1 M Sodium/Potassium Phosphate pH 6.0 100 mM CaCl2 
0.1 M Bis-Tris pH 6.0 10 mM ZnCl2 
0.1 M MES pH 6.2 100 mM ZnCl2 
0.1 M ADA pH 6.5 50 mM Arginine 50 mM Glutamic acid 
0.1 M Bis-Tris Propane pH 6.5 25 mM TCEP 
0.1 M Ammonium Acetate pH 7.0 0% Glycerol 
0.1 M MOPS pH 7.0 5% Glycerol 
0.1 M Sodium/Potassium Phosphate pH 7.0 10% Glycerol 
0.1 M HEPES pH 7.5 15% Glycerol 
0.1 M Tris pH 7.5 20% Glycerol 
0.1 M EPPS pH 8.0 25% Glycerol 
0.1 M Imidazole pH 8.0 30% Glycerol 
0.1 M Bicine pH 8.5 35% Glycerol 
0.1 M Tris pH 8.5 40% Glycerol 
0.1 M CHES pH 9.0 45% Glycerol 
0.1 M CHES pH 9.5 50% Glycerol 
0.1 M CAPS pH 10.0 55% Glycerol 
1.6 mM CHAPS  60% Glycerol 
0.08% Octyl Glucopyranoside  65% Glycerol 
0.8% Octyl Glucopyranoside  70% Glycerol 
0.08% Dodecyl Maltoside  75% Glycerol 
0.8% Dodecyl Maltoside 80% Glycerol 
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Crystal Screen Hits at 4°C 
 
Screens were prepared with 100 nl reservoir added to 100 nl 33-202-ek protein. 
 
Screen 
& well 
Picture of drop Condition 
ICL5 
A10 
 
2.2 M Sodium Chloride 
0.1 M Bis-Tris Propane pH 7.0 
ICL5 
G7 
 
0.7 M di-Ammonium Tartrate 
0.1 M Sodium Acetate pH 4.6 
ICL9 E6 
 
0.2 M magnesium chloride  
0.1 M Tris pH 8.5 
25 % w/v PEG 4000 
 
ICL10 
C12 
 
.05 M cesium chloride 
0.1 M MES 6.5 
30%(v/v) Jeffamine M-600 
ICL12 
G6 
 
2 M sodium formate  
0.1 M sodium acetate   
pH 5.0  
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Screen 
& well 
Picture of drop Condition 
ICL8 
E9 
 
1.6 M Magnesium sulfate 
0.1 M MES pH 6.5 
ICL9 
D6 
 
0.2 M calcium chloride  
0.1 M MES pH 6.5 
26 % v/v PEG 350 MME  
 
ICL9  
F3 
 
0.1 M sodium chloride  
0.12 M Tris pH 9.4 
20 % v/v PEG 400  
 
ICL10 
C9 
 
1.6M magnesium sulfate 
.1M MES 6.5 
ICL10 
D5 
 
.2M calcium chloride 
.1M HEPES 7.5 
28%(v/v) PEG 400 
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Screen 
& well 
Picture of drop Condition 
ICL11 
E8 
 
100 mM Sodium Chloride 
200 mM Calcium Chloride 
100 mM HEPES Sodium Salt 7.5 
34% v/v PEG 400 
ICL11 
H10 
 
100 mM Sodium Citrate 5.6 
40% v/v MPD 
ICL12 
G6 
 
2 M sodium formate  
0.1 M sodium acetate pH 5.0  
 
 
ICL12 
H6 
 
 
1.6 M magnesium sulfate  
0.1 M MES pH 6.5  
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Screen 
& well 
Picture of drop Condition 
ICL2 
D6 
 
0.1 M Tris pH 7.0 
15% (v/v) ethanol 
ICL3 
A5 
 
0.2 M Magnesium chloride 
hexahydrate pH 5.9 
20% w/v Polyethylene glycol 
3,350 
ICL8 E9 
 
1.6 M Magnesium sulfate 
0.1 M MES pH 6.5 
ICL8 
H3 
 
0.1 M bis-Tris pH 5.5 
25% (w/v) PEG 3350 
 
 
 
 
